Study structure

RMG

Generated: 2025-05-07 12:58

Version of eCRF: 41.0 (last edit 2025-03-07 08:04)

Structure of patient form

- **Personal data | [9]**
  - **Patient data | [37]**
    - Date of birth | [2377]
    - Sex | [2378]
    - Initials | [2379]
    - Old Patient ID (from RMG2-TrialDB2) | [2380]
    - Diagnosis | [316]
    - Inform consent form signed? | [4220]
    - ID of patients with same personal data | [4122]
    - This is not duplicate | [4123]
    - Monitored | [4881]
    - Date of monitoring | [4882]

Structure of phase forms

- **default study arm | [2]**
  - **MGUS | [2]**
    - **Diagnostics | [10]**
      - **Diagnostics | [38]**
        - ☐ Date of MGUS diagnosis | [317]
        - ☐ WHO ECOG | [318]
        - ☐ M-protein type | [319]
        - ☐ M-protein type 1 | [4883]
        - ☐ M-protein type 2 | [4884]
        - ☐ M-protein type 3 | [4885]
        - ☐ Serum M-protein quantity 1 (g/l) | [4886]
        - ☐ Serum M-protein quantity 2 (g/l) | [4887]
        - ☐ Serum M-protein quantity 3 (g/l) | [4888]
        - ☐ Light chain type | [321]

- □ Serum M-protein quantity (g/l) | [322]
- □ Cannot be measured | [320]
- □ Urine M-protein quantity (mg/24h) | [323]
- □ Urine M-protein quantity (mg/l per 24h) | [324]
- □ FLC quantity measured | [325]
- □ Date of FLC measurement | [326]
- □ Serum kappa FLC quantity (mg/l) | [327]
- □ Serum lambda FLC quantity (mg/l) | [328]
- □ Kappa/lambda ratio | [329]
- □ Bone marrow aspiration cytology performed | [330]
- □ Plasmocyte count by cytology (%) | [331]
- □ Bone marrow histology performed | [332]
- □ Monoclonal plasmocyte count (%) by histology | [333]

○ **Flow cytometry | [39]**

- □ Flow cytometry – plasma cells (bone marrow) | [334]
- □ Plasmocyte count FC (%) | [335]
- □ Clonal PC (%) | [340]
- □ Polyclonal PC (%) | [341]
- □ Flow cytometry – circulating plasma cells (peripheral blood) | [4868]
- □ cPCs (%) - peripheral blood | [4869]
- □ cPCs (absolute value/uL) - peripheral blood | [4870]
- □ Detection limit (LOD) | [4871]

○ **Medical Imaging Modalities | [40]**

- □ Osteolytic lesions - X-ray | [342]
- □ Osteolytic lesions - MRI | [343]
- □ Osteolytic lesions - CT | [344]
- □ Osteolytic lesions - LDCT | [345]
- □ Osteolytic lesions - PET | [346]
- □ Osteolytic lesions - PET/CT | [347]
- □ Osteolytic lesions - MIBI | [348]
- □ Osteolytic lesions - PET/MRI | [4330]

○ **PET, PET/CT, PET/MRI evaluation | [403]**

- □ Total number of FDG+ focuses | [5367]
- □ Deauville score | [5369]
- □ FDG+ focuses - skeleton | [5392]
- □ Skull | [5368]
- □ Axial skeleton | [5370]
- □ Appendicular skeleton | [5387]
- □ Fractures | [5388]
- □ New focuses | [5371]
- □ Number of PM lesions | [5373]
- □ Deauville score | [5372]
- □ Localization of PM lesions | [5381]
- □ Skull | [5393]
- □ Axial skeleton | [5394]
- □ Appendicular skeleton | [5395]

- □ New focuses | [5385]
- □ Number of EM lesions | [5377]
- □ Deauville score | [5382]
- □ Localization of EM lesions | [5390]
- □ Skin | [5396]
- □ Muscles | [5397]
- □ Connective tissue | [5398]
- □ Parenchymatous organs | [5399]
- □ CNS | [5406]
- □ Other | [5400]
- □ New focuses | [5386]
- □ FDG+ lymph nodes | [5379]
- □ Deauville score | [5384]
- □ New focuses | [5374]
- □ Bone marrow | [5391]
- □ Deauville score | [5383]
- □ CT/MRI: lytic focuses - skeleton | [5380]
- □ Localization of lytic focuses | [5407]
- □ Skull | [5401]
- □ Axial skeleton | [5402]
- □ Appendicular skeleton | [5403]
- □ New focuses | [5375]
- □ Other lesions - skeleton (FDG-) | [5389]
- □ Lesions <5 mm | [5404]
- □ Fractures | [5405]
- □ New focuses | [5376]
- □ | [5378]

○ **Biochemistry | [41]**

- □ Hemoglobin level (g/l) | [349]
- □ Thrombocyte count (10E9/l) | [350]
- □ Calcium total level (mmol/l) | [351]
- □ Albumin level (g/l) | [352]□
- □ Creatinine level (µmol/l) | [353]
- □ Beta2 microglobulin (mg/l) | [354]
- □ LDH (µkat/l) | [355]
- □ CRP (mg/l) | [356]
- □ IgG quantity (g/l) | [358]
- □ IgA quantity (g/l) | [359]
- □ IgM quantity (g/l) | [360]
- □ IgE quantity (IU/ml) | [361]

○ **Cytogenetic | [42]**

- □ Cytogenetics | [4096]
- □ Extended FISH questionnaire | [6260]
- □ Date of sample collection | [368]
- □ Conventional (carotype) | [4097]
- □ Result | [4098]

□ Method used | [4099]
□ Purity (%) | [4100]
□ t(11;14) | [370]
□ t(4;14) | [372]
□ t(14;16) | [376]
□ t(6;14) | [374]
□ t(14;20) | [6261]
□ del(17)(p13) | [382]
□ % | [6827]
□ gain 1q21 | [380]
□ % | [6828]
□ amp 1q21 | [6262]
□ % | [6829]
□ del(1p32) | [6263]
□ % | [6830]
□ Cytogenetic risk | [6264]
□ IGH disruption | [6265]
□ * Choose at least one of the following: | [6266]
□ Negative | [6267]
□ Rearrangement | [6268]
□ % | [6269]
□ Rearrangement + CNV | [6270]
□ % | [6271]
□ Variant rearrangement | [6272]
□ % | [6273]
□ US aberraion | [6274]
□ % | [6275]
□ Not evaluated | [6276]
□ t(4;14) | [6277]
□ * Choose at least one of the following: | [6278]
□ Negative | [6279]
□ CNV | [6280]
□ % | [6281]
□ Positive | [6282]
□ % | [6283]
□ Variant positive | [6284]
□ % | [6285]
□ Not evaluated | [6286]
□ t(11;14) | [6287]
□ * Choose at least one of the following: | [6288]
□ Negative | [6289]
□ CNV | [6290]
□ % | [6291]
□ Positive | [6292]
□ % | [6293]
□ Variant positive | [6294]

□ % | [6295]
□ Not evaluated | [6296]
□ t(14;16) | [6297]
□ * Choose at least one of the following: | [6298]
□ Negative | [6299]
□ CNV | [6300]
□ % | [6301]
□ Positive | [6302]
□ % | [6303]
□ Variant positive | [6304]
□ % | [6305]
□ Not evaluated | [6306]
□ t(6;14) | [6307]
□ * Choose at least one of the following: | [6308]
□ Negative | [6309]
□ CNV | [6310]
□ % | [6311]
□ Positive | [6312]
□ % | [6313]
□ Variant positive | [6314]
□ % | [6315]
□ Not evaluated | [6368]
□ t(14;20) | [6316]
□ * Choose at least one of the following: | [6317]
□ Negative | [6318]
□ CNV | [6319]
□ % | [6320]
□ Positive | [6321]
□ % | [6322]
□ Variant positive | [6323]
□ % | [6324]
□ Not evaluated | [6325]
□ del(17)(p13) | [6326]
□ * Choose at least one of the following: | [6327]
□ Negative | [6328]
□ Deletion/monosomy | [6329]
□ % | [6330]
□ Variant deletion | [6331]
□ % | [6332]
□ Not evaluated | [6333]
□ 1q21 | [6334]
□ * Choose at least one of the following: | [6335]
□ Negative | [6336]
□ Gain | [6337]
□ % | [6338]
□ Amp | [6339]

□ % | [6340]
□ Not evaluated | [6341]
□ del(1p32) | [6342]
□ * Choose at least one of the following: | [6343]
□ Negative | [6344]
□ Deletion | [6345]
□ % | [6346]
□ Not evaluated | [6347]
□ del(13)(q14) | [6348]
□ * Choose at least one of the following: | [6349]
□ Negative | [6350]
□ Deletion/monosomy | [6351]
□ % | [6369]
□ Variant deletion | [6352]
□ % | [6353]
□ Other | [6354]
□ % | [6355]
□ Not evaluated | [6356]
□ Hyperdiploidy | [6357]
□ * Choose at least one of the following: | [6358]
□ Negative | [6359]
□ Positive | [6360]
□ % | [6361]
□ Not evaluated | [6362]
□ Confirmative evaluations | [6363]
□ NGS | [6365]
□ ArrayCGH | [6366]
□ Optical genome mapping | [6367]

- **Molecular-biology | [43]**
  - □ Molecular-biology examination | [385]
  - □ MYD88 examination | [386]
  - □ Mutation in MYD88 gene | [387]
  - □ CXCR4 examination | [388]
  - □ Mutation in CXCR4 gene | [389]
  - □ Specify mutation type in CXCR4 gene | [390]
- **| [389]**
  - □ Form is fully filled | [4876]

- **Follow-up | [11]**
  - **| [237]**
    - □ Serum M-protein quantity or FLC quantity measured was updated according to the Diagnostics form. One extra line was added and the data (Date of sample collection, Serum M-protein quantity, FLC quantity measured) was transferred from the Diagnostics form. Data (Date of sample collection, Serum M-protein quantity, FLC quantity measured) for transfer from Diagnostics forms are empty. | [2392]
    - □ Serum M-protein quantity is greater than 30 g/l. Please fill in the form "Current status" - question "Progression MGUS to" | [2795]
    - □ Serum M-protein quantity from the Diagnosis form must be listed in one of the rows of the group below. | [2393]

□ Date of sample collection from the Diagnosis form must be listed in one of the rows of the group below. | [2394]

- **Follow-up | [44]**
  - □ Date of sample collection | [391]
  - □ M-protein type 1 | [4883]
  - □ M-protein type 2 | [4884]
  - □ M-protein type 3 | [4885]
  - □ Serum M-protein quantity 1 (g/l) | [4886]
  - □ Serum M-protein quantity 2 (g/l) | [4887]
  - □ Serum M-protein quantity 3 (g/l) | [4888]
  - □ Serum M-protein quantity (g/l) | [392]
  - □ Associated disease | [393]
  - □ Further specification | [394]
  - □ FLC quantity measured | [4145]
  - □ Serum kappa FLC quantity (mg/l) | [4146]
  - □ Serum lambda FLC quantity (mg/l) | [4147]
  - □ Kappa/lambda ratio | [4148]

- **Current status | [12]**
  - **MGUS development | [45]**
    - □ Progression MGUS to | [395]
    - □ Further specification | [396]
    - □ Date of MGUS progression | [397]
    - □ Last date when patient was without progression | [4187]
  - **Current status | [46]**
    - □ Date of the last update | [398]
    - □ Patient status | [399]
    - □ Date of death | [400]
    - □ Date of diagnosis | [2401]
    - □ Get data! | [2402]
    - □ Date of diagnosis for transfer from Diagnostics forms is empty. | [2818]
    - □ OS (days) | [2403]
    - □ Cause of death | [401]
    - □ Note | [402]

WM | [3]

- **Diagnostics | [13]**
  - **Diagnostics | [47]**
    - □ Diagnostics | [403]
    - □ Previous history of MGUS | [404]
    - □ Data not avaiable | [3993]
    - □ Previous history of IgM MGUS | [405]
    - □ Previous history of IgM MGUS since | [406]
    - □ Polyneuropathy in medical history | [4536]
  - **Asymptomatic diagnostics | [48]**
    - □ Date of diagnosis asymptomatic Waldenstrőm´s macroglobulinemia | [407]
  - **Laboratory examination (asymptomatic) | [49]**

- ☐ M-protein type | [409]
- ☐ Specify M-protein type | [4604]
- ☐ Serum M-protein quantity (g/l) | [410]
- ☐ Serum FLC quantity measured | [411]
- ☐ Serum free kappa quantity (mg/l) | [413]
- ☐ Serum free lambda quantity (mg/l) | [412]
- ☐ Kappa/lambda ratio | [414]
- ☐ Urine M-protein quantity (mg/24h) | [415]
- ☐ Urine M-protein quantity (mg/l per 24h) | [416]
- ☐ Polyclonal immunoglobuline quantitative estimation | [2408]
- ☐ IgM quantity (g/l) | [417]
- ☐ IgA quantity (g/l) | [418]
- ☐ IgG quantity (g/l) | [419]
- ☐ HLC mesaured | [420]
- ☐ Date of sample collection (HLC) | [421]
- ☐ Ig kappa HLC pair (g/l) | [422]
- ☐ Ig lambda HLC pair (g/l) | [423]
- ☐ HLC ratio | [424]

○ **Bone marrow examination (asymptomatic) | [50]**

- ☐ Bone marrow histology | [425]
- ☐ Monoclonal lymphocyte/lymphoplasmocyte count (%) | [426]
- ☐ Monoclonal plasmocyte count (%) by histology | [4542]
- ☐ Bone marrow aspiration cytology | [427]
- ☐ Lymphocyte/lymphplasmocyte count (%) | [428]
- ☐ Plasmocyte count (%) | [4543]

○ **Flow cytometry | [51]**

- ☐ Flow cytometry | [429]
- ☐ Lymphoplasmocytic cells (%) | [432]
- ☐ Clonal lymphoplasmocytic cells (%) | [433]
- ☐ Plasmocyte count FC (%) | [434]
- ☐ Clonal PC (%) | [435]

○ **Imaging methods (asymptomatic) | [52]**

- ☐ At least one Imaging methods (asymptomatic) must be performed: | [2825]
- ☐ Bone X ray - osteolytic lesions (X ray) | [436]
- ☐ Sonographic examination | [2416]
- ☐ Sonographic examination | [437]
- ☐ Lymphadenopathy inguinal | [438]
- ☐ Lymphadenopathy abdominal | [439]
- ☐ Lymphadenopathy axillar | [440]
- ☐ Lymphadenopathy cervical (neck) | [441]
- ☐ Splenomegaly | [442]
- ☐ Hepatomegaly | [443]
- ☐ CT examination | [2415]
- ☐ Mediastinal and abdominal CT examination | [444]
- ☐ Lymphadenopathy cervical | [445]
- ☐ Lymphadenopathy thoracic | [446]

□ Lymphadenopathy axillar | [447]
□ Lymphadenopathy abdominal | [448]
□ Lymphadenopathy inguinal | [449]
□ Splenomegaly | [450]
□ Hepatomegaly | [451]
□ Extralymphatic and extraosseal tissue infiltration or pathologic mass | [452]
□ FDG-PET | [2417]
□ FDG-PET (CT) activity | [453]
□ Abdominal nodal or extranodal activity | [454]
□ Thoracic nodal or extranodal activity | [455]
□ Extraabdominal and extrathoracic activity | [456]
□ MR examination | [2414]
□ MR examination | [457]
□ MR examination of bones | [458]
□ Mediastinal and abdominal MR examination | [459]
□ Lymphadenopathy cervical | [460]
□ Lymphadenopathy thoracic | [461]
□ Lymphadenopathy axillar | [462]
□ Lymphadenopathy abdominal | [463]
□ Lymphadenopathy inguinal | [464]
□ Splenomegaly | [465]
□ Hepatomegaly | [466]
□ Extralymphatic and extraosseal tissue infiltration or pathologic mass | [467]
□ PET/CT examination | [4568]
□ PET/CT examination | [4569]
□ Lymphadenopathy cervical | [4570]
□ Lymphadenopathy thoracic | [4571]
□ Lymphadenopathy axillar | [4572]
□ Lymphadenopathy abdominal | [4573]
□ Lymphadenopathy inguinal | [4574]
□ Splenomegaly | [4575]
□ Hepatomegaly | [4576]
□ Extralymphatic and extraosseal tissue infiltration or pathologic mass | [4577]

○ **Laboratory analysis (asymptomatic) | [53]**

□ Hemoglobin level (g/l) | [468]
□ Thrombocyte count (10E9/l) | [469]
□ Leukocyte count (10E9/l) | [470]
□ Neutrofil count (10E9/l) | [471]
□ Calcium total level (mmol/l) | [472]
□ Albumin level (g/l) | [473]
□ Total M-protein quantity (g/l) | [474]
□ Creatinine level (µmol/l) | [475]
□ Beta2 microglobulin (mg/l) | [476]
□ LDH (µkat/l) | [477]

- □ Upper normal value of LDH (µkat/l) | [478]
- □ LDH/upper normal value of LDH | [479]
- □ CRP (mg/l) | [480]
- □ Cholesterol (mmol/l) | [481]
- □ Absolute lymphocyte count (10E9/l) | [4589]

○ **Cytogenetic (asymptomatic) | [54]**

- □ Cytogenetic examination | [482]
- □ Date of sample collection | [483]
- □ At least one result of cytogenetic must be performed: | [2811]
- □ Del 6q | [484]
- □ Del 6q (%) | [485]
- □ Del(17)(p13) | [4592]
- □ Del(17)(p13) (%) | [4593]

○ **Molecular-biology | [55]**

- □ Molecular-biology examination | [487]
- □ MYD88 examination | [488]
- □ Mutation in MYD88 gene | [489]
- □ CXCR4 examination | [490]
- □ CXCR4 gene mutation | [491]
- □ Sample source | [4560]

○ **WM development (asymptomatic) | [56]**

- □ Date of evaluation/progression | [493]
- □ Progression asymptomatic WM | [494]

○ **Symptomatic diagnostics | [57]**

- □ Date of diagnosis symptomatic Waldenstrőm´s macroglobulinemia | [495]

○ **Clinical symptoms (symptomatic) | [58]**

- □ Hyperviskosity | [498]
- □ Cryoglobulinaemia | [499]
- □ Neuropathy | [500]
- □ Anti-MAG antibodies | [4601]
- □ Cold agglutinine disease | [501]
- □ Secondary AL – amyloidosis | [502]
- □ Nephropathy | [503]
- □ B symptoms | [504]
- □ Night sweats | [505]
- □ Subfebrile and febrile of unknown origin | [506]
- □ Weight loss greater than 10% in 6 months | [507]
- □ Other | [511]
- □ Other specification | [512]
- □ WHO ECOG | [513]
- □ Lymphadenopathy | [4594]
- □ Hepatomegaly | [4595]
- □ Splenomegaly | [4596]
- □ Extranodal infiltration | [4597]
- □ Specify extranodal infiltration | [4598]
- □ Anemia | [4599]

- ☐ Low platelets | [4600]

- ○ **Laboratory examination before therapy (symptomatic) | [59]**
  - ☐ M-protein type | [514]
  - ☐ Specify M-protein type | [4605]
  - ☐ Serum M-protein quantity (g/l) | [515]
  - ☐ Serum FLC quantity measured | [516]
  - ☐ Serum free kappa quantity (mg/l) | [518]
  - ☐ Serum free lambda quantity (mg/l) | [517]
  - ☐ Kappa/lambda ratio | [519]
  - ☐ Urine M-protein quantity (mg/24h) | [520]
  - ☐ Urine M-protein quantity (mg/l per 24h) | [521]
  - ☐ IgM quantity (g/l) | [522]
  - ☐ IgA quantity (g/l) | [523]
  - ☐ IgG quantity (g/l) | [524]
  - ☐ HLC quantity mesaured | [525]
  - ☐ Date of sample collection (HLC) | [526]
  - ☐ Ig kappa HLC pair (g/l) | [527]
  - ☐ Ig lambda HLC pair (g/l) | [528]
  - ☐ HLC ratio | [529]
- ○ **Bone marrow examination before therapy (symptomatic) | [60]**
  - ☐ Bone marrow histology | [530]
  - ☐ Monoclonal lymphocyte/lymphoplasmocyte count (%) | [531]
  - ☐ Monoclonal plasmocyte count (%) by histology | [4540]
  - ☐ Bone marrow aspiration cytology | [532]
  - ☐ Lymphocyte/lymphplasmocyte count (%) | [533]
  - ☐ Plasmocyte count (%) | [4541]
- ○ **Flow cytometry before therapy (symptomatic) | [61]**
  - ☐ Flow cytometry | [534]
  - ☐ Lymphoplasmocytic cells (%) | [537]
  - ☐ Clonal lymphoplasmocytic cells (%) | [538]
  - ☐ Plasmocyte count FC (%) | [539]
  - ☐ Clonal PC (%) | [540]
- ○ **Imaging methods before therapy (symptomatic) | [62]**
  - ☐ At least one Imaging methods before therapy (symptomatic) must be performed: | [2826]
  - ☐ Bone X ray - osteolytic lesions (X ray) | [541]
  - ☐ Sonographic examination | [2418]
  - ☐ Sonographic examination | [542]
  - ☐ Lymphadenopathy inguinal | [543]
  - ☐ Lymphadenopathy abdominal | [544]
  - ☐ Lymphadenopathy axillar | [545]
  - ☐ Lymphadenopathy cervical (neck) | [546]
  - ☐ Splenomegaly | [547]
  - ☐ Hepatomegaly | [548]
  - ☐ CT examination | [2420]
  - ☐ Mediastinal and abdominal CT examination | [549]
  - ☐ Lymphadenopathy cervical | [550]

- □ Lymphadenopathy thoracic | [551]
- □ Lymphadenopathy axillar | [552]
- □ Lymphadenopathy abdominal | [553]
- □ Lymphadenopathy inguinal | [554]
- □ Splenomegaly | [555]
- □ Hepatomegaly | [556]
- □ Extralymphatic and extraosseal tissue infiltration or pathologic mass | [557]
- □ FDG-PET (CT) | [2421]
- □ FDG-PET (CT) activity | [558]
- □ Abdominal nodal or extranodal activity | [559]
- □ Thoracic nodal or extranodal activity | [560]
- □ Extraabdominal and extrathoracic activity | [561]
- □ MR examination | [2419]
- □ MR examination | [562]
- □ MR examination of bones | [563]
- □ Mediastinal and abdominal MR examination | [564]
- □ Lymphadenopathy cervical | [565]
- □ Lymphadenopathy thoracic | [566]
- □ Lymphadenopathy axillar | [567]
- □ Lymphadenopathy abdominal | [568]
- □ Lymphadenopathy inguinal | [569]
- □ Splenomegaly | [570]
- □ Hepatomegaly | [571]
- □ Extralymphatic and extraosseal tissue infiltration or pathologic mass | [572]
- □ PET/CT examination | [4578]
- □ PET/CT examination | [4579]
- □ Lymphadenopathy cervical | [4580]
- □ Lymphadenopathy thoracic | [4581]
- □ Lymphadenopathy axillar | [4582]
- □ Lymphadenopathy abdominal | [4583]
- □ Lymphadenopathy inguinal | [4584]
- □ Splenomegaly | [4585]
- □ Hepatomegaly | [4586]
- □ Extralymphatic and extraosseal tissue infiltration or pathologic mass | [4587]

- ○ **Laboratory analysis results before therapy (symptomatic) | [63]**
  - □ Hemoglobin level (g/l) | [573]
  - □ Thrombocyte count (10E9/l) | [574]
  - □ Leukocyte count (10E9/l) | [575]
  - □ Neutrofil count (10E9/l) | [576]
  - □ Calcium total level (mmol/l) | [577]
  - □ Albumin level (g/l) | [578]
  - □ Total M-protein quantity (g/l) | [579]
  - □ Creatinine level (µmol/l) | [580]
  - □ Beta2 microglobulin (mg/l) | [581]

- ☐ LDH (µkat/l) | [582]
- ☐ Upper normal value of LDH (µkat/l) | [583]
- ☐ LDH/upper normal value of LDH | [584]
- ☐ CRP (mg/l) | [585]
- ☐ Cholesterol (mmol/l) | [586]
- ☐ Plasma viscosity | [587]
- ☐ Plasma viscosity | [588]
- ☐ Kryoglobulinemia | [589]
- ☐ Cold aglutinins | [590]
- ☐ Antierytrocytic antibody | [591]
- ☐ Antitrombocytic antibody | [592]
- ☐ AL-amyloidosis histologic confirmation | [593]
- ☐ Absolute lymphocyte count (10E9/l) | [4588]

○ **Cytogenetic before therapy (symptomatic) | [64]**

- ☐ Cytogenetic examination | [594]
- ☐ Date of sample collection | [2422]
- ☐ At least one result of cytogenetic must be performed: | [2812]
- ☐ Del 6q | [595]
- ☐ Del 6q (%) | [596]
- ☐ Del(17)(p13) | [4590]
- ☐ Del(17)(p13) (%) | [4591]

○ **Molecular-biology before therapy (symptomatic) | [65]**

- ☐ Molecular-biology examination | [598]
- ☐ MYD88 examination | [599]
- ☐ Mutation in MYD88 gene | [600]
- ☐ CXCR4 examination | [601]
- ☐ CXCR4 gene mutation | [602]
- ☐ Sample source | [4561]

○ **Prognosis before therapy (symptomatic) | [370]**

- ☐ IPSSWM score | [4602]

○ **| [389]**

- ☐ Form is fully filled | [4876]

▪ **Treatment | [14]**

○ **Line of treatment | [66]**

- ☐ Line of treatment | [604]

○ **Reason for the start of the therapy | [67]**

- ☐ Clinical symptoms of hyperviskosity | [605]
- ☐ Clinical symptoms of cryoglobulinaemia | [606]
- ☐ Clinical symptoms of neuropathy | [607]
- ☐ Clinical symptoms of AL-amyloidosis | [608]
- ☐ B symptoms | [609]
- ☐ Cytopenia - hemoglobin < 100 g/l | [610]
- ☐ Cytopenia - trombocyte < 100E9 /l | [611]
- ☐ Bulky lymphadenopathy | [612]
- ☐ Organomegaly | [613]
- ☐ Other | [614]

- □ Other specification | [615]

- **Relapse/progression | [76]**
  - □ Reason for treatment | [2413]
  - □ Date of relapse/progression | [858]
- **Treatment | [68]**
  - □ Treatment regimen | [616]
  - □ Specify combination of 6 or more drugs | [618]
  - □ Uncategorizable treatment specification | [619]
  - □ Rewritten | [2802]
  - □ Length of cycle (days) | [623]
  - □ Date of treatment initiation | [624]
  - □ Plasmapheresis | [625]
  - □ Number of plasmapheresis sessions | [626]
- **Drugs - overview | [69]**
  - □ bendamustin | [2511]
  - □ Dosage (mg/m2) | [627]
  - □ Number of administrations per cycle | [629]
  - □ Number of cycles | [630]
  - □ bortezomib | [2512]
  - □ Dosage (mg/m2) | [632]
  - □ Route of administration | [633]
  - □ Number of administrations per cycle | [634]
  - □ Number of cycles | [635]
  - □ Dose adjustment | [636]
  - □ cyklofosfamid | [2513]
  - □ Dosage (mg) | [642]
  - □ Number of administrations per cycle | [644]
  - □ Number of cycles | [645]
  - □ dexamethason | [2514]
  - □ Dosage (mg) | [647]
  - □ Number of administrations per cycle | [649]
  - □ Number of cycles | [650]
  - □ doxorubicin | [2515]
  - □ Dosage (mg/m2) | [652]
  - □ Number of administrations per cycle | [654]
  - □ Number of cycles | [655]
  - □ fludarabin | [2516]
  - □ Dosage (mg/m2) | [657]
  - □ Number of administrations per cycle | [659]
  - □ Number of cycles | [660]
  - □ chlorambucil | [2522]
  - □ Dosage (mg/kg) | [692]
  - □ Number of administrations per cycle | [694]
  - □ Number of cycles | [695]
  - □ melphalan | [2517]
  - □ Dosage (mg/m2) | [667]

- □ Number of administrations per cycle | [669]
- □ Number of cycles | [670]
- □ methylprednisolon | [2518]
- □ Dosage (mg) | [672]
- □ Number of administrations per cycle | [674]
- □ Number of cycles | [675]
- □ prednison | [2519]
- □ Dosage (mg) | [677]
- □ Number of administrations per cycle | [679]
- □ Number of cycles | [680]
- □ rituximab | [2520]
- □ Dosage (mg/m2) | [682]
- □ Route of administration | [683]
- □ Number of administrations per cycle | [684]
- □ Number of cycles | [685]
- □ Dose adjustment | [686]
- □ thalidomid | [2521]
- □ Dosage (mg) | [687]
- □ Number of administrations per cycle | [689]
- □ Number of cycles | [690]
- □ Dose adjustment | [691]
- □ ibrutinib | [4520]
- □ Dosage (mg) | [4521]
- □ Number of administrations per cycle | [4523]
- □ Number of cycles | [4522]
- □ Dose adjustment | [4524]

- **Dose adjustment - bortezomib | [242]**
  - □ Date of dose adjustment | [2532]
  - □ 1st reason | [2533]
  - □ Specify other | [2534]
  - □ Grade | [2535]
  - □ 2nd reason | [2536]
  - □ Grade | [2537]
  - □ 3rd reason | [2538]
  - □ Grade | [2539]
  - □ New dosage (mg/m2) | [2540]
  - □ Dose interruption | [4030]
  - □ Number of administrations per cycle | [5565]
- **Dose adjustment - thalidomid | [251]**
  - □ Date of dose adjustment | [2613]
  - □ 1st reason | [2614]
  - □ Specify other | [2615]
  - □ Grade | [2616]
  - □ 2nd reason | [2617]
  - □ Grade | [2618]
  - □ 3rd reason | [2619]

- □ Grade | [2620]
- □ New dosage (mg) | [2621]
- □ Dose interruption | [4031]
- □ Number of administrations per cycle | [5567]

○ **Dose adjustment - rituximab | [250]**

- □ Date of dose adjustment | [2604]
- □ 1st reason | [2605]
- □ Specify other | [2606]
- □ Grade | [2607]
- □ 2nd reason | [2608]
- □ Grade | [2609]
- □ 3rd reason | [2610]
- □ Grade | [2611]
- □ New dosage (mg/m2) | [2612]
- □ Dose interruption | [4032]
- □ Number of administrations per cycle | [5569]

○ **Dose adjustment - ibrutinib | [368]**

- □ Date of dose adjustment | [4525]
- □ 1st reason | [4526]
- □ Specify other | [4527]
- □ Grade | [4528]
- □ 2nd reason | [4529]
- □ Grade | [4530]
- □ 3rd reason | [4531]
- □ Grade | [4532]
- □ New dosage (mg) | [4533]
- □ Dose interruption | [4534]
- □ Number of administrations per cycle | [5571]

○ **Transplantation | [71]**

- □ Transplantation | [796]
- □ Response before transplant | [802]
- □ Date of transplantation | [797]
- □ Transplantation technique | [798]
- □ Type of conditioning regimen | [799]
- □ Tandem autotransplantation - identical dosage? | [800]
- □ Second conditioning regimen type | [801]
- □ Date of subsequent transplant | [803]

○ **Maintenance therapy | [367]**

- □ Maintenance therapy | [4511]
- □ Specify maintenance therapy | [4512]
- □ Specify other treatment | [4513]
- □ Treatment beginning date | [4514]
- □ Date of treatment withdrawal | [4515]
- □ Reason for treatment withdrawal | [4516]
- □ Specify other reason | [4517]
- □ Maximal response | [4518]

□ Date of maximal response | [4519]

- **Treatment withdrawal | [72]**
  - □ Date of treatment withdrawal | [804]
- **Response to treatment | [73]**
  - □ Date of best response | [809]
  - □ Best response | [818]
  - □ Therapeutic response after end of treatment (definition of end of treatment – 30 days after last cycle or last dose of drug) | [2829]
  - □ Date of first response (MR or better) | [4608]
  - □ Bone marrow biopsy after treatment | [4609]
  - □ Method | [4610]
  - □ Result | [4611]
  - □ Imaging after treatment | [4612]
  - □ Method | [4614]
  - □ Best response | [4613]
- **IgM FLARE | [372]**
  - □ IgM FLARE | [4606]
  - □ Plasmapheresis | [4607]
- **| [389]**
  - □ Form is fully filled | [4876]

- **Watch and wait | [25]**
  - **After line of treatment | [286]**
    - □ After line | [3181]
  - **Progression | [287]**
    - □ Date of progression | [3182]
- **Current status | [15]**
  - **WM development | [238]**
    - □ Transformation of WM | [862]
    - □ Date of transformation | [863]
    - □ Specify transformation | [864]
  - **Other malignant disease | [239]**
    - □ Other malignant disease | [865]
    - □ Specify other malignant disease | [866]
  - **Current status | [77]**
    - □ Date of the last update | [859]
    - □ Patient status | [860]
    - □ Patient status - alive | [861]
    - □ Date of death | [867]
    - □ Date of diagnosis | [2405]
    - □ Get data! | [2406]
    - □ Date of diagnosis for transfer from Diagnostics forms is empty. | [2819]
    - □ OS (days) | [2404]
    - □ Cause of death | [868]
    - □ Note | [869]

SMM | [6]

- **Diagnostics | [36]**

- **Diagnostics | [345]**
  - ☐ Date of SMM diagnosis | [4426]
  - ☐ Previous history of MGUS | [870]
  - ☐ Data not available | [3639]
  - ☐ History of solitary plasmacytoma | [873]
  - ☐ Polyneuropathy in medical history | [874]
  - ☐ WHO ECOG | [876]
- **Laboratory examination | [79]**
  - ☐ M-protein type | [877]
  - ☐ M-protein type 1 | [4883]
  - ☐ M-protein type 2 | [4884]
  - ☐ M-protein type 3 | [4885]
  - ☐ Serum M-protein quantity 1 (g/l) | [4886]
  - ☐ Serum M-protein quantity 2 (g/l) | [4887]
  - ☐ Serum M-protein quantity 3 (g/l) | [4888]
  - ☐ Serum M-protein quantity (g/l) | [878]
  - ☐ Cannot be measured | [879]
  - ☐ Urine M-protein quantity (mg/24h) | [880]
  - ☐ Urine M-protein quantity (mg/l per 24h) | [881]
  - ☐ FLC quantity measured | [882]
  - ☐ Serum kappa FLC quantity (mg/l) | [884]
  - ☐ Serum lambda FLC quantity (mg/l) | [883]
  - ☐ Kappa/lambda ratio | [885]
  - ☐ Light chain type | [886]
  - ☐ IgG quantity (g/l) | [887]
  - ☐ IgA quantity (g/l) | [888]
  - ☐ IgM quantity (g/l) | [889]
- **Bone marrow examination | [80]**
  - ☐ Bone marrow aspiration cytology | [897]
  - ☐ Plasmocyte count by cytology (%) | [898]
  - ☐ Bone marrow histology | [895]
  - ☐ Monoclonal plasmocyte count (%) by histology | [896]
- **Flow cytometry | [83]**
  - ☐ Flow cytometry – plasma cells (bone marrow) | [925]
  - ☐ Plasmocyte count FC (%) | [926]
  - ☐ Clonal PC (%) | [931]
  - ☐ Polyclonal PC (%) | [932]
  - ☐ Flow cytometry – circulating plasma cells (peripheral blood) | [4868]
  - ☐ cPCs (%) - peripheral blood | [4869]
  - ☐ cPCs (absolute value/uL) - peripheral blood | [4870]
  - ☐ Detection limit (LOD) | [4871]
- **Biochemistry | [81]**
  - ☐ Hemoglobin level (g/l) | [899]
  - ☐ Thrombocyte count (10E9/l) | [900]
  - ☐ Calcium total level (mmol/l) | [901]
  - ☐ Albumin level (g/l) | [902]

- ☐ Creatinine level (µmol/l) | [903]
- ☐ Beta2 microglobulin (mg/l) | [904]
- ☐ LDH (µkat/l) | [905]
- ☐ CRP (mg/l) | [906]

○ **Cytogenetic | [82]**

- ☐ Cytogenetics | [3692]
- ☐ Extended FISH questionnaire | [6389]
- ☐ Date of sample collection | [908]
- ☐ Conventional (carotype) | [3693]
- ☐ Result | [3694]
- ☐ Method used | [3695]
- ☐ Purity (%) | [3696]
- ☐ t(11;14) | [910]
- ☐ t(4;14) | [912]
- ☐ t(14;16) | [916]
- ☐ t(6;14) | [914]
- ☐ t(14;20) | [6510]
- ☐ del(17)(p13) | [922]
- ☐ % | [6831]
- ☐ gain 1q21 | [920]
- ☐ % | [6832]
- ☐ amp 1q21 | [6401]
- ☐ % | [6833]
- ☐ del(1p32) | [6402]
- ☐ % | [6834]
- ☐ Cytogenetic risk | [6400]
- ☐ IGH disruption | [6403]
- ☐ * Choose at least one of the following: | [6511]
- ☐ Negative | [6405]
- ☐ Rearrangement | [6406]
- ☐ % | [6407]
- ☐ Rearrangement + CNV | [6408]
- ☐ % | [6409]
- ☐ Variant rearrangement | [6410]
- ☐ % | [6411]
- ☐ US aberration | [6412]
- ☐ % | [6413]
- ☐ Not evaluated | [6414]
- ☐ t(4;14) | [6415]
- ☐ * Choose at least one of the following: | [6416]
- ☐ Negative | [6417]
- ☐ CNV | [6418]
- ☐ % | [6419]
- ☐ Positive | [6420]
- ☐ % | [6421]
- ☐ Variant positive | [6422]

□ % | [6423]
□ Not evaluated | [6424]
□ t(11;14) | [6425]
□ * Choose at least one of the following: | [6426]
□ Negative | [6427]
□ CNV | [6428]
□ % | [6429]
□ Positive | [6430]
□ % | [6431]
□ Variant positive | [6432]
□ % | [6433]
□ Not evaluated | [6434]
□ t(14;16) | [6435]
□ * Choose at least one of the following: | [6436]
□ Negative | [6437]
□ CNV | [6438]
□ % | [6439]
□ Positive | [6440]
□ % | [6441]
□ Variant positive | [6442]
□ % | [6443]
□ Not evaluated | [6444]
□ t(6;14) | [6445]
□ * Choose at least one of the following: | [6446]
□ Negative | [6447]
□ CNV | [6448]
□ % | [6449]
□ Positive | [6450]
□ % | [6451]
□ Variant positive | [6452]
□ % | [6453]
□ Not evaluated | [6505]
□ t(14;20) | [6454]
□ * Choose at least one of the following: | [6455]
□ Negative | [6456]
□ CNV | [6457]
□ % | [6458]
□ Positive | [6459]
□ % | [6460]
□ Variant positive | [6461]
□ % | [6462]
□ Not evaluated | [6463]
□ del(17)(p13) | [6464]
□ * Choose at least one of the following: | [6465]
□ Negative | [6466]
□ Deletion/monosomy | [6467]

- □ % | [6468]
- □ Variant deletion | [6469]
- □ % | [6470]
- □ Not evaluated | [6471]
- □ 1q21 | [6472]
- □ * Choose at least one of the following: | [6473]
- □ Negative | [6474]
- □ Gain | [6475]
- □ % | [6476]
- □ Amp | [6477]
- □ % | [6478]
- □ Not evaluated | [6479]
- □ del(1p32) | [6480]
- □ * Choose at least one of the following: | [6481]
- □ Negative | [6482]
- □ Deletion | [6483]
- □ % | [6484]
- □ Not evaluated | [6485]
- □ del(13)(q14) | [6486]
- □ * Choose at least one of the following: | [6487]
- □ Negative | [6488]
- □ Deletion/monosomy | [6489]
- □ % | [6506]
- □ Variant deletion | [6490]
- □ % | [6491]
- □ Other | [6492]
- □ % | [6493]
- □ Not evaluated | [6494]
- □ Hyperdiploidy | [6495]
- □ * Choose at least one of the following: | [6496]
- □ Negative | [6497]
- □ Positive | [6498]
- □ % | [6499]
- □ Not evaluated | [6500]
- □ Confirmative evaluations | [6501]
- □ NGS | [6502]
- □ ArrayCGH | [6503]
- □ Optical genome mapping | [6504]

- **Medical Imaging Modalities | [84]**
  - □ At least one imaging method must be performed: | [2384]
  - □ Osteolytic lesions - X-ray | [933]
  - □ Osteolytic lesions - MRI | [934]
  - □ Osteolytic lesions - CT | [936]
  - □ Osteolytic lesions - LDCT | [935]
  - □ Osteolytic lesions - PET | [937]
  - □ Osteolytic lesions - PET/CT | [938]

- □ Osteolytic lesions - MIBI | [939]
- □ Osteolytic lesions - PET/MRI | [4328]

○ **PET, PET/CT, PET/MRI evaluation | [403]**

- □ Total number of FDG+ focuses | [5367]
- □ Deauville score | [5369]
- □ FDG+ focuses - skeleton | [5392]
- □ Skull | [5368]
- □ Axial skeleton | [5370]
- □ Appendicular skeleton | [5387]
- □ Fractures | [5388]
- □ New focuses | [5371]
- □ Number of PM lesions | [5373]
- □ Deauville score | [5372]
- □ Localization of PM lesions | [5381]
- □ Skull | [5393]
- □ Axial skeleton | [5394]
- □ Appendicular skeleton | [5395]
- □ New focuses | [5385]
- □ Number of EM lesions | [5377]
- □ Deauville score | [5382]
- □ Localization of EM lesions | [5390]
- □ Skin | [5396]
- □ Muscles | [5397]
- □ Connective tissue | [5398]
- □ Parenchymatous organs | [5399]
- □ CNS | [5406]
- □ Other | [5400]
- □ New focuses | [5386]
- □ FDG+ lymph nodes | [5379]
- □ Deauville score | [5384]
- □ New focuses | [5374]
- □ Bone marrow | [5391]
- □ Deauville score | [5383]
- □ CT/MRI: lytic focuses - skeleton | [5380]
- □ Localization of lytic focuses | [5407]
- □ Skull | [5401]
- □ Axial skeleton | [5402]
- □ Appendicular skeleton | [5403]
- □ New focuses | [5375]
- □ Other lesions - skeleton (FDG-) | [5389]
- □ Lesions <5 mm | [5404]
- □ Fractures | [5405]
- □ New focuses | [5376]
- □ | [5378]

○ **Stage | [86]**

- □ Durie-Salmon stage | [947]

□ Durie-Salmon substage | [948]
□ One of ISS classification must be filled (manually or by calculation): | [3596]
□ ISS classification - calculation only | [3597]
□ ISS classification | [951]
□ R-ISS classification - calculation only | [3602]
□ R-ISS classification | [4615]

- **| [389]**
  - □ Form is fully filled | [4876]

- **Treatment | [37]**
  - **Line of treatment | [353]**
    - □ Line of treatment | [4451]
  - **Performance status before treatment | [91]**
    - □ WHO ECOG | [971]
  - **Laboratory examination before treatment | [92]**
    - □ M-protein type from diagnostics | [3640]
    - □ Change of M-protein type? | [3641]
    - □ M-protein type | [974]
    - □ M-protein type 1 | [4883]
    - □ M-protein type 2 | [4884]
    - □ M-protein type 3 | [4885]
    - □ Serum M-protein quantity 1 (g/l) | [4886]
    - □ Serum M-protein quantity 2 (g/l) | [4887]
    - □ Serum M-protein quantity 3 (g/l) | [4888]
    - □ FLC quantity measured | [3648]
    - □ Serum kappa FLC quantity (mg/l) | [3649]
    - □ Serum lambda FLC quantity (mg/l) | [3650]
    - □ Kappa/lambda ratio | [3651]
    - □ Light chain type from diagnostics | [3644]
    - □ Change of light chain type? | [3645]
    - □ Light chain type | [975]
    - □ M-protein entry type 1 | [5214]
    - □ M-protein entry type 2 | [5215]
    - □ M-protein entry type 3 | [5216]
    - □ Serum M-protein entry quantity 1 (g/l) | [5217]
    - □ Serum M-protein entry quantity 2 (g/l) | [5218]
    - □ Serum M-protein entry quantity 3 (g/l) | [5219]
    - □ Serum M-protein entry level (g/l) | [976]
    - □ Cannot be measured | [2779]
    - □ Urine M-protein entry level (mg/24h) | [977]
    - □ Urine M-protein entry level (mg/l per 24h) | [978]
  - **Bone marrow examination before treatment | [93]**
    - □ Get data from diagnostics! | [4322]
    - □ Bone marrow aspiration cytology | [979]
    - □ Plasmocyte count by cytology (%) | [980]
    - □ Bone marrow histology | [981]
    - □ Monoclonal plasmocyte count (%) by histology | [982]

- **Flow cytometry before treatment | [96]**
  - ☐ Get data from diagnostics! | [4324]
  - ☐ Flow cytometry – plasma cells (bone marrow) | [993]
  - ☐ Sample date | [994]
  - ☐ Plasmocyte count FC (%) | [4222]
  - ☐ Clonal PC (%) | [4332]
  - ☐ Polyclonal PC (%) | [4333]
  - ☐ Flow cytometry – circulating plasma cells (peripheral blood) | [4868]
  - ☐ cPCs (%) - peripheral blood | [4869]
  - ☐ cPCs (absolute value/uL) - peripheral blood | [4870]
  - ☐ Detection limit (LOD) | [4871]
- **Biochemistry before treatment | [94]**
  - ☐ Get data from diagnostics! | [4323]
  - ☐ Hemoglobin level (g/l) | [983]
  - ☐ Thrombocyte count (10E9/l) | [984]
  - ☐ Calcium total level (mmol/l) | [985]
  - ☐ Albumin level (g/l) | [986]
  - ☐ Creatinine level (µmol/l) | [987]
  - ☐ Beta2 microglobulin (mg/l) | [988]
  - ☐ LDH (µkat/l) | [989]
  - ☐ CRP (mg/l) | [990]
- **Cytogenetics before treatment | [95]**
  - ☐ Cytogenetics | [3698]
  - ☐ Extended FISH questionnaire | [6525]
  - ☐ Date of sample collection | [992]
  - ☐ Conventional (carotype) | [3699]
  - ☐ Result | [3700]
  - ☐ Method used | [3701]
  - ☐ Purity (%) | [3702]
  - ☐ t(11;14) | [3607]
  - ☐ t(4;14) | [3609]
  - ☐ t(14;16) | [3613]
  - ☐ t(6;14) | [3611]
  - ☐ t(14;20) | [6613]
  - ☐ del(17)(p13) | [3619]
  - ☐ % | [6835]
  - ☐ gain 1q21 | [3617]
  - ☐ % | [6836]
  - ☐ amp 1q21 | [6542]
  - ☐ % | [6837]
  - ☐ del(1p32) | [6617]
  - ☐ % | [6838]
  - ☐ Cytogenetic risk | [6524]
  - ☐ IGH disruption | [6526]
  - ☐ * Choose at least one of the following: | [6626]
  - ☐ Negative | [6543]

□ Rearrangement | [6544]
□ % | [6545]
□ Rearrangement + CNV | [6546]
□ % | [6547]
□ Variant rearrangement | [6529]
□ % | [6548]
□ US aberration | [6549]
□ % | [6550]
□ Not evaluated | [6551]
□ t(4;14) | [6552]
□ * Choose at least one of the following: | [6553]
□ Negative | [6554]
□ CNV | [6530]
□ % | [6534]
□ Positive | [6555]
□ % | [6531]
□ Variant positive | [6537]
□ % | [6558]
□ Not evaluated | [6623]
□ t(11;14) | [6556]
□ * Choose at least one of the following: | [6561]
□ Negative | [6541]
□ CNV | [6533]
□ % | [6557]
□ Positive | [6535]
□ % | [6536]
□ Variant positive | [6559]
□ % | [6539]
□ Not evaluated | [6540]
□ t(14;16) | [6627]
□ * Choose at least one of the following: | [6628]
□ Negative | [6563]
□ CNV | [6573]
□ % | [6575]
□ Positive | [6571]
□ % | [6562]
□ Variant positive | [6564]
□ % | [6565]
□ Not evaluated | [6560]
□ t(6;14) | [6568]
□ * Choose at least one of the following: | [6570]
□ Negative | [6572]
□ CNV | [6591]
□ % | [6593]
□ Positive | [6574]
□ % | [6576]

□ Variant positive | [6577]
□ % | [6578]
□ Not evaluated | [6566]
□ t(14;20) | [6580]
□ * Choose at least one of the following: | [6584]
□ Negative | [6583]
□ CNV | [6630]
□ % | [6631]
□ Positive | [6595]
□ % | [6597]
□ Variant positive | [6598]
□ % | [6599]
□ Not evaluated | [6596]
□ del(17)(p13) | [6603]
□ * Choose at least one of the following: | [6605]
□ Negative | [6588]
□ Deletion/monosomy | [6581]
□ % | [6585]
□ Variant deletion | [6589]
□ % | [6590]
□ Not evaluated | [6567]
□ 1q21 | [6600]
□ * Choose at least one of the following: | [6606]
□ Negative | [6604]
□ Gain | [6610]
□ % | [6612]
□ Amp | [6527]
□ % | [6528]
□ Not evaluated | [6607]
□ del(1p32) | [6587]
□ * Choose at least one of the following: | [6594]
□ Negative | [6609]
□ Deletion | [6608]
□ % | [6614]
□ Not evaluated | [6615]
□ del(13)(q14) | [6616]
□ * Choose at least one of the following: | [6618]
□ Negative | [6619]
□ Deletion/monosomy | [6620]
□ % | [6611]
□ Variant deletion | [6621]
□ % | [6622]
□ Other | [6624]
□ % | [6625]
□ Not evaluated | [6582]
□ Hyperdiploidy | [6538]

- □ * Choose at least one of the following: | [6629]
- □ Negative | [6532]
- □ Positive | [6632]
- □ % | [6569]
- □ Not evaluated | [6601]
- □ Confirmative evaluations | [6579]
- □ NGS | [6586]
- □ ArrayCGH | [6592]
- □ Optical genome mapping | [6602]

○ **Medical Imaging Modalities before treatment | [97]**

- □ Get data from diagnostics! | [4325]
- □ At least one imaging method must be performed in first line: | [2385]
- □ Osteolytic lesions - X-ray | [995]
- □ Osteolytic lesions - MRI | [996]
- □ Osteolytic lesions - CT | [997]
- □ Osteolytic lesions - LDCT | [2386]
- □ Osteolytic lesions - PET | [998]
- □ Osteolytic lesions - PET/CT | [999]
- □ Osteolytic lesions - MIBI | [1000]
- □ Osteolytic lesions - PET/MRI | [4329]

○ **PET, PET/CT, PET/MRI evaluation | [400]**

- □ Get data from diagnostics! | [5366]
- □ Total number of FDG+ focuses | [5242]
- □ Deauville score | [5244]
- □ FDG+ focuses - skeleton | [5267]
- □ Skull | [5243]
- □ Axial skeleton | [5245]
- □ Appendicular skeleton | [5262]
- □ Fractures | [5263]
- □ New focuses | [5246]
- □ Number of PM lesions | [5248]
- □ Deauville score | [5257]
- □ Localization of PM lesions | [5256]
- □ Skull | [5268]
- □ Axial skeleton | [5269]
- □ Appendicular skeleton | [5270]
- □ New focuses | [5260]
- □ Number of EM lesions | [5252]
- □ Deauville score | [5258]
- □ Localization of EM lesions | [5265]
- □ Skin | [5271]
- □ Muscles | [5272]
- □ Connective tissue | [5273]
- □ Parenchymatous organs | [5274]
- □ CNS | [5281]
- □ Other | [5275]

- □ New focuses | [5261]
- □ FDG+ lymph nodes | [5254]
- □ Deauville score | [5259]
- □ New focuses | [5249]
- □ Bone marrow | [5266]
- □ Deauville score | [5247]
- □ CT/MRI: lytic focuses - skeleton | [5255]
- □ Localization of lytic focuses | [5282]
- □ Skull | [5276]
- □ Axial skeleton | [5277]
- □ Appendicular skeleton | [5278]
- □ New focuses | [5250]
- □ Other lesions - skeleton (FDG-) | [5264]
- □ Lesions <5 mm | [5279]
- □ Fractures | [5280]
- □ New focuses | [5251]
- □ | [5253]

- **Stage before treatment | [99]**
  - □ Get data from diagnostics! | [4327]
  - □ Durie-Salmon stage | [1008]
  - □ Durie-Salmon substage | [1009]
  - □ ISS classification - calculation only | [3599]
  - □ ISS classification | [1010]
  - □ R-ISS classification - calculation only | [3603]
  - □ R-ISS classification | [4616]
- **Treatment | [355]**
  - □ Treatment regimen | [4455]
  - □ Specify combination of 6 or more drugs | [3690]
  - □ Health insurance company | [1015]
  - □ Clinical study | [1016]
  - □ Name of clinical study | [4456]
  - □ Specification name of other | [1018]
  - □ Double blinded study | [3177]
  - □ Specification of clinical study | [3657]
  - □ Length of cycle (days) | [1019]
  - □ Date of treatment initiation | [1020]
  - □ Hide toxicity and dosage | [4681]
- **Drugs - overview | [101]**
  - □ bendamustin | [2445]
  - □ Dosage (mg/m2) | [1021]
  - □ Number of administrations per cycle | [1023]
  - □ Number of cycles | [1024]
  - □ bortezomib | [2446]
  - □ Dosage (mg/m2) | [1026]
  - □ Route of administration | [1027]
  - □ Number of administrations per cycle | [1028]

□ Number of cycles | [1029]
□ Dose adjustment | [1030]
□ busulfan | [2447]
□ Dosage (mg/kg) | [1031]
□ Number of administrations per cycle | [1033]
□ Number of cycles | [1034]
□ cyklofosfamid | [2450]
□ Dosage (mg) | [1036]
□ Number of administrations per cycle | [1038]
□ Number of cycles | [1039]
□ dexamethason | [2452]
□ Dosage (mg) | [1041]
□ Number of administrations per cycle | [1043]
□ Number of cycles | [1044]
□ doxorubicin | [2453]
□ Dosage (mg/m2) | [1046]
□ Number of administrations per cycle | [1048]
□ Number of cycles | [1049]
□ melphalan | [2459]
□ Dosage (mg/m2) | [1061]
□ Number of administrations per cycle | [1063]
□ Number of cycles | [1064]
□ methylprednisolon | [2460]
□ Dosage (mg) | [1066]
□ Number of administrations per cycle | [1068]
□ Number of cycles | [1069]
□ prednison | [2463]
□ Dosage (mg) | [1071]
□ Number of administrations per cycle | [1073]
□ Number of cycles | [1074]
□ rituximab | [2464]
□ Dosage (mg/m2) | [1076]
□ Route of administration | [1077]
□ Number of administrations per cycle | [1078]
□ Number of cycles | [1079]
□ Dose adjustment | [1080]
□ thalidomid | [2465]
□ Dosage (mg) | [1081]
□ Number of administrations per cycle | [1083]
□ Number of cycles | [1084]
□ carfilzomib | [2448]
□ Dosage (mg/m2) | [1086]
□ Route of administration | [1087]
□ Number of administrations per cycle | [1088]
□ Number of cycles | [1089]
□ Dose adjustment | [1090]

□ cisplatinum | [2449]
□ Dosage (mg/m2) | [1091]
□ Number of administrations per cycle | [1093]
□ Number of cycles | [1094]
□ daratumumab | [2451]
□ Dosage | [1096]
□ Units | [4660]
□ Do you really want to enter value different from 16 mg/kg? | [4877]
□ Route of administration | [1097]
□ Number of administrations per cycle | [1098]
□ Number of cycles | [1099]
□ Dose adjustment | [1100]
□ elotuzumab | [2454]
□ Dosage (mg/kg) | [1101]
□ Route of administration | [1102]
□ Number of administrations per cycle | [1103]
□ Number of cycles | [1104]
□ Dose adjustment | [1105]
□ idarubicin | [2456]
□ Dosage (mg/m2) | [1106]
□ Number of administrations per cycle | [1108]
□ Number of cycles | [1109]
□ ixazomib | [2457]
□ Dosage (mg) | [1111]
□ Number of administrations per cycle | [1113]
□ Number of cycles | [1114]
□ Dose adjustment | [1115]
□ lenalidomid | [2458]
□ Dosage (mg) | [1116]
□ Number of administrations per cycle | [1118]
□ Number of cycles | [1119]
□ Dose adjustment | [1120]
□ Pokud došlo v průběhu linie k výměně dexamethasonu prednisonem, zapište informaci do formuláře Mandatory questions for VILP Revlimid. | [4231]
□ panobinostat | [2461]
□ Dosage (mg) | [1121]
□ Route of administration | [1122]
□ Number of administrations per cycle | [1123]
□ Number of cycles | [1124]
□ Dose adjustment | [1125]
□ pomalidomid | [2462]
□ Dosage (mg) | [1126]
□ Number of administrations per cycle | [1128]
□ Number of cycles | [1129]
□ Dose adjustment | [1130]
□ etoposid | [2455]
□ Dosage (mg/m2) | [1131]

□ Number of administrations per cycle | [1133]
□ Number of cycles | [1134]
□ vincristin | [2466]
□ Dosage (mg/m2) | [1136]
□ Number of administrations per cycle | [1138]
□ Number of cycles | [1139]
□ ibrutinib | [3073]
□ Dosage (mg) | [3074]
□ Number of administrations per cycle | [3075]
□ Number of cycles | [3076]
□ Dose adjustment | [3077]
□ isatuximab | [3078]
□ Dosage | [3079]
□ Units | [5794]
□ Do you really want to enter value different from 10 mg/kg? | [5795]
□ Route of administration | [3080]
□ Number of administrations per cycle | [3081]
□ Number of cycles | [3082]
□ Dose adjustment | [3083]
□ selinexor | [3084]
□ Dosage (mg) | [3085]
□ Number of administrations per cycle | [3086]
□ Number of cycles | [3087]
□ Dose adjustment | [3088]
□ cobimetinib | [3187]
□ Dosage (mg) | [3188]
□ Number of administrations per cycle | [3189]
□ Number of cycles | [3190]
□ Dose adjustment | [3191]
□ masitinib | [3221]
□ Dosage (mg/kg) | [3222]
□ Number of administrations per cycle | [3223]
□ Number of cycles | [3224]
□ Dose adjustment | [3225]
□ interferon alfa-2b | [3255]
□ Dosage (MIU) | [3256]
□ Number of administrations per cycle | [3257]
□ Number of cycles | [3258]
□ Dose adjustment | [3259]
□ denosumab | [3289]
□ Dosage (mg) | [3290]
□ Number of administrations per cycle | [3291]
□ Number of cycles | [3292]
□ Dose adjustment | [3293]
□ plitidepsin | [3323]
□ Dosage (mg/m2) | [3324]

□ Number of administrations per cycle | [3325]
□ Number of cycles | [3326]
□ Dose adjustment | [3327]
□ melflufen | [3357]
□ Dosage (mg) | [3358]
□ Number of administrations per cycle | [3359]
□ Number of cycles | [3360]
□ Dose adjustment | [3361]
□ nivolumab | [3391]
□ Dosage (mg/kg) | [3392]
□ Number of administrations per cycle | [3393]
□ Number of cycles | [3394]
□ Dose adjustment | [3395]
□ perifosine | [3425]
□ Dosage (mg) | [3426]
□ Number of administrations per cycle | [3427]
□ Number of cycles | [3428]
□ Dose adjustment | [3429]
□ siltuximab | [3459]
□ Dosage (mg/kg) | [3460]
□ Number of administrations per cycle | [3461]
□ Number of cycles | [3462]
□ Dose adjustment | [3463]
□ vorinostat | [3493]
□ Dosage (mg) | [3494]
□ Number of administrations per cycle | [3495]
□ Number of cycles | [3496]
□ Dose adjustment | [3497]
□ cytosin-arabinosid | [3527]
□ Dosage (mg) | [3528]
□ Number of administrations per cycle | [3529]
□ Number of cycles | [3530]
□ Dose adjustment | [3531]
□ doxorubicin-liposomal | [3561]
□ Dosage (mg/m2) | [3562]
□ Number of administrations per cycle | [3563]
□ Number of cycles | [3564]
□ Dose adjustment | [3565]
□ lomustine | [3711]
□ Dosage (mg) | [3712]
□ Number of administrations per cycle | [3713]
□ Number of cycles | [3714]
□ carmustine | [3745]
□ Dosage (mg) | [3746]
□ Number of administrations per cycle | [3747]
□ Number of cycles | [3748]

□ cytarabine | [3779]
□ Dosage (mg) | [3780]
□ Route of administration | [3813]
□ Number of administrations per cycle | [3781]
□ Number of cycles | [3782]
□ methotrexat | [3815]
□ Dosage (mg) | [3816]
□ Route of administration | [3849]
□ Number of administrations per cycle | [3817]
□ Number of cycles | [3818]
□ vinorelbini-ditartras | [3851]
□ Dosage (mg) | [3852]
□ Number of administrations per cycle | [3853]
□ Number of cycles | [3854]
□ epirubicin-hydrochloride | [3885]
□ Dosage (mg) | [3886]
□ Number of administrations per cycle | [3887]
□ Number of cycles | [3888]
□ ifosfamide | [3919]
□ Dosage (mg) | [3920]
□ Number of administrations per cycle | [3921]
□ Number of cycles | [3922]
□ venetoclax | [3953]
□ Dosage (mg) | [3954]
□ Number of administrations per cycle | [3955]
□ Number of cycles | [3956]
□ cemiplimab | [4149]
□ Dosage (mg) | [4150]
□ Route of administration | [4185]
□ Number of administrations per cycle | [4151]
□ Number of cycles | [4152]
□ Dose adjustment | [4153]
□ belantamab mafodotin | [4462]
□ Dosage (mg/kg) | [4463]
□ Route of administration | [4498]
□ Number of administrations per cycle | [4464]
□ Number of cycles | [4465]
□ Dose adjustment | [4466]
□ SAR442085 | [4624]
□ Dosage (mg) | [4625]
□ Number of administrations per cycle | [4626]
□ Number of cycles | [4627]
□ Dose adjustment | [4628]
□ iberdomide | [4953]
□ Dosage (mg) | [4954]
□ Number of administrations per cycle | [4955]

- □ Number of cycles | [4956]
- □ Dose adjustment | [4957]
- □ cevostamab | [5098]
- □ Dosage (mg) | [5099]
- □ Number of administrations per cycle | [6760]
- □ Route of administration | [5171]
- □ Number of cycles | [5101]
- □ Dose adjustment | [5102]
- □ atezolizumab | [5589]
- □ Dosage (mg) | [5590]
- □ Number of administrations per cycle | [5591]
- □ Number of cycles | [5592]
- □ talquetamab | [5627]
- □ Dosage (mg/kg) | [5628]
- □ Number of administrations per cycle | [5629]
- □ Number of cycles | [5630]
- □ Dose adjustment | [5631]
- □ elranatamab | [5665]
- □ Dosage (mg) | [5666]
- □ Number of administrations per cycle | [5667]
- □ Number of cycles | [5668]
- □ mezigdomide | [5703]
- □ Number of cycles | [5706]
- □ teclistamab | [5741]
- □ Dosage (mg/kg) | [5742]
- □ Number of administrations per cycle | [5743]
- □ Number of cycles | [5744]
- □ Dose adjustment | [5745]
- □ SAR445514 | [6783]
- □ Number of cycles | [6786]

- **Dose adjustment - lenalidomid | [117]**
  - □ Date of dose adjustment | [1276]
  - □ 1st reason | [1277]
  - □ Specify other | [1278]
  - □ Grade | [1279]
  - □ 2nd reason | [1280]
  - □ Grade | [1281]
  - □ 3rd reason | [1282]
  - □ Grade | [1283]
  - □ New dosage (mg) | [1284]
  - □ Dose interruption | [4041]
  - □ Number of administrations per cycle | [5507]
- **Dose adjustment - pomalidomid | [122]**
  - □ Date of dose adjustment | [1321]
  - □ 1st reason | [1322]
  - □ Specify other | [1323]

- □ Grade | [1324]
- □ 2nd reason | [1325]
- □ Grade | [1326]
- □ 3rd reason | [1327]
- □ Grade | [1328]
- □ New dosage (mg) | [1329]
- □ Dose interruption | [4042]
- □ Number of administrations per cycle | [5509]

○ **Dose adjustment - carfilzomib | [105]**

- □ Date of dose adjustment | [1168]
- □ 1st reason | [1169]
- □ Specify other | [1170]
- □ Grade | [1171]
- □ 2nd reason | [1172]
- □ Grade | [1173]
- □ 3rd reason | [1174]
- □ Grade | [1175]
- □ New dosage (mg/m2) | [1176]
- □ Dose interruption | [4043]
- □ Number of administrations per cycle | [5511]

○ **Dose adjustment - ixazomib | [114]**

- □ Date of dose adjustment | [1249]
- □ 1st reason | [1250]
- □ Specify other | [1251]
- □ Grade | [1252]
- □ 2nd reason | [1253]
- □ Grade | [1254]
- □ 3rd reason | [1255]
- □ Grade | [1256]
- □ New dosage (mg) | [1257]
- □ Dose interruption | [4044]
- □ Number of administrations per cycle | [5515]

○ **Dose adjustment - daratumumab | [108]**

- □ Date of dose adjustment | [1195]
- □ 1st reason | [1196]
- □ Specify other | [1197]
- □ Grade | [1198]
- □ 2nd reason | [1199]
- □ Grade | [1200]
- □ 3rd reason | [1201]
- □ Grade | [1202]
- □ New dosage | [1203]
- □ Units | [4663]
- □ Do you really want to enter value different from 16 mg/kg? | [4878]
- □ Dose interruption | [4045]
- □ Number of administrations per cycle | [5517]

- **Dose adjustment - elotuzumab | [111]**
  - ☐ Date of dose adjustment | [1222]
  - ☐ 1st reason | [1223]
  - ☐ Specify other | [1224]
  - ☐ Grade | [1225]
  - ☐ 2nd reason | [1226]
  - ☐ Grade | [1227]
  - ☐ 3rd reason | [1228]
  - ☐ Grade | [1229]
  - ☐ New dosage (mg/kg) | [1230]
  - ☐ Dose interruption | [4046]
  - ☐ Number of administrations per cycle | [5519]
- **Dose adjustment - panobinostat | [121]**
  - ☐ Date of dose adjustment | [1312]
  - ☐ 1st reason | [1313]
  - ☐ Specify other | [1314]
  - ☐ Grade | [1315]
  - ☐ 2nd reason | [1316]
  - ☐ Grade | [1317]
  - ☐ 3rd reason | [1318]
  - ☐ Grade | [1319]
  - ☐ New dosage (mg) | [1320]
  - ☐ Dose interruption | [4047]
  - ☐ Number of administrations per cycle | [5521]
- **Dose adjustment - rituximab | [124]**
  - ☐ Date of dose adjustment | [1339]
  - ☐ 1st reason | [1340]
  - ☐ Specify other | [1341]
  - ☐ Grade | [1342]
  - ☐ 2nd reason | [1343]
  - ☐ Grade | [1344]
  - ☐ 3rd reason | [1345]
  - ☐ Grade | [1346]
  - ☐ New dosage (mg/m2) | [1347]
  - ☐ Dose interruption | [4048]
  - ☐ Number of administrations per cycle | [5523]
- **Dose adjustment - ibrutinib | [279]**
  - ☐ Date of dose adjustment | [3105]
  - ☐ 1st reason | [3106]
  - ☐ Specify other | [3107]
  - ☐ Grade | [3108]
  - ☐ 2nd reason | [3109]
  - ☐ Grade | [3110]
  - ☐ 3rd reason | [3111]
  - ☐ Grade | [3112]
  - ☐ New dosage (mg) | [3113]

- ☐ Dose interruption | [4049]
- ☐ Number of administrations per cycle | [5525]

- **Dose adjustment - isatuximab | [280]**
  - ☐ Date of dose adjustment | [3114]
  - ☐ 1st reason | [3115]
  - ☐ Specify other | [3116]
  - ☐ Grade | [3117]
  - ☐ 2nd reason | [3118]
  - ☐ Grade | [3119]
  - ☐ 3rd reason | [3120]
  - ☐ Grade | [3121]
  - ☐ New dosage | [3122]
  - ☐ Units | [5796]
  - ☐ Do you really want to enter value different from 10 mg/kg? | [5797]
  - ☐ Dose interruption | [4050]
  - ☐ Number of administrations per cycle | [5527]
- **Dose adjustment - selinexor | [281]**
  - ☐ Date of dose adjustment | [3123]
  - ☐ 1st reason | [3124]
  - ☐ Specify other | [3125]
  - ☐ Grade | [3126]
  - ☐ 2nd reason | [3127]
  - ☐ Grade | [3128]
  - ☐ 3rd reason | [3129]
  - ☐ Grade | [3130]
  - ☐ New dosage (mg) | [3131]
  - ☐ Dose interruption | [4051]
  - ☐ Number of administrations per cycle | [5529]
- **Dose adjustment - cobimetinib | [292]**
  - ☐ Date of dose adjustment | [3192]
  - ☐ 1st reason | [3193]
  - ☐ Specify other | [3194]
  - ☐ Grade | [3195]
  - ☐ 2nd reason | [3196]
  - ☐ Grade | [3197]
  - ☐ 3rd reason | [3198]
  - ☐ Grade | [3199]
  - ☐ New dosage (mg) | [3200]
  - ☐ Dose interruption | [4052]
  - ☐ Number of administrations per cycle | [5531]
- **Dose adjustment - masitinib | [293]**
  - ☐ Date of dose adjustment | [3226]
  - ☐ 1st reason | [3227]
  - ☐ Specify other | [3228]
  - ☐ Grade | [3229]
  - ☐ 2nd reason | [3230]

- □ Grade | [3231]
- □ 3rd reason | [3232]
- □ Grade | [3233]
- □ New dosage (mg/kg) | [3234]
- □ Dose interruption | [4053]
- □ Number of administrations per cycle | [5533]

○ **Dose adjustment - interferon alfa-2b | [294]**

- □ Date of dose adjustment | [3260]
- □ 1st reason | [3261]
- □ Specify other | [3262]
- □ Grade | [3263]
- □ 2nd reason | [3264]
- □ Grade | [3265]
- □ 3rd reason | [3266]
- □ Grade | [3267]
- □ New dosage (MIU) | [3268]
- □ Dose interruption | [4054]
- □ Number of administrations per cycle | [5535]

○ **Dose adjustment - denosumab | [295]**

- □ Date of dose adjustment | [3294]
- □ 1st reason | [3295]
- □ Specify other | [3296]
- □ Grade | [3297]
- □ 2nd reason | [3298]
- □ Grade | [3299]
- □ 3rd reason | [3300]
- □ Grade | [3301]
- □ New dosage (mg) | [3302]
- □ Dose interruption | [4055]
- □ Number of administrations per cycle | [5537]

○ **Dose adjustment - plitidepsin | [296]**

- □ Date of dose adjustment | [3328]
- □ 1st reason | [3329]
- □ Specify other | [3330]
- □ Grade | [3331]
- □ 2nd reason | [3332]
- □ Grade | [3333]
- □ 3rd reason | [3334]
- □ Grade | [3335]
- □ New dosage (mg/m2) | [3336]
- □ Dose interruption | [4056]
- □ Number of administrations per cycle | [5539]

○ **Dose adjustment - melflufen | [297]**

- □ Date of dose adjustment | [3362]
- □ 1st reason | [3363]
- □ Specify other | [3364]

- □ Grade | [3365]
- □ 2nd reason | [3366]
- □ Grade | [3367]
- □ 3rd reason | [3368]
- □ Grade | [3369]
- □ New dosage (mg) | [3370]
- □ Dose interruption | [4057]
- □ Number of administrations per cycle | [5541]

○ **Dose adjustment - nivolumab | [298]**

- □ Date of dose adjustment | [3396]
- □ 1st reason | [3397]
- □ Specify other | [3398]
- □ Grade | [3399]
- □ 2nd reason | [3400]
- □ Grade | [3401]
- □ 3rd reason | [3402]
- □ Grade | [3403]
- □ New dosage (mg/kg) | [3404]
- □ Dose interruption | [4058]
- □ Number of administrations per cycle | [5543]

○ **Dose adjustment - perifosine | [299]**

- □ Date of dose adjustment | [3430]
- □ 1st reason | [3431]
- □ Specify other | [3432]
- □ Grade | [3433]
- □ 2nd reason | [3434]
- □ Grade | [3435]
- □ 3rd reason | [3436]
- □ Grade | [3437]
- □ New dosage (mg) | [3438]
- □ Dose interruption | [4059]
- □ Number of administrations per cycle | [5545]

○ **Dose adjustment - siltuximab | [300]**

- □ Date of dose adjustment | [3464]
- □ 1st reason | [3465]
- □ Specify other | [3466]
- □ Grade | [3467]
- □ 2nd reason | [3468]
- □ Grade | [3469]
- □ 3rd reason | [3470]
- □ Grade | [3471]
- □ New dosage (mg/kg) | [3472]
- □ Dose interruption | [4060]
- □ Number of administrations per cycle | [5547]

○ **Dose adjustment - vorinostat | [301]**

- □ Date of dose adjustment | [3498]

- □ 1st reason | [3499]
- □ Specify other | [3500]
- □ Grade | [3501]
- □ 2nd reason | [3502]
- □ Grade | [3503]
- □ 3rd reason | [3504]
- □ Grade | [3505]
- □ New dosage (mg) | [3506]
- □ Dose interruption | [4061]
- □ Number of administrations per cycle | [5549]

○ **Dose adjustment - cytosin-arabinosid | [302]**

- □ Date of dose adjustment | [3532]
- □ 1st reason | [3533]
- □ Specify other | [3534]
- □ Grade | [3535]
- □ 2nd reason | [3536]
- □ Grade | [3537]
- □ 3rd reason | [3538]
- □ Grade | [3539]
- □ New dosage (mg) | [3540]
- □ Dose interruption | [4062]
- □ Number of administrations per cycle | [5551]

○ **Dose adjustment - doxorubicin-liposomal | [303]**

- □ Date of dose adjustment | [3566]
- □ 1st reason | [3567]
- □ Specify other | [3568]
- □ Grade | [3569]
- □ 2nd reason | [3570]
- □ Grade | [3571]
- □ 3rd reason | [3572]
- □ Grade | [3573]
- □ New dosage (mg/m2) | [3574]
- □ Dose interruption | [4063]
- □ Number of administrations per cycle | [5553]

○ **Dose adjustment - cemiplimab | [329]**

- □ Date of dose adjustment | [4154]
- □ 1st reason | [4155]
- □ Specify other | [4156]
- □ Grade | [4157]
- □ 2nd reason | [4158]
- □ Grade | [4159]
- □ 3rd reason | [4160]
- □ Grade | [4161]
- □ New dosage (mg) | [4162]
- □ Dose interruption | [4163]
- □ Number of administrations per cycle | [5555]

- **Dose adjustment - belantamab mafodotin | [358]**
  - ☐ Date of dose adjustment | [4467]
  - ☐ 1st reason | [4468]
  - ☐ Specify other | [4469]
  - ☐ Grade | [4470]
  - ☐ 2nd reason | [4471]
  - ☐ Grade | [4472]
  - ☐ 3rd reason | [4473]
  - ☐ Grade | [4474]
  - ☐ New dosage (mg/kg) | [4475]
  - ☐ Dose interruption | [4476]
  - ☐ Number of administrations per cycle | [5557]
- **Drugs - overview of total cumulative doses | [127]**
  - ☐ bortezomib | [2424]
  - ☐ Total number of administrations | [1368]
  - ☐ Total cumulative dosage (mg) | [1369]
  - ☐ carfilzomib | [2426]
  - ☐ Total number of administrations | [1372]
  - ☐ Total cumulative dosage (mg) | [1373]
  - ☐ daratumumab | [2429]
  - ☐ Total number of administrations | [1379]
  - ☐ Total cumulative dosage (mg) | [1378]
  - ☐ Total number of intravenous administrations | [4666]
  - ☐ Total number of subcutaneous administrations | [4667]
  - ☐ Total cumulative intravenous dosage (mg) | [4668]
  - ☐ Total cumulative subcutaneous dosage (mg) | [4669]
  - ☐ In case of route of administration intravenous and change to subcutaneous or subcutaneous and change to intravenous please fill in the total number of administration and total cumulative dosage for every route of administration separately. These values will be automatically added up and filled in the questions Total number of administrations and Total comulative dosage (mg). | [4670]
  - ☐ dexamethason | [2430]
  - ☐ Total number of administrations | [1380]
  - ☐ Total cumulative dosage (mg) | [1381]
  - ☐ elotuzumab | [2432]
  - ☐ Total number of administrations | [1384]
  - ☐ Total cumulative dosage (mg) | [1385]
  - ☐ ixazomib | [2435]
  - ☐ Total number of administrations | [1392]
  - ☐ Total cumulative dosage (mg) | [1393]
  - ☐ lenalidomid | [2436]
  - ☐ Total number of administrations | [1394]
  - ☐ Total cumulative dosage (mg) | [1395]
  - ☐ panobinostat | [2439]
  - ☐ Total number of administrations | [1402]
  - ☐ Total cumulative dosage (mg) | [1403]
  - ☐ pomalidomid | [2440]

□ Total number of administrations | [1404]
□ Total cumulative dosage (mg) | [1405]
□ rituximab | [2442]
□ Total number of administrations | [1408]
□ Total cumulative dosage (mg) | [1409]
□ ibrutinib | [3162]
□ Total number of administrations | [3163]
□ Total cumulative dosage (mg) | [3164]
□ isatuximab | [3165]
□ Total number of administrations | [3166]
□ Total cumulative dosage (mg) | [3167]
□ Total number of intravenous administrations | [5798]
□ Total number of subcutaneous administrations | [5799]
□ Total cumulative intravenous dosage (mg) | [5800]
□ Total cumulative subcutaneous dosage (mg) | [5801]
□ In case of route of administration intravenous and change to subcutaneous or subcutaneous and change to intravenous please fill in the total number of administration and total cumulative dosage for every route of administration separately. These values will be automatically added up and filled in the questions Total number of administrations and Total comulative dosage (mg). | [5802]
□ selinexor | [3168]
□ Total number of administrations | [3169]
□ Total cumulative dosage (mg) | [3170]
□ cobimetinib | [3201]
□ Total number of administrations | [3202]
□ Total cumulative dosage (mg) | [3203]
□ masitinib | [3235]
□ Total number of administrations | [3236]
□ Total cumulative dosage (mg) | [3237]
□ denosumab | [3303]
□ Total number of administrations | [3304]
□ Total cumulative dosage (mg) | [3305]
□ plitidepsin | [3337]
□ Total number of administrations | [3338]
□ Total cumulative dosage (mg) | [3339]
□ melflufen | [3371]
□ Total number of administrations | [3372]
□ Total cumulative dosage (mg) | [3373]
□ nivolumab | [3405]
□ Total number of administrations | [3406]
□ Total cumulative dosage (mg) | [3407]
□ perifosine | [3439]
□ Total number of administrations | [3440]
□ Total cumulative dosage (mg) | [3441]
□ siltuximab | [3473]
□ Total number of administrations | [3474]
□ Total cumulative dosage (mg) | [3475]

- □ vorinostat | [3507]
- □ Total number of administrations | [3508]
- □ Total cumulative dosage (mg) | [3509]
- □ venetoclax | [3967]
- □ Total number of administrations | [3968]
- □ Total cumulative dosage (mg) | [3969]
- □ cemiplimab | [4164]
- □ Total number of administrations | [4165]
- □ Total cumulative dosage (mg) | [4166]
- □ belantamab mafodotin | [4477]
- □ Total number of administrations | [4478]
- □ Total cumulative dosage (mg) | [4479]
- □ SAR442085 | [4639]
- □ Total number of administrations | [4640]
- □ Total cumulative dosage (mg) | [4641]
- □ atezolizumab | [5605]
- □ Total number of administrations | [5606]
- □ Total cumulative dosage (mg) | [5607]
- □ talquetamab | [5643]
- □ Total number of administrations | [5644]
- □ Total cumulative dosage (mg) | [5645]
- □ elranatamab | [5681]
- □ Total number of administrations | [5682]
- □ Total cumulative dosage (mg) | [5683]
- □ teclistamab | [5757]
- □ Total number of administrations | [5758]
- □ Total cumulative dosage (mg) | [5759]
- □ cevostamab | [6821]
- □ Total number of administrations | [6822]
- □ Total cumulative dosage (mg) | [6823]

- ○ **Toxicity before treatment | [131]**
  - □ Grade of thrombocytopenia before treatment | [1437]
  - □ Grade of neuropathy before treatment | [1438]
- ○ **Toxicity during treatment | [132]**
  - □ Neuropathy - grade | [1439]
  - □ Related | [1440]
  - □ Nausea, vomiting - grade | [1441]
  - □ Related | [1442]
  - □ Anorexia - grade | [1443]
  - □ Related | [1444]
  - □ Diarrhoea - grade | [1445]
  - □ Related | [1446]
  - □ Constipation - grade | [1447]
  - □ Related | [1448]
  - □ Fatigue - grade | [1449]
  - □ Related | [1450]

□ Thrombosis/Thrombus/Embolism - grade | [1451]
□ Related | [1452]
□ Infection - grade | [1453]
□ Related | [1454]
□ Thrombocytopenia - grade | [1455]
□ Related | [1456]
□ Neutropenia - grade | [1457]
□ Related | [1458]
□ Anemia - grade | [1459]
□ Related | [1460]
□ Rash (exanthema) - grade | [4024]
□ Related | [4025]
□ IRR (infusion related reaction) - grade | [4207]
□ Related | [4208]
□ Dyspnoe - grade | [4367]
□ Decompensated diabetes mellitus - grade | [4369]
□ Related | [4368]
□ Related | [4370]
□ Hepatotoxicity - grade | [4371]
□ Related | [4372]
□ Cytokine release syndrom (CRS) - grade | [5457]
□ Related | [5458]
□ ICANS - grade | [5459]
□ Related | [5460]
□ Hemophagocytic lymphohistiocytosis - grade | [5461]
□ Related | [5462]
□ Pneumotoxicity - grade | [5463]
□ Related | [5464]
□ Keratopathy - grade | [5465]
□ Related | [5467]
□ Nail changes - grade | [5466]
□ Related | [5468]
□ Palmar/plantar desquamations - grade | [5469]
□ Related | [5470]
□ Headache – grade | [5471]
□ Related | [5472]
□ Hypogammaglobulinemia - grade | [5910]
□ Related | [6237]
□ Leukopenia - grade | [5916]
□ Related | [6238]
□ Lymfopenia - grade | [5917]
□ Related | [6239]
□ Hyponatremia - grade | [5918]
□ Related | [6240]
□ Hypofibrinogenemia - grade | [5919]
□ Related | [6241]

- ☐ Other neurotoxicity - grade | [5921]
- ☐ Related | [6242]
- ☐ Renal toxicity - grade | [5926]
- ☐ Related | [6243]
- ☐ Cardiotoxicity - grade | [5928]
- ☐ Related | [6244]
- ☐ CMV reactivation - grade | [5929]
- ☐ Related | [6245]
- ☐ Other unexpected toxicity | [4379]

○ **Other toxicity | [341]**

- ☐ Specify toxicity | [4380]
- ☐ Specify other toxicity | [4387]
- ☐ Grade of toxicity | [4381]
- ☐ Related | [4382]

○ **Venous thromboembolism prevention (VTE prevention) | [133]**

- ☐ VTE prevention | [1468]
- ☐ Type of VTE prevention | [4506]
- ☐ Acetylsalicylic acid | [4338]
- ☐ Warfarin | [4339]
- ☐ LMWH | [4340]
- ☐ NOAC | [4341]
- ☐ Other | [4342]
- ☐ Specify anticoagulant treatment | [1470]

○ **Laboratory examination after treatment | [130]**

- ☐ Serum M-protein level after treatment (g/l) | [1425]
- ☐ Cannot be measured | [4095]
- ☐ Urine M-protein level after treatment (mg/24h) | [1426]
- ☐ Urine M-protein level after treatment (mg/l per 24h) | [1427]
- ☐ Serum M-protein - ratio after treatment/entry (%) | [1428]
- ☐ Urine M-protein (mg/24h) - ratio after treatment/entry (%) | [1429]
- ☐ Urine M-protein (mg/l per 24h) - ratio after treatment/entry (%) | [1430]
- ☐ Immunofixation after treatment - serum | [1431]
- ☐ Immunofixation after treatment - urine | [1432]
- ☐ Plasmocyte count (%) in bone marrow aspiration after treatment | [4235]
- ☐ Plasmocyte count (%) in bone marrow aspiration after treatment - exact number | [1433]
- ☐ Serum kappa FLC quantity after treatment (mg/l) | [4232]
- ☐ Serum lambda FLC quantity after treatment (mg/l) | [4233]
- ☐ Kappa/lambda ratio after treatment | [4234]
- ☐ Kappa/lambda ratio after treatment | [1436]

○ **Radiotherapy | [128]**

- ☐ Radiotherapy | [1414]
- ☐ Type of radiotherapy | [1415]
- ☐ Total dose [Gy] | [1416]

○ **Transplantation | [129]**

- ☐ Transplantation | [1417]

- ☐ Response before transplant | [1423]
- ☐ Date of transplantation | [1418]
- ☐ Transplantation technique | [1419]
- ☐ Type of conditioning regimen | [1420]
- ☐ Tandem autotransplantation - identical dosage? | [1421]
- ☐ Second conditioning regimen type | [1422]
- ☐ Date of subsequent transplant | [1424]

○ **Treatment withdrawal | [178]**

- ☐ Date of treatment withdrawal | [1937]
- ☐ Reason for treatment withdrawal | [1938]
- ☐ Specify other reason | [1939]
- ☐ Interruption of treatment | [1959]

○ **Interruption of treatment | [179]**

- ☐ Date of interruption | [1960]
- ☐ 1st reason | [1963]
- ☐ Specify other | [1964]
- ☐ Grade | [1965]
- ☐ 2nd reason | [1966]
- ☐ Grade | [1967]
- ☐ 3rd reason | [1968]
- ☐ Grade | [1969]

○ **Response to induction treatment | [266]**

- ☐ PR after cycle | [1942]
- ☐ Date of partial response (for DOR calculation) | [1948]
- ☐ Maximal response after cycle | [2830]
- ☐ Date of maximal response | [1949]
- ☐ Maximal response to treatment | [2827]
- ☐ Final response after induction therapy | [3178]

○ **MRD evaluation | [332]**

- ☐ MRD evaluation | [3987]

○ **MRD evaluation - specification | [318]**

- ☐ Response in time of MRD | [4213]
- ☐ Method | [3988]
- ☐ Date of MRD | [3989]
- ☐ Result of MRD | [3990]
- ☐ PET/CT, PET/MRI evaluation | [5365]
- ☐ Total number of FDG+ focuses | [5324]
- ☐ Deauville score | [5326]
- ☐ FDG+ focuses - skeleton | [5349]
- ☐ Skull | [5325]
- ☐ Axial skeleton | [5327]
- ☐ Appendicular skeleton | [5344]
- ☐ Fractures | [5345]
- ☐ New focuses | [5328]
- ☐ Number of PM lesions | [5330]
- ☐ Deauville score | [5339]

- □ Localization of PM lesions | [5338]
- □ Skull | [5350]
- □ Axial skeleton | [5351]
- □ Appendicular skeleton | [5352]
- □ New focuses | [5342]
- □ Number of EM lesions | [5334]
- □ Deauville score | [5329]
- □ Localization of EM lesions | [5347]
- □ Skin | [5353]
- □ Muscles | [5354]
- □ Connective tissue | [5355]
- □ Parenchymatous organs | [5356]
- □ CNS | [5363]
- □ Other | [5357]
- □ New focuses | [5343]
- □ FDG+ lymph nodes | [5336]
- □ Deauville score | [5341]
- □ New focuses | [5331]
- □ Bone marrow | [5348]
- □ Deauville score | [5340]
- □ CT: lytic focuses - skeleton | [5337]
- □ Localization of lytic focuses | [5364]
- □ Skull | [5358]
- □ Axial skeleton | [5359]
- □ Appendicular skeleton | [5360]
- □ New focuses | [5332]
- □ Other lesions - skeleton (FDG-) | [5346]
- □ Lesions <5 mm | [5361]
- □ Fractures | [5362]
- □ New focuses | [5333]
- □ | [5335]
- □ Sensitivity | [3991]
- □ Grade | [3992]
- □ Limit of detection (LOD) (%) | [4365]
- □ Level (%) | [4366]

- ○ **Consolidation treatment | [180]**
  - □ Consolidation treatment (! except for PBSCT) | [1970]
  - □ Specify consolidation treatment | [1971]
  - □ Specify other treatment | [1972]
  - □ Date of treatment initiation | [1973]
  - □ Date of treatment withdrawal | [1974]
  - □ Reason for treatment withdrawal | [1975]
  - □ Number of cycles | [1976]
  - □ Maximal response | [1977]
  - □ Date of maximal response | [3689]
- ○ **Consolidation treatment - adverse events | [181]**

□ Toxicity | [1978]
□ Specify other | [1979]
□ Grade | [1980]

- **Maintenance therapy | [357]**
  - □ Maintenance therapy | [1981]
  - □ Specify maintenance therapy | [4460]
  - □ Specify other treatment | [1983]
  - □ Treatment beginning date | [1984]
  - □ Date of treatment withdrawal | [1985]
  - □ Reason for treatment withdrawal | [1986]
  - □ Specify other reason | [4319]
  - □ Maximal response | [1987]
  - □ Date of maximal response | [3688]
- **Maintenance therapy - adverse events | [183]**
  - □ Toxicity | [1988]
  - □ Specify other | [1989]
  - □ Grade | [1990]
- **Response after treatment line | [356]**
  - □ Final response after treatment line | [3180]
- **| [389]**
  - □ Form is fully filled | [4876]

- **Watch and wait | [39]**
  - **After line of treatment | [347]**
    - □ After line | [4429]
  - **Progression | [348]**
    - □ Date of progression | [4430]
- **Current status | [38]**
  - **SMM development | [350]**
    - □ Progression SMM to | [4433]
    - □ Further specification | [4434]
    - □ Date of SMM progression | [4435]
    - □ Last date when patient was without progression | [4436]
  - **Current status | [351]**

□ EN: Do not fill in the date of form update! Fill in the date of last examination, to which „patient status“ below is related. In case of the answer „Unknown“ fill in the date of the last contact with the patient, do not fill in the date of loss of follow-up, because in this case data cannot be used for calculation of patient´s survival. CZ: Do otázky nezapisujte datum vyplnění formuláře! Zapište datum poslední kontroly pacienta, ke které se vztahuje stav pacienta v otázce níže. I v případě „Unknown“ nechávejte v otázce datum posledního kontaktu s pacientem a nepřepisujte jej na datum, ke kterému je pacient ztracen se sledování. Data pak nelze použít k výpočtu přežití pacienta. | [4437]

□ Date of the last update | [4438]
□ Patient status | [4439]
□ Patient status - alive | [4440]
□ Date of death | [4441]
□ Date of diagnosis | [4442]
□ Get data! | [4443]

□ Date of diagnosis for transfer from Diagnostics forms is empty. | [4444]

□ OS (days) | [4445]

□ Cause of death | [4446]

□ Note | [4447]

- **Covid-19 | [33]**
  - **Record of COVID-19 infection for RMG | [335]**

□ Date of COVID-19 diagnosis | [4236]

□ Test used | [4237]

□ PCR | [4238]

□ Antigen test | [4348]

□ Tested material | [4240]

□ Bronchoalveolar lavage (fluid) | [4280]

□ Nasopharyngeal swab | [4281]

□ Throat swab | [4282]

□ Other material | [4283]

□ Specify other tested material | [4241]

□ Course of infection | [4242]

□ Symptoms * Choose any one or more of the following checkboxes: | [4243]

□ Fever > 37 °C | [4244]

□ Cough | [4245]

□ Shortness of breath or difficulty breathing | [4246]

□ Chills | [4247]

□ Muscle or joint pains | [4248]

□ Headache | [4249]

□ Sore throat | [4250]

□ New loss of taste or smell | [4251]

□ „Covid toe“ (itchy rash on toes) | [4252]

□ Nausea/vomiting | [4349]

□ Diarrhoea | [4350]

□ Neuropathy | [4351]

□ Neurologic symptoms | [4352]

□ Other | [4353]

□ Specify other | [4354]

□ Severity | [4253]

□ Hospitalization | [4254]

□ Type of hospitalization | [4255]

□ Standard department | [4284]

□ Intensive care unit | [4285]

□ Length of hospitalization (days) | [4256]

□ Breath support | [4257]

□ Without support | [4286]

□ AIRVO or non-invasive LV | [4287]

□ ALV | [4288]

□ ECMO | [4289]

□ Oxygen | [4290]

- □ Treatment used | [4258]
- □ Without treatment | [4291]
- □ Convalescent plasma | [4292]
- □ Lopinavir + ritonavir | [4293]
- □ Favipiravir | [4294]
- □ Hydroxychloroquine + clarithromycin | [4295]
- □ Remdesivir | [4296]
- □ Other treatment | [4297]
- □ Specify other treatment | [4298]
- □ Date of negative test | [4259]
- □ Length of positivity (days) | [4260]
- □ Antibody test performed | [4261]
- □ Comorbidities | [4278]
- □ * Choose any one or more of the following checkboxes: | [4264]
- □ Diabetes mellitus | [4265]
- □ Heart disease | [4266]
- □ Hypertension | [4267]
- □ Lung disease | [4268]
- □ Obesity (BMI > 30) | [4269]
- □ Other comorbidity | [4270]
- □ Specify other comorbidity | [4271]
- □ Bacterial superinfection | [4272]
- □ Specify type of bacterial superinfection | [4273]
- □ Relation to neutropenia < 0.5 | [4274]
- □ Thrombotic complications during COVID-19 infection | [4275]
- □ Specify complications | [4276]
- □ Final state | [4277]

- **Antibody detection | [336]**
  - □ Date of test | [4262]
  - □ Antibody detected? | [4263]
  - □ Time from diagnosis | [4299]
- **| [389]**
  - □ Form is fully filled | [4876]

- **Covid-19 vaccination | [35]**
  - **Covid-19 vaccination | [340]**
    - □ Vaccination date (1st dose) | [4355]
    - □ Received as scheduled (all doses) | [4356]
    - □ Vaccine type | [4357]
    - □ Specify other vaccine | [4358]
    - □ Antibody test performed | [4359]
    - □ Date of antibody test | [4360]
    - □ Result (IgG) | [4361]
    - □ Serum virus neutralization test performed | [4362]
    - □ Date of test | [4363]
    - □ Result | [4364]
  - **| [389]**

□ Form is fully filled | [4876]

- **MM | [4]**
  - **Diagnostics | [16]**
    - **Diagnostics | [78]**
      - □ Previous history of MGUS | [870]
      - □ Data not available | [3639]
      - □ Previous history of SMM | [4423]
      - □ Data not available | [4424]
      - □ SMM diagnosis | [871]
      - □ EN: If data in this form belong to MM diagnosis, it has to be NO in this question. If data in this form belong to SMM diagnosis, it has to be YES in this question. CZ: Pokud se data v tomto formuláři vztahují k MM diagnóze, v této otázce musí být NE. Pokud se data v tomto formuláři vztahují k SMM diagnóze, pak v této otázce musí být ANO. | [4425]
      - □ History of solitary plasmacytoma | [873]
      - □ Polyneuropathy in medical history | [874]
      - □ Date of MM diagnosis | [875]
      - □ WHO ECOG | [876]
    - **Transfer data from Laboratory values form | [386]**
      - □ Date and time of examination and ID of Laboratory values form | [4864]
    - **Laboratory examination | [79]**
      - □ M-protein type | [877]
      - □ M-protein type 1 | [4883]
      - □ M-protein type 2 | [4884]
      - □ M-protein type 3 | [4885]
      - □ Serum M-protein quantity 1 (g/l) | [4886]
      - □ Serum M-protein quantity 2 (g/l) | [4887]
      - □ Serum M-protein quantity 3 (g/l) | [4888]
      - □ Serum M-protein quantity (g/l) | [878]
      - □ Cannot be measured | [879]
      - □ Urine M-protein quantity (mg/24h) | [880]
      - □ Urine M-protein quantity (mg/l per 24h) | [881]
      - □ FLC quantity measured | [882]
      - □ Serum kappa FLC quantity (mg/l) | [884]
      - □ Serum lambda FLC quantity (mg/l) | [883]
      - □ Kappa/lambda ratio | [885]
      - □ Light chain type | [886]
      - □ IgG quantity (g/l) | [887]
      - □ IgA quantity (g/l) | [888]
      - □ IgM quantity (g/l) | [889]
    - **Bone marrow examination | [80]**
      - □ Bone marrow aspiration cytology | [897]
      - □ Plasmocyte count by cytology (%) | [898]
      - □ Bone marrow histology | [895]
      - □ Monoclonal plasmocyte count (%) by histology | [896]
    - **Flow cytometry | [83]**
      - □ Flow cytometry – plasma cells (bone marrow) | [925]

- ☐ Plasmocyte count FC (%) | [926]
- ☐ Clonal PC (%) | [931]
- ☐ Polyclonal PC (%) | [932]
- ☐ Flow cytometry – circulating plasma cells (peripheral blood) | [4868]
- ☐ cPCs (%) - peripheral blood | [4869]
- ☐ cPCs (absolute value/uL) - peripheral blood | [4870]
- ☐ Detection limit (LOD) | [4871]

○ **Biochemistry | [81]**

- ☐ Hemoglobin level (g/l) | [899]
- ☐ Thrombocyte count (10E9/l) | [900]
- ☐ Calcium total level (mmol/l) | [901]
- ☐ Albumin level (g/l) | [902]
- ☐ Creatinine level (µmol/l) | [903]
- ☐ Beta2 microglobulin (mg/l) | [904]
- ☐ LDH (µkat/l) | [905]
- ☐ CRP (mg/l) | [906]

○ **Cytogenetic | [82]**

- ☐ Cytogenetics | [3692]
- ☐ Extended FISH questionnaire | [6389]
- ☐ Date of sample collection | [908]
- ☐ Conventional (carotype) | [3693]
- ☐ Result | [3694]
- ☐ Method used | [3695]
- ☐ Purity (%) | [3696]
- ☐ t(11;14) | [910]
- ☐ t(4;14) | [912]
- ☐ t(14;16) | [916]
- ☐ t(6;14) | [914]
- ☐ t(14;20) | [6510]
- ☐ del(17)(p13) | [922]
- ☐ % | [6831]
- ☐ gain 1q21 | [920]
- ☐ % | [6832]
- ☐ amp 1q21 | [6401]
- ☐ % | [6833]
- ☐ del(1p32) | [6402]
- ☐ % | [6834]
- ☐ Cytogenetic risk | [6400]
- ☐ IGH disruption | [6403]
- ☐ * Choose at least one of the following: | [6511]
- ☐ Negative | [6405]
- ☐ Rearrangement | [6406]
- ☐ % | [6407]
- ☐ Rearrangement + CNV | [6408]
- ☐ % | [6409]
- ☐ Variant rearrangement | [6410]

□ % | [6411]
□ US aberration | [6412]
□ % | [6413]
□ Not evaluated | [6414]
□ t(4;14) | [6415]
□ * Choose at least one of the following: | [6416]
□ Negative | [6417]
□ CNV | [6418]
□ % | [6419]
□ Positive | [6420]
□ % | [6421]
□ Variant positive | [6422]
□ % | [6423]
□ Not evaluated | [6424]
□ t(11;14) | [6425]
□ * Choose at least one of the following: | [6426]
□ Negative | [6427]
□ CNV | [6428]
□ % | [6429]
□ Positive | [6430]
□ % | [6431]
□ Variant positive | [6432]
□ % | [6433]
□ Not evaluated | [6434]
□ t(14;16) | [6435]
□ * Choose at least one of the following: | [6436]
□ Negative | [6437]
□ CNV | [6438]
□ % | [6439]
□ Positive | [6440]
□ % | [6441]
□ Variant positive | [6442]
□ % | [6443]
□ Not evaluated | [6444]
□ t(6;14) | [6445]
□ * Choose at least one of the following: | [6446]
□ Negative | [6447]
□ CNV | [6448]
□ % | [6449]
□ Positive | [6450]
□ % | [6451]
□ Variant positive | [6452]
□ % | [6453]
□ Not evaluated | [6505]
□ t(14;20) | [6454]
□ * Choose at least one of the following: | [6455]

□ Negative | [6456]
□ CNV | [6457]
□ % | [6458]
□ Positive | [6459]
□ % | [6460]
□ Variant positive | [6461]
□ % | [6462]
□ Not evaluated | [6463]
□ del(17)(p13) | [6464]
□ * Choose at least one of the following: | [6465]
□ Negative | [6466]
□ Deletion/monosomy | [6467]
□ % | [6468]
□ Variant deletion | [6469]
□ % | [6470]
□ Not evaluated | [6471]
□ 1q21 | [6472]
□ * Choose at least one of the following: | [6473]
□ Negative | [6474]
□ Gain | [6475]
□ % | [6476]
□ Amp | [6477]
□ % | [6478]
□ Not evaluated | [6479]
□ del(1p32) | [6480]
□ * Choose at least one of the following: | [6481]
□ Negative | [6482]
□ Deletion | [6483]
□ % | [6484]
□ Not evaluated | [6485]
□ del(13)(q14) | [6486]
□ * Choose at least one of the following: | [6487]
□ Negative | [6488]
□ Deletion/monosomy | [6489]
□ % | [6506]
□ Variant deletion | [6490]
□ % | [6491]
□ Other | [6492]
□ % | [6493]
□ Not evaluated | [6494]
□ Hyperdiploidy | [6495]
□ * Choose at least one of the following: | [6496]
□ Negative | [6497]
□ Positive | [6498]
□ % | [6499]
□ Not evaluated | [6500]

- □ Confirmative evaluations | [6501]
- □ NGS | [6502]
- □ ArrayCGH | [6503]
- □ Optical genome mapping | [6504]

○ **Medical Imaging Modalities | [84]**

- □ At least one imaging method must be performed: | [2384]
- □ Osteolytic lesions - X-ray | [933]
- □ Osteolytic lesions - MRI | [934]
- □ Osteolytic lesions - CT | [936]
- □ Osteolytic lesions - LDCT | [935]
- □ Osteolytic lesions - PET | [937]
- □ Osteolytic lesions - PET/CT | [938]
- □ Osteolytic lesions - MIBI | [939]
- □ Osteolytic lesions - PET/MRI | [4328]

○ **PET, PET/CT, PET/MRI evaluation | [403]**

- □ Total number of FDG+ focuses | [5367]
- □ Deauville score | [5369]
- □ FDG+ focuses - skeleton | [5392]
- □ Skull | [5368]
- □ Axial skeleton | [5370]
- □ Appendicular skeleton | [5387]
- □ Fractures | [5388]
- □ New focuses | [5371]
- □ Number of PM lesions | [5373]
- □ Deauville score | [5372]
- □ Localization of PM lesions | [5381]
- □ Skull | [5393]
- □ Axial skeleton | [5394]
- □ Appendicular skeleton | [5395]
- □ New focuses | [5385]
- □ Number of EM lesions | [5377]
- □ Deauville score | [5382]
- □ Localization of EM lesions | [5390]
- □ Skin | [5396]
- □ Muscles | [5397]
- □ Connective tissue | [5398]
- □ Parenchymatous organs | [5399]
- □ CNS | [5406]
- □ Other | [5400]
- □ New focuses | [5386]
- □ FDG+ lymph nodes | [5379]
- □ Deauville score | [5384]
- □ New focuses | [5374]
- □ Bone marrow | [5391]
- □ Deauville score | [5383]
- □ CT/MRI: lytic focuses - skeleton | [5380]

□ Localization of lytic focuses | [5407]
□ Skull | [5401]
□ Axial skeleton | [5402]
□ Appendicular skeleton | [5403]
□ New focuses | [5375]
□ Other lesions - skeleton (FDG-) | [5389]
□ Lesions <5 mm | [5404]
□ Fractures | [5405]
□ New focuses | [5376]
□ | [5378]

- **MM with Extraosseous disease | [85]**
  - □ Extraosseous disease | [4895]
  - □ Extraosseous mass histology (ev. cytology) | [942]
  - □ Extraosseous disease – relation | [941]
  - □ Extramedullary lesion - localization | [4398]
  - □ * At least one localization must be chosen: | [4389]
  - □ SKIN or ORAL MUCOSE | [4393]
  - □ CONNECTIVE TISSUE (subcutaneous fat, connective tissue, articular cartilage) | [4896]
  - □ MUSCLE | [4897]
  - □ LYMPHNODES or SPLEEN | [4391]
  - □ PARENCHYMATOUS ORGANS | [4898]
  - □ Respiratory tract | [4390]
  - □ Urogenital tract | [4392]
  - □ Gastrointestinal tract | [4899]
  - □ Liver or Pancreas | [4900]
  - □ CNS (brain, spinal cord, possibly cerebrospinal fluid, including the positivity of liquor) | [4394]
  - □ Other | [4395]
  - □ Specify other | [4396]
  - □ The correctness of the extraosseous disease data was checked. | [4901]
  - □ Extramedullary lesion - counts | [943]
  - □ Paramedullary lesion - localization | [4903]
  - □ * At least one localization must be chosen: | [4904]
  - □ LIMBS | [4905]
  - □ AXIAL SKELETON | [4906]
  - □ SKULL | [4907]
  - □ Other | [4908]
  - □ Specify other | [4909]
  - □ The correctness of the extraosseous disease data was checked and the localizations located in Other were categorized. | [4910]
  - □ Paramedullary lesion – counts | [4912]
  - □ Method used for diagnosis | [4939]
  - □ * At least one method must be chosen: | [4951]
  - □ Physical examination | [4929]
  - □ X-ray | [4930]
  - □ Ultrasound | [4931]

□ Scintigraphy | [4932]
□ Whole body LD-CT | [4933]
□ HD-CT | [4934]
□ PET/CT | [4935]
□ Focused MRI | [4936]
□ Whole body MRI | [4937]
□ PET/MRI | [4938]

- **Stage | [86]**
  - □ Durie-Salmon stage | [947]
  - □ Durie-Salmon substage | [948]
  - □ One of ISS classification must be filled (manually or by calculation): | [3596]
  - □ ISS classification - calculation only | [3597]
  - □ ISS classification | [951]
  - □ R-ISS classification - calculation only | [3602]
  - □ R-ISS classification | [4615]
- **| [389]**
  - □ Form is fully filled | [4876]

- **Treatment | [18]**
  - **Line of treatment | [88]**
    - □ Line of treatment | [960]
    - □ 1st line of therapy in SMM phase | [4461]
  - **SMM | [89]**
    - □ Progression SMM to MM | [961]
    - □ Date of progression | [962]
  - **Reason for the start of the therapy | [90]**
    - □ For the new diagnosis (first line) at least one of the questions must be filled in as "Yes". | [2839]
    - □ For the second and other lines at least one of the questions must be filled in as "Yes". | [2840]
    - □ Myeloma defining events: Evidence of end organ damage that can be attributed to the underlying plasma cell Proliferative disorder, specifically: | [2813]
    - □ Hypercalcaemia: serum calcium >0.25 mmol/L (>1 mg/dL) higher than the upper limit of normal or >2.75 mmol/L (>11 mg/dL) | [963]
    - □ Renal insufficiency: creatinine clearance <40 mL per min† or serum creatinine >177 µmol/L (>2 mg/dL) | [964]
    - □ Anaemia: hemoglobin value of >20 g/L below the lower limit of normal, or a hemoglobin value <100 g/L | [965]
    - □ Bone lesions: one or more osteolytic lesions on skeletal radiography, CT, or PET-CT | [966]
    - □ At least one of the following biomarkers of malignancy must be filled in: | [2409]
    - □ Clonal bone marrow plasma cell percentage* ≥60% | [2410]
    - □ Involved: uninvolved serum free light chain ratio ≥100 | [2411]
    - □ >1 focal lesions on MRI studies | [2412]
    - □ Other | [967]
    - □ Rewritten | [2837]
    - □ Other specification | [968]
    - □ Choose any one or more of the following checkbox: | [2838]
    - □ Progression of paraprotein | [2831]

- □ FLC escape | [3595]
- □ Hyperviscosity | [2832]
- □ Extraosseous disease | [2833]
- □ ALA associated with MM | [2834]
- □ Recurrent infection | [2835]
- □ Other | [2836]

○ **Relapse/progression | [253]**

- □ Reason for treatment | [969]
- □ Date of relapse/progression | [970]
- □ Date of initiation of previous treatment line | [4301]
- □ Get data! | [4302]
- □ PFS (days) | [4303]
- □ PFS from | [4304]

○ **Performance status before treatment | [91]**

- □ WHO ECOG | [971]

○ **Transfer data from Laboratory values form | [386]**

- □ Date and time of examination and ID of Laboratory values form | [4864]

○ **Laboratory examination before treatment | [92]**

- □ M-protein type from diagnostics | [3640]
- □ Change of M-protein type? | [3641]
- □ M-protein type | [974]
- □ M-protein type 1 | [4883]
- □ M-protein type 2 | [4884]
- □ M-protein type 3 | [4885]
- □ Serum M-protein quantity 1 (g/l) | [4886]
- □ Serum M-protein quantity 2 (g/l) | [4887]
- □ Serum M-protein quantity 3 (g/l) | [4888]
- □ FLC quantity measured | [3648]
- □ Serum kappa FLC quantity (mg/l) | [3649]
- □ Serum lambda FLC quantity (mg/l) | [3650]
- □ Kappa/lambda ratio | [3651]
- □ Light chain type from diagnostics | [3644]
- □ Change of light chain type? | [3645]
- □ Light chain type | [975]
- □ M-protein entry type 1 | [5214]
- □ M-protein entry type 2 | [5215]
- □ M-protein entry type 3 | [5216]
- □ Serum M-protein entry quantity 1 (g/l) | [5217]
- □ Serum M-protein entry quantity 2 (g/l) | [5218]
- □ Serum M-protein entry quantity 3 (g/l) | [5219]
- □ Serum M-protein entry level (g/l) | [976]
- □ Cannot be measured | [2779]
- □ Urine M-protein entry level (mg/24h) | [977]
- □ Urine M-protein entry level (mg/l per 24h) | [978]

○ **Bone marrow examination before treatment | [93]**

- □ Get data from diagnostics! | [4322]

- ☐ Bone marrow aspiration cytology | [979]
- ☐ Plasmocyte count by cytology (%) | [980]
- ☐ Bone marrow histology | [981]
- ☐ Monoclonal plasmocyte count (%) by histology | [982]

○ **Flow cytometry before treatment | [96]**

- ☐ Get data from diagnostics! | [4324]
- ☐ Flow cytometry – plasma cells (bone marrow) | [993]
- ☐ Sample date | [994]
- ☐ Plasmocyte count FC (%) | [4222]
- ☐ Clonal PC (%) | [4332]
- ☐ Polyclonal PC (%) | [4333]
- ☐ Flow cytometry – circulating plasma cells (peripheral blood) | [4868]
- ☐ cPCs (%) - peripheral blood | [4869]
- ☐ cPCs (absolute value/uL) - peripheral blood | [4870]
- ☐ Detection limit (LOD) | [4871]

○ **Biochemistry before treatment | [94]**

- ☐ Get data from diagnostics! | [4323]
- ☐ Hemoglobin level (g/l) | [983]
- ☐ Thrombocyte count (10E9/l) | [984]
- ☐ Calcium total level (mmol/l) | [985]
- ☐ Albumin level (g/l) | [986]
- ☐ Creatinine level (µmol/l) | [987]
- ☐ Beta2 microglobulin (mg/l) | [988]
- ☐ LDH (µkat/l) | [989]
- ☐ CRP (mg/l) | [990]

○ **Cytogenetics before treatment | [95]**

- ☐ Cytogenetics | [3698]
- ☐ Extended FISH questionnaire | [6525]
- ☐ Date of sample collection | [992]
- ☐ Conventional (carotype) | [3699]
- ☐ Result | [3700]
- ☐ Method used | [3701]
- ☐ Purity (%) | [3702]
- ☐ t(11;14) | [3607]
- ☐ t(4;14) | [3609]
- ☐ t(14;16) | [3613]
- ☐ t(6;14) | [3611]
- ☐ t(14;20) | [6613]
- ☐ del(17)(p13) | [3619]
- ☐ % | [6835]
- ☐ gain 1q21 | [3617]
- ☐ % | [6836]
- ☐ amp 1q21 | [6542]
- ☐ % | [6837]
- ☐ del(1p32) | [6617]
- ☐ % | [6838]

□ Cytogenetic risk | [6524]
□ IGH disruption | [6526]
□ * Choose at least one of the following: | [6626]
□ Negative | [6543]
□ Rearrangement | [6544]
□ % | [6545]
□ Rearrangement + CNV | [6546]
□ % | [6547]
□ Variant rearrangement | [6529]
□ % | [6548]
□ US aberration | [6549]
□ % | [6550]
□ Not evaluated | [6551]
□ t(4;14) | [6552]
□ * Choose at least one of the following: | [6553]
□ Negative | [6554]
□ CNV | [6530]
□ % | [6534]
□ Positive | [6555]
□ % | [6531]
□ Variant positive | [6537]
□ % | [6558]
□ Not evaluated | [6623]
□ t(11;14) | [6556]
□ * Choose at least one of the following: | [6561]
□ Negative | [6541]
□ CNV | [6533]
□ % | [6557]
□ Positive | [6535]
□ % | [6536]
□ Variant positive | [6559]
□ % | [6539]
□ Not evaluated | [6540]
□ t(14;16) | [6627]
□ * Choose at least one of the following: | [6628]
□ Negative | [6563]
□ CNV | [6573]
□ % | [6575]
□ Positive | [6571]
□ % | [6562]
□ Variant positive | [6564]
□ % | [6565]
□ Not evaluated | [6560]
□ t(6;14) | [6568]
□ * Choose at least one of the following: | [6570]
□ Negative | [6572]

□ CNV | [6591]
□ % | [6593]
□ Positive | [6574]
□ % | [6576]
□ Variant positive | [6577]
□ % | [6578]
□ Not evaluated | [6566]
□ t(14;20) | [6580]
□ * Choose at least one of the following: | [6584]
□ Negative | [6583]
□ CNV | [6630]
□ % | [6631]
□ Positive | [6595]
□ % | [6597]
□ Variant positive | [6598]
□ % | [6599]
□ Not evaluated | [6596]
□ del(17)(p13) | [6603]
□ * Choose at least one of the following: | [6605]
□ Negative | [6588]
□ Deletion/monosomy | [6581]
□ % | [6585]
□ Variant deletion | [6589]
□ % | [6590]
□ Not evaluated | [6567]
□ 1q21 | [6600]
□ * Choose at least one of the following: | [6606]
□ Negative | [6604]
□ Gain | [6610]
□ % | [6612]
□ Amp | [6527]
□ % | [6528]
□ Not evaluated | [6607]
□ del(1p32) | [6587]
□ * Choose at least one of the following: | [6594]
□ Negative | [6609]
□ Deletion | [6608]
□ % | [6614]
□ Not evaluated | [6615]
□ del(13)(q14) | [6616]
□ * Choose at least one of the following: | [6618]
□ Negative | [6619]
□ Deletion/monosomy | [6620]
□ % | [6611]
□ Variant deletion | [6621]
□ % | [6622]

- □ Other | [6624]
- □ % | [6625]
- □ Not evaluated | [6582]
- □ Hyperdiploidy | [6538]
- □ * Choose at least one of the following: | [6629]
- □ Negative | [6532]
- □ Positive | [6632]
- □ % | [6569]
- □ Not evaluated | [6601]
- □ Confirmative evaluations | [6579]
- □ NGS | [6586]
- □ ArrayCGH | [6592]
- □ Optical genome mapping | [6602]

○ **Medical Imaging Modalities before treatment | [97]**

- □ Get data from diagnostics! | [4325]
- □ At least one imaging method must be performed in first line: | [2385]
- □ Osteolytic lesions - X-ray | [995]
- □ Osteolytic lesions - MRI | [996]
- □ Osteolytic lesions - CT | [997]
- □ Osteolytic lesions - LDCT | [2386]
- □ Osteolytic lesions - PET | [998]
- □ Osteolytic lesions - PET/CT | [999]
- □ Osteolytic lesions - MIBI | [1000]
- □ Osteolytic lesions - PET/MRI | [4329]

○ **PET, PET/CT, PET/MRI evaluation | [400]**

- □ Get data from diagnostics! | [5366]
- □ Total number of FDG+ focuses | [5242]
- □ Deauville score | [5244]
- □ FDG+ focuses - skeleton | [5267]
- □ Skull | [5243]
- □ Axial skeleton | [5245]
- □ Appendicular skeleton | [5262]
- □ Fractures | [5263]
- □ New focuses | [5246]
- □ Number of PM lesions | [5248]
- □ Deauville score | [5257]
- □ Localization of PM lesions | [5256]
- □ Skull | [5268]
- □ Axial skeleton | [5269]
- □ Appendicular skeleton | [5270]
- □ New focuses | [5260]
- □ Number of EM lesions | [5252]
- □ Deauville score | [5258]
- □ Localization of EM lesions | [5265]
- □ Skin | [5271]
- □ Muscles | [5272]

□ Connective tissue | [5273]
□ Parenchymatous organs | [5274]
□ CNS | [5281]
□ Other | [5275]
□ New focuses | [5261]
□ FDG+ lymph nodes | [5254]
□ Deauville score | [5259]
□ New focuses | [5249]
□ Bone marrow | [5266]
□ Deauville score | [5247]
□ CT/MRI: lytic focuses - skeleton | [5255]
□ Localization of lytic focuses | [5282]
□ Skull | [5276]
□ Axial skeleton | [5277]
□ Appendicular skeleton | [5278]
□ New focuses | [5250]
□ Other lesions - skeleton (FDG-) | [5264]
□ Lesions <5 mm | [5279]
□ Fractures | [5280]
□ New focuses | [5251]
□ | [5253]

- **MM with Extraosseous disease before treatment | [98]**
  □ Get data from diagnostics! | [4326]
  □ Extraosseous disease | [4913]
  □ Extraosseous mass histology (ev. cytology) | [1003]
  □ Extraosseous disease – relation | [1002]
  □ Extramedullary lesion - localization | [4398]
  □ * At least one localization must be chosen: | [4389]
  □ SKIN or ORAL MUCOSE | [4393]
  □ CONNECTIVE TISSUE (subcutaneous fat, connective tissue, articular cartilage) | [4896]
  □ MUSCLE | [4897]
  □ LYMPHNODES or SPLEEN | [4391]
  □ PARENCHYMATOUS ORGANS | [4898]
  □ Respiratory tract | [4390]
  □ Urogenital tract | [4392]
  □ Gastrointestinal tract | [4899]
  □ Liver or Pancreas | [4900]
  □ CNS (brain, spinal cord, possibly cerebrospinal fluid, including the positivity of liquor) | [4394]
  □ Other | [4395]
  □ Specify other | [4396]
  □ The correctness of the extraosseous disease data was checked. | [4901]
  □ Extramedullary lesion – counts | [1004]
  □ Paramedullary lesion - localization | [4903]
  □ * At least one localization must be chosen: | [4904]

- ☐ LIMBS | [4905]
- ☐ AXIAL SKELETON | [4906]
- ☐ SKULL | [4907]
- ☐ Other | [4908]
- ☐ Specify other | [4909]
- ☐ The correctness of the extraosseous disease data was checked and the localizations located in Other were categorized. | [4910]
- ☐ Paramedullary lesion – counts | [4914]
- ☐ Method used for diagnosis | [4939]
- ☐ * At least one method must be chosen: | [4951]
- ☐ Physical examination | [4929]
- ☐ X-ray | [4930]
- ☐ Ultrasound | [4931]
- ☐ Scintigraphy | [4932]
- ☐ Whole body LD-CT | [4933]
- ☐ HD-CT | [4934]
- ☐ PET/CT | [4935]
- ☐ Focused MRI | [4936]
- ☐ Whole body MRI | [4937]
- ☐ PET/MRI | [4938]

- **Stage before treatment | [99]**
  - ☐ Get data from diagnostics! | [4327]
  - ☐ Durie-Salmon stage | [1008]
  - ☐ Durie-Salmon substage | [1009]
  - ☐ ISS classification - calculation only | [3599]
  - ☐ ISS classification | [1010]
  - ☐ R-ISS classification - calculation only | [3603]
  - ☐ R-ISS classification | [4616]
- **Toxicity before treatment | [131]**
  - ☐ Grade of thrombocytopenia before treatment | [1437]
  - ☐ Grade of neuropathy before treatment | [1438]
- **Treatment | [100]**
  - ☐ CAR-T therapy | [5816]
  - ☐ Extended questionnaire | [5817]
  - ☐ Date of approval by the health insurance company | [5847]
  - ☐ Source of cells | [5818]
  - ☐ Date of apheresis | [5848]
  - ☐ Treatment before CAR-T infusion | [5819]
  - ☐ Treatment regimen | [1011]
  - ☐ Specify combination of 6 or more drugs | [3690]
  - ☐ Uncategorizable treatment specification | [1014]
  - ☐ Rewritten | [2800]
  - ☐ Health insurance company | [1015]
  - ☐ Clinical study | [1016]
  - ☐ Name of clinical study | [1017]
  - ☐ Specification name of other | [1018]
  - ☐ Double blinded study | [3177]

□ Specification of clinical study | [3657]
□ Length of cycle (days) | [1019]
□ Date of treatment initiation | [1020]
□ Hide toxicity and dosage | [4681]
□ Response before CAR-T cells infusion | [5820]
□ Lymphodepleting chemotherapy before CAR-T | [5821]
□ Specify other | [5822]
□ Date of initiation of lymphodepleting chemotherapy | [5849]
□ CAR-T product | [5823]
□ Date of CAR-T cells infusion | [5824]
□ Dose of CAR-T cells (x106 CAR-T/kg) | [5850]
□ Number of CAR-T cells (cells/µL) | [6182]
□ Day 7 | [6183]
□ Limit of detection (LOD) | [6184]
□ Day 14 | [6185]
□ Limit of detection (LOD) | [6186]
□ Day 21 | [6187]
□ Limit of detection (LOD) | [6188]
□ Month 1 | [6189]
□ Limit of detection (LOD) | [6190]
□ Month 2 | [6191]
□ Limit of detection (LOD) | [6192]
□ Month 3 | [6193]
□ Limit of detection (LOD) | [6194]
□ Month 6 | [6195]
□ Limit of detection (LOD) | [6196]
□ Month 9 | [6197]
□ Limit of detection (LOD) | [6198]
□ Month 12 | [6199]
□ Limit of detection (LOD) | [6200]
□ % of T-lymphocytes | [6201]
□ % of B-lymphocytes | [6202]
□ % of NK-lymphocytes | [6203]
□ Before lymphodepletion | [6204]
□ Before CAR-T infusion | [6205]
□ Before lymphodepletion | [6206]
□ Before CAR-T infusion | [6207]
□ Before lymphodepletion | [6208]
□ Before CAR-T infusion | [6209]
□ Day 7 | [6210]
□ Day 14 | [6211]
□ Day 7 | [6212]
□ Day 14 | [6213]
□ Day 7 | [6214]
□ Day 14 | [6215]
□ Day 21 | [6216]

□ Month 1 | [6217]
□ Day 21 | [6218]
□ Month 1 | [6219]
□ Day 21 | [6220]
□ Month 1 | [6221]
□ Month 2 | [6222]
□ Month 3 | [6223]
□ Month 2 | [6224]
□ Month 3 | [6225]
□ Month 2 | [6226]
□ Month 3 | [6227]
□ Month 6 | [6228]
□ Month 9 | [6229]
□ Month 6 | [6230]
□ Month 9 | [6231]
□ Month 6 | [6232]
□ Month 9 | [6233]
□ Month 12 | [6234]
□ Month 12 | [6235]
□ Month 12 | [6236]
□ Prophylaxis related to CAR-T therapy | [5825]
□ Tocilizumab | [5826]
□ From | [5852]
□ To | [5853]
□ Anakinra | [5827]
□ From | [5854]
□ To | [5855]
□ Immunoglobulins | [5828]
□ From | [5856]
□ To | [5857]
□ Anti-Seizures therapy: levetiracetam (Keppra) (or other) | [6755]
□ From | [6756]
□ To | [6757]
□ IgG value before CAR-T infusion (g/l) | [5829]
□ Specific treatment | [5830]
□ Tocilizumab | [5831]
□ Number of applications/day | [5858]
□ Number of days | [5859]
□ Anakinra | [5832]
□ Number of applications/day | [5860]
□ Number of days | [5861]
□ Corticosteroids | [5833]
□ Number of applications/day | [5862]
□ Number of days | [5863]
□ Anti-Seizures therapy: levetiracetam (Keppra) (or other) | [5834]
□ Number of applications/day | [5864]

- □ Number of days | [5865]
- □ Other | [5835]
- □ Toxicity related to CART-T therapy | [5931]
- □ Cytokine release syndrom (CRS) - grade | [5838]
- □ ICANS - grade | [5842]
- □ Hemophagocytic lymphohistiocytosis - grade | [5839]
- □ Hypogammaglobulinemia - grade | [5840]
- □ Other toxicity | [5841]
- □ GVHD after ALLO-CAR-T therapy | [5843]
- □ Acute/chronic | [5844]
- □ Response to CAR-T therapy (D+30) | [5845]

○ **Other specific treatment related to CAR-T therapy | [422]**

- □ Specify other treatment | [5836]
- □ Number of applications/day | [5866]
- □ Number of days | [5867]

○ **Other toxicity related to CAR-T therapy | [415]**

- □ Toxicity | [6174]
- □ Specify other toxicity | [6255]
- □ Grade | [6175]

○ **Toxicity related to CAR-T therapy: Short-term complications/toxicity (< D+31) | [416]**

- □ Toxicity | [6178]
- □ Specify other toxicity | [6256]
- □ Grade | [6179]
- □ From | [5934]
- □ To | [5935]

○ **Toxicity related to CAR-T therapy: Medium-term complications/toxicity (D+31 – D+100) | [417]**

- □ Toxicity | [6176]
- □ Specify other toxicity | [6257]
- □ Grade | [6180]
- □ From | [5939]
- □ To | [5940]

○ **Toxicity related to CAR-T therapy: Long-term complications/toxicity (> D+100) | [418]**

- □ Toxicity | [6181]
- □ Specify other toxicity | [6258]
- □ Grade | [6177]
- □ From | [5944]
- □ To | [5945]

○ **Drugs - overview | [101]**

- □ bendamustin | [2445]
- □ Dosage (mg/m2) | [1021]
- □ Number of administrations per cycle | [1023]
- □ Number of cycles | [1024]
- □ bortezomib | [2446]
- □ Dosage (mg/m2) | [1026]

□ Route of administration | [1027]
□ Number of administrations per cycle | [1028]
□ Number of cycles | [1029]
□ Dose adjustment | [1030]
□ busulfan | [2447]
□ Dosage (mg/kg) | [1031]
□ Number of administrations per cycle | [1033]
□ Number of cycles | [1034]
□ cyklofosfamid | [2450]
□ Dosage (mg) | [1036]
□ Number of administrations per cycle | [1038]
□ Number of cycles | [1039]
□ dexamethason | [2452]
□ Dosage (mg) | [1041]
□ Number of administrations per cycle | [1043]
□ Number of cycles | [1044]
□ doxorubicin | [2453]
□ Dosage (mg/m2) | [1046]
□ Number of administrations per cycle | [1048]
□ Number of cycles | [1049]
□ melphalan | [2459]
□ Dosage (mg/m2) | [1061]
□ Number of administrations per cycle | [1063]
□ Number of cycles | [1064]
□ methylprednisolon | [2460]
□ Dosage (mg) | [1066]
□ Number of administrations per cycle | [1068]
□ Number of cycles | [1069]
□ prednison | [2463]
□ Dosage (mg) | [1071]
□ Number of administrations per cycle | [1073]
□ Number of cycles | [1074]
□ rituximab | [2464]
□ Dosage (mg/m2) | [1076]
□ Route of administration | [1077]
□ Number of administrations per cycle | [1078]
□ Number of cycles | [1079]
□ Dose adjustment | [1080]
□ thalidomid | [2465]
□ Dosage (mg) | [1081]
□ Number of administrations per cycle | [1083]
□ Number of cycles | [1084]
□ carfilzomib | [2448]
□ Dosage (mg/m2) | [1086]
□ Route of administration | [1087]
□ Number of administrations per cycle | [1088]

□ Number of cycles | [1089]
□ Dose adjustment | [1090]
□ cisplatinum | [2449]
□ Dosage (mg/m2) | [1091]
□ Number of administrations per cycle | [1093]
□ Number of cycles | [1094]
□ daratumumab | [2451]
□ Dosage | [1096]
□ Units | [4660]
□ Do you really want to enter value different from 16 mg/kg? | [4877]
□ Route of administration | [1097]
□ Number of administrations per cycle | [1098]
□ Number of cycles | [1099]
□ Dose adjustment | [1100]
□ elotuzumab | [2454]
□ Dosage (mg/kg) | [1101]
□ Route of administration | [1102]
□ Number of administrations per cycle | [1103]
□ Number of cycles | [1104]
□ Dose adjustment | [1105]
□ idarubicin | [2456]
□ Dosage (mg/m2) | [1106]
□ Number of administrations per cycle | [1108]
□ Number of cycles | [1109]
□ ixazomib | [2457]
□ Dosage (mg) | [1111]
□ Number of administrations per cycle | [1113]
□ Number of cycles | [1114]
□ Dose adjustment | [1115]
□ lenalidomid | [2458]
□ Dosage (mg) | [1116]
□ Number of administrations per cycle | [1118]
□ Number of cycles | [1119]
□ Dose adjustment | [1120]
□ Pokud došlo v průběhu linie k výměně dexamethasonu prednisonem, zapište informaci do formuláře Mandatory questions for VILP Revlimid. | [4231]
□ panobinostat | [2461]
□ Dosage (mg) | [1121]
□ Route of administration | [1122]
□ Number of administrations per cycle | [1123]
□ Number of cycles | [1124]
□ Dose adjustment | [1125]
□ pomalidomid | [2462]
□ Dosage (mg) | [1126]
□ Number of administrations per cycle | [1128]
□ Number of cycles | [1129]
□ Dose adjustment | [1130]

□ etoposid | [2455]
□ Dosage (mg/m2) | [1131]
□ Number of administrations per cycle | [1133]
□ Number of cycles | [1134]
□ vincristin | [2466]
□ Dosage (mg/m2) | [1136]
□ Number of administrations per cycle | [1138]
□ Number of cycles | [1139]
□ ibrutinib | [3073]
□ Dosage (mg) | [3074]
□ Number of administrations per cycle | [3075]
□ Number of cycles | [3076]
□ Dose adjustment | [3077]
□ isatuximab | [3078]
□ Dosage | [3079]
□ Units | [5794]
□ Do you really want to enter value different from 10 mg/kg? | [5795]
□ Route of administration | [3080]
□ Number of administrations per cycle | [3081]
□ Number of cycles | [3082]
□ Dose adjustment | [3083]
□ selinexor | [3084]
□ Dosage (mg) | [3085]
□ Number of administrations per cycle | [3086]
□ Number of cycles | [3087]
□ Dose adjustment | [3088]
□ cobimetinib | [3187]
□ Dosage (mg) | [3188]
□ Number of administrations per cycle | [3189]
□ Number of cycles | [3190]
□ Dose adjustment | [3191]
□ masitinib | [3221]
□ Dosage (mg/kg) | [3222]
□ Number of administrations per cycle | [3223]
□ Number of cycles | [3224]
□ Dose adjustment | [3225]
□ interferon alfa-2b | [3255]
□ Dosage (MIU) | [3256]
□ Number of administrations per cycle | [3257]
□ Number of cycles | [3258]
□ Dose adjustment | [3259]
□ denosumab | [3289]
□ Dosage (mg) | [3290]
□ Number of administrations per cycle | [3291]
□ Number of cycles | [3292]
□ Dose adjustment | [3293]

□ plitidepsin | [3323]
□ Dosage (mg/m2) | [3324]
□ Number of administrations per cycle | [3325]
□ Number of cycles | [3326]
□ Dose adjustment | [3327]
□ melflufen | [3357]
□ Dosage (mg) | [3358]
□ Number of administrations per cycle | [3359]
□ Number of cycles | [3360]
□ Dose adjustment | [3361]
□ nivolumab | [3391]
□ Dosage (mg/kg) | [3392]
□ Number of administrations per cycle | [3393]
□ Number of cycles | [3394]
□ Dose adjustment | [3395]
□ perifosine | [3425]
□ Dosage (mg) | [3426]
□ Number of administrations per cycle | [3427]
□ Number of cycles | [3428]
□ Dose adjustment | [3429]
□ siltuximab | [3459]
□ Dosage (mg/kg) | [3460]
□ Number of administrations per cycle | [3461]
□ Number of cycles | [3462]
□ Dose adjustment | [3463]
□ vorinostat | [3493]
□ Dosage (mg) | [3494]
□ Number of administrations per cycle | [3495]
□ Number of cycles | [3496]
□ Dose adjustment | [3497]
□ cytosin-arabinosid | [3527]
□ Dosage (mg) | [3528]
□ Number of administrations per cycle | [3529]
□ Number of cycles | [3530]
□ Dose adjustment | [3531]
□ doxorubicin-liposomal | [3561]
□ Dosage (mg/m2) | [3562]
□ Number of administrations per cycle | [3563]
□ Number of cycles | [3564]
□ Dose adjustment | [3565]
□ lomustine | [3711]
□ Dosage (mg) | [3712]
□ Number of administrations per cycle | [3713]
□ Number of cycles | [3714]
□ carmustine | [3745]
□ Dosage (mg) | [3746]

□ Number of administrations per cycle | [3747]
□ Number of cycles | [3748]
□ cytarabine | [3779]
□ Dosage (mg) | [3780]
□ Route of administration | [3813]
□ Number of administrations per cycle | [3781]
□ Number of cycles | [3782]
□ methotrexat | [3815]
□ Dosage (mg) | [3816]
□ Route of administration | [3849]
□ Number of administrations per cycle | [3817]
□ Number of cycles | [3818]
□ vinorelbini-ditartras | [3851]
□ Dosage (mg) | [3852]
□ Number of administrations per cycle | [3853]
□ Number of cycles | [3854]
□ epirubicin-hydrochloride | [3885]
□ Dosage (mg) | [3886]
□ Number of administrations per cycle | [3887]
□ Number of cycles | [3888]
□ ifosfamide | [3919]
□ Dosage (mg) | [3920]
□ Number of administrations per cycle | [3921]
□ Number of cycles | [3922]
□ venetoclax | [3953]
□ Dosage (mg) | [3954]
□ Number of administrations per cycle | [3955]
□ Number of cycles | [3956]
□ cemiplimab | [4149]
□ Dosage (mg) | [4150]
□ Route of administration | [4185]
□ Number of administrations per cycle | [4151]
□ Number of cycles | [4152]
□ Dose adjustment | [4153]
□ belantamab mafodotin | [4462]
□ Dosage (mg/kg) | [4463]
□ Route of administration | [4498]
□ Number of administrations per cycle | [4464]
□ Number of cycles | [4465]
□ Dose adjustment | [4466]
□ SAR442085 | [4624]
□ Dosage (mg) | [4625]
□ Number of administrations per cycle | [4626]
□ Number of cycles | [4627]
□ Dose adjustment | [4628]
□ iberdomide | [4953]

- □ Dosage (mg) | [4954]
- □ Number of administrations per cycle | [4955]
- □ Number of cycles | [4956]
- □ Dose adjustment | [4957]
- □ cevostamab | [5098]
- □ Dosage (mg) | [5099]
- □ Number of administrations per cycle | [6760]
- □ Route of administration | [5171]
- □ Number of cycles | [5101]
- □ Dose adjustment | [5102]
- □ atezolizumab | [5589]
- □ Dosage (mg) | [5590]
- □ Number of administrations per cycle | [5591]
- □ Number of cycles | [5592]
- □ talquetamab | [5627]
- □ Dosage (mg/kg) | [5628]
- □ Number of administrations per cycle | [5629]
- □ Number of cycles | [5630]
- □ Dose adjustment | [5631]
- □ elranatamab | [5665]
- □ Dosage (mg) | [5666]
- □ Number of administrations per cycle | [5667]
- □ Number of cycles | [5668]
- □ mezigdomide | [5703]
- □ Number of cycles | [5706]
- □ teclistamab | [5741]
- □ Dosage (mg/kg) | [5742]
- □ Number of administrations per cycle | [5743]
- □ Number of cycles | [5744]
- □ Dose adjustment | [5745]
- □ SAR445514 | [6783]
- □ Number of cycles | [6786]

- ○ **Dose adjustment - bortezomib | [103]**
  - □ Date of dose adjustment | [1150]
  - □ 1st reason | [1151]
  - □ Specify other | [1152]
  - □ Grade | [1153]
  - □ 2nd reason | [1154]
  - □ Grade | [1155]
  - □ 3rd reason | [1156]
  - □ Grade | [1157]
  - □ New dosage (mg/m2) | [1158]
  - □ Dose interruption | [4039]
  - □ Number of administrations per cycle | [5505]
- ○ **Dose adjustment - lenalidomid | [117]**
  - □ Date of dose adjustment | [1276]

- □ 1st reason | [1277]
- □ Specify other | [1278]
- □ Grade | [1279]
- □ 2nd reason | [1280]
- □ Grade | [1281]
- □ 3rd reason | [1282]
- □ Grade | [1283]
- □ New dosage (mg) | [1284]
- □ Dose interruption | [4041]
- □ Number of administrations per cycle | [5507]

○ **Dose adjustment - pomalidomid | [122]**

- □ Date of dose adjustment | [1321]
- □ 1st reason | [1322]
- □ Specify other | [1323]
- □ Grade | [1324]
- □ 2nd reason | [1325]
- □ Grade | [1326]
- □ 3rd reason | [1327]
- □ Grade | [1328]
- □ New dosage (mg) | [1329]
- □ Dose interruption | [4042]
- □ Number of administrations per cycle | [5509]

○ **Dose adjustment - carfilzomib | [105]**

- □ Date of dose adjustment | [1168]
- □ 1st reason | [1169]
- □ Specify other | [1170]
- □ Grade | [1171]
- □ 2nd reason | [1172]
- □ Grade | [1173]
- □ 3rd reason | [1174]
- □ Grade | [1175]
- □ New dosage (mg/m2) | [1176]
- □ Dose interruption | [4043]
- □ Number of administrations per cycle | [5511]

○ **Dose adjustment - ixazomib | [114]**

- □ Date of dose adjustment | [1249]
- □ 1st reason | [1250]
- □ Specify other | [1251]
- □ Grade | [1252]
- □ 2nd reason | [1253]
- □ Grade | [1254]
- □ 3rd reason | [1255]
- □ Grade | [1256]
- □ New dosage (mg) | [1257]
- □ Dose interruption | [4044]
- □ Number of administrations per cycle | [5515]

- **Dose adjustment - daratumumab | [108]**
  - ☐ Date of dose adjustment | [1195]
  - ☐ 1st reason | [1196]
  - ☐ Specify other | [1197]
  - ☐ Grade | [1198]
  - ☐ 2nd reason | [1199]
  - ☐ Grade | [1200]
  - ☐ 3rd reason | [1201]
  - ☐ Grade | [1202]
  - ☐ New dosage | [1203]
  - ☐ Units | [4663]
  - ☐ Do you really want to enter value different from 16 mg/kg? | [4878]
  - ☐ Dose interruption | [4045]
  - ☐ Number of administrations per cycle | [5517]
- **Dose adjustment - elotuzumab | [111]**
  - ☐ Date of dose adjustment | [1222]
  - ☐ 1st reason | [1223]
  - ☐ Specify other | [1224]
  - ☐ Grade | [1225]
  - ☐ 2nd reason | [1226]
  - ☐ Grade | [1227]
  - ☐ 3rd reason | [1228]
  - ☐ Grade | [1229]
  - ☐ New dosage (mg/kg) | [1230]
  - ☐ Dose interruption | [4046]
  - ☐ Number of administrations per cycle | [5519]
- **Dose adjustment - panobinostat | [121]**
  - ☐ Date of dose adjustment | [1312]
  - ☐ 1st reason | [1313]
  - ☐ Specify other | [1314]
  - ☐ Grade | [1315]
  - ☐ 2nd reason | [1316]
  - ☐ Grade | [1317]
  - ☐ 3rd reason | [1318]
  - ☐ Grade | [1319]
  - ☐ New dosage (mg) | [1320]
  - ☐ Dose interruption | [4047]
  - ☐ Number of administrations per cycle | [5521]
- **Dose adjustment - rituximab | [124]**
  - ☐ Date of dose adjustment | [1339]
  - ☐ 1st reason | [1340]
  - ☐ Specify other | [1341]
  - ☐ Grade | [1342]
  - ☐ 2nd reason | [1343]
  - ☐ Grade | [1344]
  - ☐ 3rd reason | [1345]

- □ Grade | [1346]
- □ New dosage (mg/m2) | [1347]
- □ Dose interruption | [4048]
- □ Number of administrations per cycle | [5523]

○ **Dose adjustment - ibrutinib | [279]**

- □ Date of dose adjustment | [3105]
- □ 1st reason | [3106]
- □ Specify other | [3107]
- □ Grade | [3108]
- □ 2nd reason | [3109]
- □ Grade | [3110]
- □ 3rd reason | [3111]
- □ Grade | [3112]
- □ New dosage (mg) | [3113]
- □ Dose interruption | [4049]
- □ Number of administrations per cycle | [5525]

○ **Dose adjustment - isatuximab | [280]**

- □ Date of dose adjustment | [3114]
- □ 1st reason | [3115]
- □ Specify other | [3116]
- □ Grade | [3117]
- □ 2nd reason | [3118]
- □ Grade | [3119]
- □ 3rd reason | [3120]
- □ Grade | [3121]
- □ New dosage | [3122]
- □ Units | [5796]
- □ Do you really want to enter value different from 10 mg/kg? | [5797]
- □ Dose interruption | [4050]
- □ Number of administrations per cycle | [5527]

○ **Dose adjustment - selinexor | [281]**

- □ Date of dose adjustment | [3123]
- □ 1st reason | [3124]
- □ Specify other | [3125]
- □ Grade | [3126]
- □ 2nd reason | [3127]
- □ Grade | [3128]
- □ 3rd reason | [3129]
- □ Grade | [3130]
- □ New dosage (mg) | [3131]
- □ Dose interruption | [4051]
- □ Number of administrations per cycle | [5529]

○ **Dose adjustment - cobimetinib | [292]**

- □ Date of dose adjustment | [3192]
- □ 1st reason | [3193]
- □ Specify other | [3194]

- □ Grade | [3195]
- □ 2nd reason | [3196]
- □ Grade | [3197]
- □ 3rd reason | [3198]
- □ Grade | [3199]
- □ New dosage (mg) | [3200]
- □ Dose interruption | [4052]
- □ Number of administrations per cycle | [5531]

○ **Dose adjustment - masitinib | [293]**

- □ Date of dose adjustment | [3226]
- □ 1st reason | [3227]
- □ Specify other | [3228]
- □ Grade | [3229]
- □ 2nd reason | [3230]
- □ Grade | [3231]
- □ 3rd reason | [3232]
- □ Grade | [3233]
- □ New dosage (mg/kg) | [3234]
- □ Dose interruption | [4053]
- □ Number of administrations per cycle | [5533]

○ **Dose adjustment - interferon alfa-2b | [294]**

- □ Date of dose adjustment | [3260]
- □ 1st reason | [3261]
- □ Specify other | [3262]
- □ Grade | [3263]
- □ 2nd reason | [3264]
- □ Grade | [3265]
- □ 3rd reason | [3266]
- □ Grade | [3267]
- □ New dosage (MIU) | [3268]
- □ Dose interruption | [4054]
- □ Number of administrations per cycle | [5535]

○ **Dose adjustment - denosumab | [295]**

- □ Date of dose adjustment | [3294]
- □ 1st reason | [3295]
- □ Specify other | [3296]
- □ Grade | [3297]
- □ 2nd reason | [3298]
- □ Grade | [3299]
- □ 3rd reason | [3300]
- □ Grade | [3301]
- □ New dosage (mg) | [3302]
- □ Dose interruption | [4055]
- □ Number of administrations per cycle | [5537]

○ **Dose adjustment - plitidepsin | [296]**

- □ Date of dose adjustment | [3328]

- ☐ 1st reason | [3329]
- ☐ Specify other | [3330]
- ☐ Grade | [3331]
- ☐ 2nd reason | [3332]
- ☐ Grade | [3333]
- ☐ 3rd reason | [3334]
- ☐ Grade | [3335]
- ☐ New dosage (mg/m2) | [3336]
- ☐ Dose interruption | [4056]
- ☐ Number of administrations per cycle | [5539]

○ **Dose adjustment - melflufen | [297]**

- ☐ Date of dose adjustment | [3362]
- ☐ 1st reason | [3363]
- ☐ Specify other | [3364]
- ☐ Grade | [3365]
- ☐ 2nd reason | [3366]
- ☐ Grade | [3367]
- ☐ 3rd reason | [3368]
- ☐ Grade | [3369]
- ☐ New dosage (mg) | [3370]
- ☐ Dose interruption | [4057]
- ☐ Number of administrations per cycle | [5541]

○ **Dose adjustment - nivolumab | [298]**

- ☐ Date of dose adjustment | [3396]
- ☐ 1st reason | [3397]
- ☐ Specify other | [3398]
- ☐ Grade | [3399]
- ☐ 2nd reason | [3400]
- ☐ Grade | [3401]
- ☐ 3rd reason | [3402]
- ☐ Grade | [3403]
- ☐ New dosage (mg/kg) | [3404]
- ☐ Dose interruption | [4058]
- ☐ Number of administrations per cycle | [5543]

○ **Dose adjustment - perifosine | [299]**

- ☐ Date of dose adjustment | [3430]
- ☐ 1st reason | [3431]
- ☐ Specify other | [3432]
- ☐ Grade | [3433]
- ☐ 2nd reason | [3434]
- ☐ Grade | [3435]
- ☐ 3rd reason | [3436]
- ☐ Grade | [3437]
- ☐ New dosage (mg) | [3438]
- ☐ Dose interruption | [4059]
- ☐ Number of administrations per cycle | [5545]

- **Dose adjustment - siltuximab | [300]**
  - ☐ Date of dose adjustment | [3464]
  - ☐ 1st reason | [3465]
  - ☐ Specify other | [3466]
  - ☐ Grade | [3467]
  - ☐ 2nd reason | [3468]
  - ☐ Grade | [3469]
  - ☐ 3rd reason | [3470]
  - ☐ Grade | [3471]
  - ☐ New dosage (mg/kg) | [3472]
  - ☐ Dose interruption | [4060]
  - ☐ Number of administrations per cycle | [5547]
- **Dose adjustment - vorinostat | [301]**
  - ☐ Date of dose adjustment | [3498]
  - ☐ 1st reason | [3499]
  - ☐ Specify other | [3500]
  - ☐ Grade | [3501]
  - ☐ 2nd reason | [3502]
  - ☐ Grade | [3503]
  - ☐ 3rd reason | [3504]
  - ☐ Grade | [3505]
  - ☐ New dosage (mg) | [3506]
  - ☐ Dose interruption | [4061]
  - ☐ Number of administrations per cycle | [5549]
- **Dose adjustment - cytosin-arabinosid | [302]**
  - ☐ Date of dose adjustment | [3532]
  - ☐ 1st reason | [3533]
  - ☐ Specify other | [3534]
  - ☐ Grade | [3535]
  - ☐ 2nd reason | [3536]
  - ☐ Grade | [3537]
  - ☐ 3rd reason | [3538]
  - ☐ Grade | [3539]
  - ☐ New dosage (mg) | [3540]
  - ☐ Dose interruption | [4062]
  - ☐ Number of administrations per cycle | [5551]
- **Dose adjustment - doxorubicin-liposomal | [303]**
  - ☐ Date of dose adjustment | [3566]
  - ☐ 1st reason | [3567]
  - ☐ Specify other | [3568]
  - ☐ Grade | [3569]
  - ☐ 2nd reason | [3570]
  - ☐ Grade | [3571]
  - ☐ 3rd reason | [3572]
  - ☐ Grade | [3573]
  - ☐ New dosage (mg/m2) | [3574]

- ☐ Dose interruption | [4063]
- ☐ Number of administrations per cycle | [5553]

- **Dose adjustment - cemiplimab | [329]**
  - ☐ Date of dose adjustment | [4154]
  - ☐ 1st reason | [4155]
  - ☐ Specify other | [4156]
  - ☐ Grade | [4157]
  - ☐ 2nd reason | [4158]
  - ☐ Grade | [4159]
  - ☐ 3rd reason | [4160]
  - ☐ Grade | [4161]
  - ☐ New dosage (mg) | [4162]
  - ☐ Dose interruption | [4163]
  - ☐ Number of administrations per cycle | [5555]
- **Dose adjustment - belantamab mafodotin | [358]**
  - ☐ Date of dose adjustment | [4467]
  - ☐ 1st reason | [4468]
  - ☐ Specify other | [4469]
  - ☐ Grade | [4470]
  - ☐ 2nd reason | [4471]
  - ☐ Grade | [4472]
  - ☐ 3rd reason | [4473]
  - ☐ Grade | [4474]
  - ☐ New dosage (mg/kg) | [4475]
  - ☐ Dose interruption | [4476]
  - ☐ Number of administrations per cycle | [5557]
- **Dose adjustment - SAR442085 | [373]**
  - ☐ Date of dose adjustment | [4629]
  - ☐ 1st reason | [4630]
  - ☐ Specify other | [4631]
  - ☐ Grade | [4632]
  - ☐ 2nd reason | [4633]
  - ☐ Grade | [4634]
  - ☐ 3rd reason | [4635]
  - ☐ Grade | [4636]
  - ☐ New dosage (mg) | [4637]
  - ☐ Dose interruption | [4638]
  - ☐ Number of administrations per cycle | [5559]
- **Dose adjustment - iberdomide | [390]**
  - ☐ Date of dose adjustment | [4958]
  - ☐ 1st reason | [4959]
  - ☐ Specify other | [4960]
  - ☐ Grade | [4961]
  - ☐ 2nd reason | [4962]
  - ☐ Grade | [4963]
  - ☐ 3rd reason | [4964]

- □ Grade | [4965]
- □ New dosage (mg) | [4966]
- □ Dose interruption | [4967]
- □ Number of administrations per cycle | [5561]

○ **Dose adjustment - cevostamab | [392]**

- □ Date of dose adjustment | [5103]
- □ 1st reason | [5104]
- □ Specify other | [5105]
- □ Grade | [5106]
- □ 2nd reason | [5107]
- □ Grade | [5108]
- □ 3rd reason | [5109]
- □ Grade | [5110]
- □ New dosage (mg) | [5111]
- □ Dose interruption | [5112]
- □ Number of administrations per cycle | [5563]

○ **Dose adjustment - talquetamab | [405]**

- □ Date of dose adjustment | [5632]
- □ 1st reason | [5633]
- □ Specify other | [5634]
- □ Grade | [5635]
- □ 2nd reason | [5636]
- □ Grade | [5637]
- □ 3rd reason | [5638]
- □ Grade | [5639]
- □ New dosage (mg/kg) | [5640]
- □ Dose interruption | [5641]
- □ Number of administrations per cycle | [5642]

○ **Dose adjustment - teclistamab | [407]**

- □ Date of dose adjustment | [5746]
- □ 1st reason | [5747]
- □ Specify other | [5748]
- □ Grade | [5749]
- □ 2nd reason | [5750]
- □ Grade | [5751]
- □ 3rd reason | [5752]
- □ Grade | [5753]
- □ New dosage (mg/kg) | [5754]
- □ Dose interruption | [5755]
- □ Number of administrations per cycle | [5756]

○ **Drugs - overview of total cumulative doses | [127]**

- □ bortezomib | [2424]
- □ Total number of administrations | [1368]
- □ Total cumulative dosage (mg) | [1369]
- □ carfilzomib | [2426]
- □ Total number of administrations | [1372]

□ Total cumulative dosage (mg) | [1373]
□ daratumumab | [2429]
□ Total number of administrations | [1379]
□ Total cumulative dosage (mg) | [1378]
□ Total number of intravenous administrations | [4666]
□ Total number of subcutaneous administrations | [4667]
□ Total cumulative intravenous dosage (mg) | [4668]
□ Total cumulative subcutaneous dosage (mg) | [4669]
□ In case of route of administration intravenous and change to subcutaneous or subcutaneous and change to intravenous please fill in the total number of administration and total cumulative dosage for every route of administration separately. These values will be automatically added up and filled in the questions Total number of administrations and Total comulative dosage (mg). | [4670]
□ dexamethason | [2430]
□ Total number of administrations | [1380]
□ Total cumulative dosage (mg) | [1381]
□ elotuzumab | [2432]
□ Total number of administrations | [1384]
□ Total cumulative dosage (mg) | [1385]
□ ixazomib | [2435]
□ Total number of administrations | [1392]
□ Total cumulative dosage (mg) | [1393]
□ lenalidomid | [2436]
□ Total number of administrations | [1394]
□ Total cumulative dosage (mg) | [1395]
□ panobinostat | [2439]
□ Total number of administrations | [1402]
□ Total cumulative dosage (mg) | [1403]
□ pomalidomid | [2440]
□ Total number of administrations | [1404]
□ Total cumulative dosage (mg) | [1405]
□ rituximab | [2442]
□ Total number of administrations | [1408]
□ Total cumulative dosage (mg) | [1409]
□ ibrutinib | [3162]
□ Total number of administrations | [3163]
□ Total cumulative dosage (mg) | [3164]
□ isatuximab | [3165]
□ Total number of administrations | [3166]
□ Total cumulative dosage (mg) | [3167]
□ Total number of intravenous administrations | [5798]
□ Total number of subcutaneous administrations | [5799]
□ Total cumulative intravenous dosage (mg) | [5800]
□ Total cumulative subcutaneous dosage (mg) | [5801]
□ In case of route of administration intravenous and change to subcutaneous or subcutaneous and change to intravenous please fill in the total number of administration and total cumulative dosage for every route of administration separately. These values

will be automatically added up and filled in the questions Total number of administrations and Total comulative dosage (mg). | [5802]

- ☐ selinexor | [3168]
- ☐ Total number of administrations | [3169]
- ☐ Total cumulative dosage (mg) | [3170]
- ☐ cobimetinib | [3201]
- ☐ Total number of administrations | [3202]
- ☐ Total cumulative dosage (mg) | [3203]
- ☐ masitinib | [3235]
- ☐ Total number of administrations | [3236]
- ☐ Total cumulative dosage (mg) | [3237]
- ☐ denosumab | [3303]
- ☐ Total number of administrations | [3304]
- ☐ Total cumulative dosage (mg) | [3305]
- ☐ plitidepsin | [3337]
- ☐ Total number of administrations | [3338]
- ☐ Total cumulative dosage (mg) | [3339]
- ☐ melflufen | [3371]
- ☐ Total number of administrations | [3372]
- ☐ Total cumulative dosage (mg) | [3373]
- ☐ nivolumab | [3405]
- ☐ Total number of administrations | [3406]
- ☐ Total cumulative dosage (mg) | [3407]
- ☐ perifosine | [3439]
- ☐ Total number of administrations | [3440]
- ☐ Total cumulative dosage (mg) | [3441]
- ☐ siltuximab | [3473]
- ☐ Total number of administrations | [3474]
- ☐ Total cumulative dosage (mg) | [3475]
- ☐ vorinostat | [3507]
- ☐ Total number of administrations | [3508]
- ☐ Total cumulative dosage (mg) | [3509]
- ☐ venetoclax | [3967]
- ☐ Total number of administrations | [3968]
- ☐ Total cumulative dosage (mg) | [3969]
- ☐ cemiplimab | [4164]
- ☐ Total number of administrations | [4165]
- ☐ Total cumulative dosage (mg) | [4166]
- ☐ belantamab mafodotin | [4477]
- ☐ Total number of administrations | [4478]
- ☐ Total cumulative dosage (mg) | [4479]
- ☐ SAR442085 | [4639]
- ☐ Total number of administrations | [4640]
- ☐ Total cumulative dosage (mg) | [4641]
- ☐ atezolizumab | [5605]
- ☐ Total number of administrations | [5606]
- ☐ Total cumulative dosage (mg) | [5607]

- □ talquetamab | [5643]
- □ Total number of administrations | [5644]
- □ Total cumulative dosage (mg) | [5645]
- □ elranatamab | [5681]
- □ Total number of administrations | [5682]
- □ Total cumulative dosage (mg) | [5683]
- □ teclistamab | [5757]
- □ Total number of administrations | [5758]
- □ Total cumulative dosage (mg) | [5759]
- □ cevostamab | [6821]
- □ Total number of administrations | [6822]
- □ Total cumulative dosage (mg) | [6823]

- ○ **Bispecific, Trispecific and Multispecific Antibodies | [411]**
  - □ Extended questionnaire | [5912]
  - □ Specific treatment | [5888]
  - □ Tocilizumab | [5889]
  - □ Number of applications/day | [5895]
  - □ Number of days | [5896]
  - □ Anakinra | [5890]
  - □ Number of applications/day | [5897]
  - □ Number of days | [5898]
  - □ Corticosteroids | [5891]
  - □ Number of applications/day | [5899]
  - □ Number of days | [5900]
  - □ Anti-Seizures therapy: levetiracetam (Keppra) (or other) | [5892]
  - □ Number of applications/day | [5901]
  - □ Number of days | [5902]
  - □ Other | [5893]
  - □ Specify other | [5894]
  - □ Number of applications/day | [5903]
  - □ Number of days | [5904]
  - □ IgG value before treatment by bi- and trispecific antibodies (g/l) | [5905]

- ○ **Toxicity during treatment | [132]**
  - □ Neuropathy - grade | [1439]
  - □ Related | [1440]
  - □ Nausea, vomiting - grade | [1441]
  - □ Related | [1442]
  - □ Anorexia - grade | [1443]
  - □ Related | [1444]
  - □ Diarrhoea - grade | [1445]
  - □ Related | [1446]
  - □ Constipation - grade | [1447]
  - □ Related | [1448]
  - □ Fatigue - grade | [1449]
  - □ Related | [1450]
  - □ Thrombosis/Thrombus/Embolism - grade | [1451]

□ Related | [1452]
□ Infection - grade | [1453]
□ Related | [1454]
□ Thrombocytopenia - grade | [1455]
□ Related | [1456]
□ Neutropenia - grade | [1457]
□ Related | [1458]
□ Anemia - grade | [1459]
□ Related | [1460]
□ Rash (exanthema) - grade | [4024]
□ Related | [4025]
□ IRR (infusion related reaction) - grade | [4207]
□ Related | [4208]
□ Dyspnoe - grade | [4367]
□ Decompensated diabetes mellitus - grade | [4369]
□ Related | [4368]
□ Related | [4370]
□ Hepatotoxicity - grade | [4371]
□ Related | [4372]
□ Cytokine release syndrom (CRS) - grade | [5457]
□ Related | [5458]
□ ICANS - grade | [5459]
□ Related | [5460]
□ Hemophagocytic lymphohistiocytosis - grade | [5461]
□ Related | [5462]
□ Pneumotoxicity - grade | [5463]
□ Related | [5464]
□ Keratopathy - grade | [5465]
□ Related | [5467]
□ Nail changes - grade | [5466]
□ Related | [5468]
□ Palmar/plantar desquamations - grade | [5469]
□ Related | [5470]
□ Headache – grade | [5471]
□ Related | [5472]
□ Hypogammaglobulinemia - grade | [5910]
□ Related | [6237]
□ Leukopenia - grade | [5916]
□ Related | [6238]
□ Lymfopenia - grade | [5917]
□ Related | [6239]
□ Hyponatremia - grade | [5918]
□ Related | [6240]
□ Hypofibrinogenemia - grade | [5919]
□ Related | [6241]
□ Other neurotoxicity - grade | [5921]

- □ Related | [6242]
- □ Renal toxicity - grade | [5926]
- □ Related | [6243]
- □ Cardiotoxicity - grade | [5928]
- □ Related | [6244]
- □ CMV reactivation - grade | [5929]
- □ Related | [6245]
- □ Other unexpected toxicity | [4379]

○ **Other toxicity | [341]**

- □ Specify toxicity | [4380]
- □ Specify other toxicity | [4387]
- □ Grade of toxicity | [4381]
- □ Related | [4382]

○ **Venous thromboembolism prevention (VTE prevention) | [133]**

- □ VTE prevention | [1468]
- □ Type of VTE prevention | [4506]
- □ Acetylsalicylic acid | [4338]
- □ Warfarin | [4339]
- □ LMWH | [4340]
- □ NOAC | [4341]
- □ Other | [4342]
- □ Specify anticoagulant treatment | [1470]

○ **Comments | [135]**

- □ Comments | [1474]

○ **Switch of therapy | [136]**

- □ Switch of therapy regimen | [1475]
- □ Reason for switch | [1476]

○ **Performance status before treatment (switch) | [137]**

- □ WHO ECOG | [1477]

○ **Transfer data from Laboratory values form (switch) | [388]**

- □ Date and time of examination and ID of Laboratory values form | [4866]

○ **Laboratory examination before treatment (switch) | [138]**

- □ M-protein type from diagnostics | [3642]
- □ Change of M-protein type? | [3643]
- □ M-protein type | [1480]
- □ M-protein type 1 | [4889]
- □ M-protein type 2 | [4890]
- □ M-protein type 3 | [4891]
- □ Serum M-protein quantity 1 (g/l) | [4892]
- □ Serum M-protein quantity 2 (g/l) | [4893]
- □ Serum M-protein quantity 3 (g/l) | [4894]
- □ FLC quantity measured | [3652]
- □ Serum kappa FLC quantity (mg/l) | [3653]
- □ Serum lambda FLC quantity (mg/l) | [3654]
- □ Kappa/lambda ratio | [3655]
- □ Light chain type from diagnostics | [3646]

- □ Change of light chain type? | [3647]
- □ Light chain type | [1481]
- □ M-protein entry type 1 | [5451]
- □ M-protein entry type 2 | [5452]
- □ M-protein entry type 3 | [5453]
- □ Serum M-protein entry quantity 1 (g/l) | [5454]
- □ Serum M-protein entry quantity 2 (g/l) | [5455]
- □ Serum M-protein entry quantity 3 (g/l) | [5456]
- □ Serum M-protein entry level (g/l) | [1482]
- □ Cannot be measured | [2783]
- □ Urine M-protein entry level (mg/24h) | [1483]
- □ Urine M-protein quantity (mg/l per 24h) | [2782]

○ **Bone marrow examination before treatment (switch) | [139]**

- □ Get data from examination before treatment switch! | [4617]
- □ Bone marrow aspiration cytology | [1484]
- □ Plasmocyte count by cytology (%) | [1485]
- □ Bone marrow histology | [1486]
- □ Monoclonal plasmocyte count (%) by histology | [1487]

○ **Flow cytometry before treatment (switch) | [142]**

- □ Get data from examination before treatment switch! | [4618]
- □ Flow cytometry – plasma cells (bone marrow) | [1498]
- □ Sample date | [1499]
- □ Plasmocyte count FC (%) | [4223]
- □ Clonal PC (%) | [4336]
- □ Polyclonal PC (%) | [4334]
- □ Flow cytometry – circulating plasma cells (peripheral blood) | [4872]
- □ cPCs (%) - peripheral blood | [4873]
- □ cPCs (absolute value/uL) - peripheral blood | [4874]
- □ Detection limit (LOD) | [4875]

○ **Biochemistry before treatment (switch) | [140]**

- □ Get data from examination before treatment switch! | [4619]
- □ Hemoglobin level (g/l) | [1488]
- □ Thrombocyte count (10E9/l) | [1489]
- □ Calcium total level (mmol/l) | [1490]
- □ Albumin level (g/l) | [1491]
- □ Creatinine level (µmol/l) | [1492]
- □ Beta2 microglobulin (mg/l) | [1493]
- □ LDH (µkat/l) | [1494]
- □ CRP (mg/l) | [1495]

○ **Cytogenetics before treatment (switch) | [141]**

- □ Get data from examination before treatment switch! | [4620]
- □ Cytogenetics | [3704]
- □ Extended FISH questionnaire | [6646]
- □ Date of sample collection | [1497]
- □ Conventional (carotype) | [3705]
- □ Result | [3706]

□ Method used | [3707]
□ Purity (%) | [3708]
□ t(11;14) | [3624]
□ t(4;14) | [3626]
□ t(14;16) | [3630]
□ t(6;14) | [3628]
□ t(14;20) | [6734]
□ del(17)(p13) | [3636]
□ % | [6839]
□ gain 1q21 | [3634]
□ % | [6840]
□ amp 1q21 | [6663]
□ % | [6841]
□ del(1p32) | [6738]
□ % | [6842]
□ Cytogenetic risk | [6645]
□ IGH disruption | [6647]
□ Negative | [6730]
□ Rearrangement | [6665]
□ % | [6666]
□ Rearrangement + CNV | [6667]
□ % | [6668]
□ Variant rearrangement | [6650]
□ % | [6669]
□ US aberration | [6670]
□ % | [6671]
□ Not evaluated | [6672]
□ t(4;14) | [6673]
□ Negative | [6653]
□ CNV | [6651]
□ % | [6655]
□ Positive | [6656]
□ % | [6652]
□ Variant positive | [6658]
□ % | [6660]
□ Not evaluated | [6661]
□ t(11;14) | [6677]
□ Negative | [6662]
□ CNV | [6654]
□ % | [6678]
□ Positive | [6676]
□ % | [6657]
□ Variant positive | [6680]
□ % | [6679]
□ Not evaluated | [6681]
□ t(14;16) | [6748]

□ Negative | [6675]
□ CNV | [6712]
□ % | [6714]
□ Positive | [6695]
□ % | [6690]
□ Variant positive | [6698]
□ % | [6699]
□ Not evaluated | [6688]
□ t(6;14) | [6689]
□ Negative | [6664]
□ CNV | [6694]
□ % | [6696]
□ Positive | [6692]
□ % | [6683]
□ Variant positive | [6685]
□ % | [6686]
□ Not evaluated | [6687]
□ t(14;20) | [6701]
□ Negative | [6684]
□ CNV | [6751]
□ % | [6752]
□ Positive | [6716]
□ % | [6697]
□ Variant positive | [6719]
□ % | [6720]
□ Not evaluated | [6703]
□ del(17)(p13) | [6724]
□ Negative | [6693]
□ Deletion/monosomy | [6702]
□ % | [6706]
□ Variant deletion | [6710]
□ % | [6711]
□ Not evaluated | [6717]
□ 1q21 | [6721]
□ Negative | [6704]
□ Gain | [6731]
□ % | [6733]
□ Amp | [6648]
□ % | [6649]
□ Not evaluated | [6744]
□ del(1p32) | [6708]
□ Negative | [6709]
□ Deletion | [6729]
□ % | [6735]
□ Not evaluated | [6736]
□ del(13)(q14) | [6737]

- □ Negative | [6740]
- □ Deletion/monosomy | [6741]
- □ % | [6732]
- □ Variant deletion | [6742]
- □ % | [6743]
- □ Other | [6745]
- □ % | [6746]
- □ Not evaluated | [6728]
- □ Hyperdiploidy | [6659]
- □ Negative | [6725]
- □ Positive | [6753]
- □ % | [6718]
- □ Not evaluated | [6722]
- □ Confirmative evaluations | [6700]
- □ NGS | [6707]
- □ ArrayCGH | [6713]
- □ Optical genome mapping | [6723]

○ **Medical Imaging Modalities before treatment (switch) | [143]**

- □ Get data from examination before treatment switch! | [4621]
- □ Osteolytic lesions - X-ray | [1500]
- □ Osteolytic lesions - MRI | [1501]
- □ Osteolytic lesions - CT | [1502]
- □ Osteolytic lesions - LDCT | [2789]
- □ Osteolytic lesions - PET | [1503]
- □ Osteolytic lesions - PET/CT | [1504]
- □ Osteolytic lesions - MIBI | [1505]
- □ Osteolytic lesions - PET/MRI | [4331]

○ **PET, PET/CT, PET/MRI evaluation (switch) | [404]**

- □ Get data from examination before treatment switch! | [5450]
- □ Total number of FDG+ focuses | [5409]
- □ Deauville score | [5411]
- □ FDG+ focuses - skeleton | [5434]
- □ Skull | [5410]
- □ Axial skeleton | [5412]
- □ Appendicular skeleton | [5429]
- □ Fractures | [5430]
- □ New focuses | [5413]
- □ Number of PM lesions | [5415]
- □ Deauville score | [5425]
- □ Localization of PM lesions | [5423]
- □ Skull | [5435]
- □ Axial skeleton | [5436]
- □ Appendicular skeleton | [5437]
- □ New focuses | [5427]
- □ Number of EM lesions | [5419]
- □ Deauville score | [5414]

□ Localization of EM lesions | [5432]
□ Skin | [5438]
□ Muscles | [5439]
□ Connective tissue | [5440]
□ Parenchymatous organs | [5441]
□ CNS | [5448]
□ Other | [5442]
□ New focuses | [5428]
□ FDG+ lymph nodes | [5421]
□ Deauville score | [5426]
□ New focuses | [5416]
□ Bone marrow | [5433]
□ Deauville score | [5424]
□ CT/MRI: lytic focuses - skeleton | [5422]
□ Localization of lytic focuses | [5449]
□ Skull | [5443]
□ Axial skeleton | [5444]
□ Appendicular skeleton | [5445]
□ New focuses | [5417]
□ Other lesions - skeleton (FDG-) | [5431]
□ Lesions <5 mm | [5446]
□ Fractures | [5447]
□ New focuses | [5418]
□ | [5420]

- **MM with Extraosseous disease before treatment (switch) | [144]**
  - □ Get data from examination before treatment switch! | [4622]
  - □ Extraosseous disease | [4915]
  - □ Extraosseous mass histology (ev. cytology) | [1508]
  - □ Extraosseous disease – relation | [1507]
  - □ Extramedullary lesion - localization | [4405]
  - □ SKIN or ORAL MUCOSE | [4410]
  - □ CONNECTIVE TISSUE (subcutaneous fat, connective tissue, articular cartilage) | [4916]
  - □ MUSCLE | [4917]
  - □ LYMPHNODES or SPLEEN | [4408]
  - □ PARENCHYMATOUS ORGANS | [4918]
  - □ Respiratory tract | [4407]
  - □ Urogenital tract | [4409]
  - □ Gastrointestinal tract | [4919]
  - □ Liver or Pancreas | [4920]
  - □ CNS | [4411]
  - □ Other | [4412]
  - □ Specify other | [4413]
  - □ Extramedullary lesion – counts | [1509]
  - □ Paramedullary lesion – localization | [4921]
  - □ LIMBS | [4923]
  - □ AXIAL SKELETON | [4924]

- ☐ SKULL | [4925]
- ☐ Other | [4927]
- ☐ Specify other | [4928]
- ☐ Paramedullary lesion – counts | [4926]
- ☐ Method used for diagnosis | [4940]
- ☐ Physical examination | [4942]
- ☐ X-ray | [4943]
- ☐ Ultrasound | [4944]
- ☐ Scintigraphy | [4945]
- ☐ Whole body LD-CT | [4946]
- ☐ HD-CT | [4947]
- ☐ PET/CT | [4948]
- ☐ Focused MRI | [4949]
- ☐ Whole body MRI | [4950]
- ☐ PET/MRI | [4952]

○ **Stage before treatment (switch) | [145]**

- ☐ Get data from examination before treatment switch! | [4623]
- ☐ Durie-Salmon stage | [1513]
- ☐ Durie-Salmon substage | [1514]
- ☐ ISS classification - calculation only | [3601]
- ☐ ISS classification | [1515]
- ☐ R-ISS classification - calculation only | [3604]
- ☐ R-ISS classification | [5176]

○ **Toxicity before treatment (switch) | [173]**

- ☐ Grade of thrombocytopenia before treatment | [1900]
- ☐ Grade of neuropathy before treatment | [1901]

○ **Treatment (switch) | [146]**

- ☐ Treatment regimen | [1516]
- ☐ Specify combination of 6 or more drugs | [3691]
- ☐ Uncategorizable treatment specification | [1519]
- ☐ Rewritten | [2801]
- ☐ Health insurance company | [1520]
- ☐ Clinical study | [4090]
- ☐ Name of clinical study | [4091]
- ☐ Specification name of other | [4092]
- ☐ Double blinded study | [4093]
- ☐ Specification of clinical study | [4094]
- ☐ Length of cycle (days) | [1524]
- ☐ Date of treatment initiation (switch) | [1525]
- ☐ Hide toxicity and dosage | [4682]

○ **Drugs - overview (switch) | [147]**

- ☐ bendamustin | [2467]
- ☐ Dosage (mg/m2) | [1526]
- ☐ Number of administrations per cycle | [1528]
- ☐ Number of cycles | [1529]
- ☐ carfilzomib | [2470]

□ Dosage (mg/m2) | [1531]
□ Route of administration | [1532]
□ Number of administrations per cycle | [1533]
□ Number of cycles | [1534]
□ Dose adjustment | [1535]
□ cisplatinum | [2471]
□ Dosage (mg/m2) | [1536]
□ Number of administrations per cycle | [1538]
□ Number of cycles | [1539]
□ daratumumab | [2473]
□ Dosage | [1541]
□ Units | [4664]
□ Do you really want to enter value different from 16 mg/kg? | [4879]
□ Route of administration | [1542]
□ Number of administrations per cycle | [1543]
□ Number of cycles | [1544]
□ Dose adjustment | [1545]
□ elotuzumab | [2476]
□ Dosage (mg/kg) | [1546]
□ Route of administration | [1547]
□ Number of administrations per cycle | [1548]
□ Number of cycles | [1549]
□ Dose adjustment | [1550]
□ idarubicin | [2478]
□ Dosage (mg/m2) | [1551]
□ Number of administrations per cycle | [1553]
□ Number of cycles | [1554]
□ ixazomib | [2479]
□ Dosage (mg) | [1556]
□ Number of administrations per cycle | [1558]
□ Number of cycles | [1559]
□ Dose adjustment | [1560]
□ lenalidomid | [2480]
□ Dosage (mg) | [1561]
□ Number of administrations per cycle | [1563]
□ Number of cycles | [1564]
□ Dose adjustment | [1565]
□ methylprednisolon | [2482]
□ Dosage (mg) | [1566]
□ Number of administrations per cycle | [1568]
□ Number of cycles | [1569]
□ panobinostat | [2483]
□ Dosage (mg) | [1571]
□ Route of administration | [1572]
□ Number of administrations per cycle | [1573]
□ Number of cycles | [1574]

□ Dose adjustment | [1575]
□ pomalidomid | [2484]
□ Dosage (mg) | [1576]
□ Number of administrations per cycle | [1578]
□ Number of cycles | [1579]
□ Dose adjustment | [1580]
□ etoposid | [2477]
□ Dosage (mg/m2) | [1581]
□ Number of administrations per cycle | [1583]
□ Number of cycles | [1584]
□ vincristin | [2488]
□ Dosage (mg/m2) | [1586]
□ Number of administrations per cycle | [1588]
□ Number of cycles | [1589]
□ bortezomib | [2468]
□ Dosage (mg/m2) | [1591]
□ Number of administrations per cycle | [1593]
□ Number of cycles | [1594]
□ busulfan | [2469]
□ Dosage (mg/kg) | [1596]
□ Number of administrations per cycle | [1598]
□ Number of cycles | [1599]
□ cyklofosfamid | [2472]
□ Dosage (mg) | [1601]
□ Number of administrations per cycle | [1603]
□ Number of cycles | [1604]
□ dexamethason | [2474]
□ Dosage (mg) | [1606]
□ Number of administrations per cycle | [1608]
□ Number of cycles | [1609]
□ doxorubicin | [2475]
□ Dosage (mg/m2) | [1611]
□ Number of administrations per cycle | [1613]
□ Number of cycles | [1614]
□ melphalan | [2481]
□ Dosage (mg/m2) | [1616]
□ Number of administrations per cycle | [1618]
□ Number of cycles | [1619]
□ prednison | [2485]
□ Dosage (mg) | [1621]
□ Number of administrations per cycle | [1623]
□ Number of cycles | [1624]
□ rituximab | [2486]
□ Dosage (mg/m2) | [1626]
□ Route of administration | [1627]
□ Number of administrations per cycle | [1628]

□ Number of cycles | [1629]
□ Dose adjustment | [1630]
□ thalidomid | [2487]
□ Dosage (mg) | [1631]
□ Number of administrations per cycle | [1633]
□ Number of cycles | [1634]
□ ibrutinib | [3089]
□ Dosage (mg) | [3090]
□ Number of administrations per cycle | [3091]
□ Number of cycles | [3092]
□ Dose adjustment | [3093]
□ isatuximab | [3094]
□ Dosage | [3095]
□ Units | [5803]
□ Do you really want to enter value different from 10 mg/kg? | [5804]
□ Route of administration | [3096]
□ Number of administrations per cycle | [3097]
□ Number of cycles | [3098]
□ Dose adjustment | [3099]
□ selinexor | [3100]
□ Dosage (mg) | [3101]
□ Number of administrations per cycle | [3102]
□ Number of cycles | [3103]
□ Dose adjustment | [3104]
□ cobimetinib | [3204]
□ Dosage (mg) | [3205]
□ Number of administrations per cycle | [3206]
□ Number of cycles | [3207]
□ Dose adjustment | [3208]
□ masitinib | [3238]
□ Dosage (mg/kg) | [3239]
□ Number of administrations per cycle | [3240]
□ Number of cycles | [3241]
□ Dose adjustment | [3242]
□ interferon alfa-2b | [3272]
□ Dosage (MIU) | [3273]
□ Number of administrations per cycle | [3274]
□ Number of cycles | [3275]
□ Dose adjustment | [3276]
□ denosumab | [3306]
□ Dosage (mg) | [3307]
□ Number of administrations per cycle | [3308]
□ Number of cycles | [3309]
□ Dose adjustment | [3310]
□ plitidepsin | [3340]
□ Dosage (mg/m2) | [3341]

□ Number of administrations per cycle | [3342]
□ Number of cycles | [3343]
□ Dose adjustment | [3344]
□ melflufen | [3374]
□ Dosage (mg) | [3375]
□ Number of administrations per cycle | [3376]
□ Number of cycles | [3377]
□ Dose adjustment | [3378]
□ nivolumab | [3408]
□ Dosage (mg/kg) | [3409]
□ Number of administrations per cycle | [3410]
□ Number of cycles | [3411]
□ Dose adjustment | [3412]
□ perifosine | [3442]
□ Dosage (mg) | [3443]
□ Number of administrations per cycle | [3444]
□ Number of cycles | [3445]
□ Dose adjustment | [3446]
□ siltuximab | [3476]
□ Dosage (mg/kg) | [3477]
□ Number of administrations per cycle | [3478]
□ Number of cycles | [3479]
□ Dose adjustment | [3480]
□ vorinostat | [3510]
□ Dosage (mg) | [3511]
□ Number of administrations per cycle | [3512]
□ Number of cycles | [3513]
□ Dose adjustment | [3514]
□ cytosin-arabinosid | [3544]
□ Dosage (mg) | [3545]
□ Number of administrations per cycle | [3546]
□ Number of cycles | [3547]
□ Dose adjustment | [3548]
□ doxorubicin-liposomal | [3578]
□ Dosage (mg/m2) | [3579]
□ Number of administrations per cycle | [3580]
□ Number of cycles | [3581]
□ Dose adjustment | [3582]
□ lomustine | [3728]
□ Dosage (mg) | [3729]
□ Number of administrations per cycle | [3730]
□ Number of cycles | [3731]
□ carmustine | [3762]
□ Dosage (mg) | [3763]
□ Number of administrations per cycle | [3764]
□ Number of cycles | [3765]

□ cytarabine | [3796]
□ Dosage (mg) | [3797]
□ Route of administration | [3814]
□ Number of administrations per cycle | [3798]
□ Number of cycles | [3799]
□ methotrexat | [3832]
□ Dosage (mg) | [3833]
□ Route of administration | [3850]
□ Number of administrations per cycle | [3834]
□ Number of cycles | [3835]
□ vinorelbini-ditartras | [3868]
□ Dosage (mg) | [3869]
□ Number of administrations per cycle | [3870]
□ Number of cycles | [3871]
□ epirubicin-hydrochloride | [3902]
□ Dosage (mg) | [3903]
□ Number of administrations per cycle | [3904]
□ Number of cycles | [3905]
□ ifosfamide | [3936]
□ Dosage (mg) | [3937]
□ Number of administrations per cycle | [3938]
□ Number of cycles | [3939]
□ venetoclax | [3970]
□ Dosage (mg) | [3971]
□ Number of administrations per cycle | [3972]
□ Number of cycles | [3973]
□ cemiplimab | [4167]
□ Dosage (mg) | [4168]
□ Route of administration | [4186]
□ Number of administrations per cycle | [4169]
□ Number of cycles | [4170]
□ Dose adjustment | [4171]
□ belantamab mafodotin | [4480]
□ Dosage (mg/kg) | [4481]
□ Route of administration | [4499]
□ Number of administrations per cycle | [4482]
□ Number of cycles | [4483]
□ Dose adjustment | [4484]
□ SAR442085 | [4642]
□ Dosage (mg) | [4643]
□ Number of administrations per cycle | [4644]
□ Number of cycles | [4645]
□ Dose adjustment | [4646]
□ iberdomide | [4971]
□ Dosage (mg) | [4972]
□ Number of administrations per cycle | [4973]

- □ Number of cycles | [4974]
- □ Dose adjustment | [4975]
- □ cevostamab | [5116]
- □ Dosage (mg) | [5117]
- □ Number of administrations per cycle | [6761]
- □ Route of administration | [5172]
- □ Number of cycles | [5119]
- □ Dose adjustment | [5120]
- □ atezolizumab | [5608]
- □ Dosage (mg) | [5609]
- □ Number of administrations per cycle | [5610]
- □ Number of cycles | [5611]
- □ talquetamab | [5646]
- □ Dosage (mg/kg) | [5647]
- □ Number of administrations per cycle | [5648]
- □ Number of cycles | [5649]
- □ Dose adjustment | [5650]
- □ elranatamab | [5684]
- □ Dosage (mg) | [5685]
- □ Number of administrations per cycle | [5686]
- □ Number of cycles | [5687]
- □ mezigdomide | [5722]
- □ Number of cycles | [5725]
- □ teclistamab | [5760]
- □ Dosage (mg/kg) | [5761]
- □ Number of administrations per cycle | [5762]
- □ Number of cycles | [5763]
- □ Dose adjustment | [5764]
- □ SAR445514 | [6799]
- □ Number of cycles | [6805]

- ○ **Dose adjustment - lenalidomid (switch) | [163]**
  - □ Date of dose adjustment | [1779]
  - □ 1st reason | [1771]
  - □ Specify other | [1772]
  - □ Grade | [1773]
  - □ 2nd reason | [1774]
  - □ Grade | [1775]
  - □ 3rd reason | [1776]
  - □ Grade | [1777]
  - □ New dosage (mg) | [1778]
  - □ Dose interruption | [4066]
  - □ Number of administrations per cycle | [5508]
- ○ **Dose adjustment - pomalidomid (switch) | [167]**
  - □ Date of dose adjustment | [1815]
  - □ 1st reason | [1807]
  - □ Specify other | [1808]

- ☐ Grade | [1809]
- ☐ 2nd reason | [1810]
- ☐ Grade | [1811]
- ☐ 3rd reason | [1812]
- ☐ Grade | [1813]
- ☐ New dosage (mg) | [1814]
- ☐ Dose interruption | [4067]
- ☐ Number of administrations per cycle | [5510]

○ **Dose adjustment - carfilzomib (switch) | [151]**

- ☐ Date of dose adjustment | [1671]
- ☐ 1st reason | [1663]
- ☐ Specify other | [1664]
- ☐ Grade | [1665]
- ☐ 2nd reason | [1666]
- ☐ Grade | [1667]
- ☐ 3rd reason | [1668]
- ☐ Grade | [1669]
- ☐ New dosage (mg/m2) | [1670]
- ☐ Dose interruption | [4068]
- ☐ Number of administrations per cycle | [5512]

○ **Dose adjustment - ixazomib (switch) | [161]**

- ☐ Date of dose adjustment | [1761]
- ☐ 1st reason | [1753]
- ☐ Specify other | [1754]
- ☐ Grade | [1755]
- ☐ 2nd reason | [1756]
- ☐ Grade | [1757]
- ☐ 3rd reason | [1758]
- ☐ Grade | [1759]
- ☐ New dosage (mg) | [1760]
- ☐ Dose interruption | [4069]
- ☐ Number of administrations per cycle | [5516]

○ **Dose adjustment - daratumumab (switch) | [154]**

- ☐ Date of dose adjustment | [1698]
- ☐ 1st reason | [1690]
- ☐ Specify other | [1691]
- ☐ Grade | [1692]
- ☐ 2nd reason | [1693]
- ☐ Grade | [1694]
- ☐ 3rd reason | [1695]
- ☐ Grade | [1696]
- ☐ New dosage | [1697]
- ☐ Units | [4665]
- ☐ Do you really want to enter value different from 16 mg/kg? | [4880]
- ☐ Dose interruption | [4070]
- ☐ | [5518]

- **Dose adjustment - elotuzumab (switch) | [157]**
  - ☐ Date of dose adjustment | [1725]
  - ☐ 1st reason | [1717]
  - ☐ Specify other | [1718]
  - ☐ Grade | [1719]
  - ☐ 2nd reason | [1720]
  - ☐ Grade | [1721]
  - ☐ 3rd reason | [1722]
  - ☐ Grade | [1723]
  - ☐ New dosage (mg/kg) | [1724]
  - ☐ Dose interruption | [4071]
  - ☐ Number of administrations per cycle | [5520]
- **Dose adjustment - panobinostat (switch) | [166]**
  - ☐ Date of dose adjustment | [1806]
  - ☐ 1st reason | [1798]
  - ☐ Specify other | [1799]
  - ☐ Grade | [1800]
  - ☐ 2nd reason | [1801]
  - ☐ Grade | [1802]
  - ☐ 3rd reason | [1803]
  - ☐ Grade | [1804]
  - ☐ New dosage (mg) | [1805]
  - ☐ Dose interruption | [4072]
  - ☐ Number of administrations per cycle | [5522]
- **Dose adjustment - rituximab (switch) | [169]**
  - ☐ Date of dose adjustment | [1833]
  - ☐ 1st reason | [1825]
  - ☐ Specify other | [1826]
  - ☐ Grade | [1827]
  - ☐ 2nd reason | [1828]
  - ☐ Grade | [1829]
  - ☐ 3rd reason | [1830]
  - ☐ Grade | [1831]
  - ☐ New dosage (mg/m2) | [1832]
  - ☐ Dose interruption | [4073]
  - ☐ Number of administrations per cycle | [5524]
- **Dose adjustment - ibrutinib (switch) | [282]**
  - ☐ Date of dose adjustment | [3132]
  - ☐ 1st reason | [3133]
  - ☐ Specify other | [3134]
  - ☐ Grade | [3135]
  - ☐ 2nd reason | [3136]
  - ☐ Grade | [3137]
  - ☐ 3rd reason | [3138]
  - ☐ Grade | [3139]
  - ☐ New dosage (mg) | [3140]

- ☐ Dose interruption | [4074]
- ☐ Number of administrations per cycle | [5526]

- **Dose adjustment - isatuximab (switch) | [283]**
  - ☐ Date of dose adjustment | [3141]
  - ☐ 1st reason | [3142]
  - ☐ Specify other | [3143]
  - ☐ Grade | [3144]
  - ☐ 2nd reason | [3145]
  - ☐ Grade | [3146]
  - ☐ 3rd reason | [3147]
  - ☐ Grade | [3148]
  - ☐ New dosage | [3149]
  - ☐ Units | [5805]
  - ☐ Do you really want to enter value different from 10 mg/kg? | [5806]
  - ☐ Dose interruption | [4075]
  - ☐ Number of administrations per cycle | [5528]
- **Dose adjustment - selinexor (switch) | [284]**
  - ☐ Date of dose adjustment | [3150]
  - ☐ 1st reason | [3151]
  - ☐ Specify other | [3152]
  - ☐ Grade | [3153]
  - ☐ 2nd reason | [3154]
  - ☐ Grade | [3155]
  - ☐ 3rd reason | [3156]
  - ☐ Grade | [3157]
  - ☐ New dosage (mg) | [3158]
  - ☐ Dose interruption | [4076]
  - ☐ Number of administrations per cycle | [5530]
- **Dose adjustment - cobimetinib (switch) | [304]**
  - ☐ Date of dose adjustment | [3209]
  - ☐ 1st reason | [3210]
  - ☐ Specify other | [3211]
  - ☐ Grade | [3212]
  - ☐ 2nd reason | [3213]
  - ☐ Grade | [3214]
  - ☐ 3rd reason | [3215]
  - ☐ Grade | [3216]
  - ☐ New dosage (mg) | [3217]
  - ☐ Dose interruption | [4077]
  - ☐ Number of administrations per cycle | [5532]
  - ☐ Date of dose adjustment | [3243]
  - ☐ 1st reason | [3244]
  - ☐ Specify other | [3245]
  - ☐ Grade | [3246]
  - ☐ 2nd reason | [3247]
  - ☐ Grade | [3248]

- □ 3rd reason | [3249]
- □ Grade | [3250]
- □ New dosage (mg/kg) | [3251]
- □ Dose interruption | [4078]
- □ Number of administrations per cycle | [5534]

○ **Dose adjustment - interferon alfa-2b (switch) | [306]**

- □ Date of dose adjustment | [3277]
- □ 1st reason | [3278]
- □ Specify other | [3279]
- □ Grade | [3280]
- □ 2nd reason | [3281]
- □ Grade | [3282]
- □ 3rd reason | [3283]
- □ Grade | [3284]
- □ New dosage (MIU) | [3285]
- □ Dose interruption | [4079]
- □ Number of administrations per cycle | [5536]

○ **Dose adjustment - denosumab (switch) | [307]**

- □ Date of dose adjustment | [3311]
- □ 1st reason | [3312]
- □ Specify other | [3313]
- □ Grade | [3314]
- □ 2nd reason | [3315]
- □ Grade | [3316]
- □ 3rd reason | [3317]
- □ Grade | [3318]
- □ New dosage (mg) | [3319]
- □ Dose interruption | [4080]
- □ Number of administrations per cycle | [5538]

○ **Dose adjustment - plitidepsin (switch) | [308]**

- □ Date of dose adjustment | [3345]
- □ 1st reason | [3346]
- □ Specify other | [3347]
- □ Grade | [3348]
- □ 2nd reason | [3349]
- □ Grade | [3350]
- □ 3rd reason | [3351]
- □ Grade | [3352]
- □ New dosage (mg/m2) | [3353]
- □ Dose interruption | [4081]
- □ Number of administrations per cycle | [5540]

○ **Dose adjustment - melflufen (switch) | [309]**

- □ Date of dose adjustment | [3379]
- □ 1st reason | [3380]
- □ Specify other | [3381]
- □ Grade | [3382]

- □ 2nd reason | [3383]
- □ Grade | [3384]
- □ 3rd reason | [3385]
- □ Grade | [3386]
- □ New dosage (mg) | [3387]
- □ Dose interruption | [4082]
- □ Number of administrations per cycle | [5542]

○ **Dose adjustment - nivolumab (switch) | [310]**

- □ Date of dose adjustment | [3413]
- □ 1st reason | [3414]
- □ Specify other | [3415]
- □ Grade | [3416]
- □ 2nd reason | [3417]
- □ Grade | [3418]
- □ 3rd reason | [3419]
- □ Grade | [3420]
- □ New dosage (mg/kg) | [3421]
- □ Dose interruption | [4083]
- □ Number of administrations per cycle | [5544]

○ **Dose adjustment - perifosine (switch) | [311]**

- □ Date of dose adjustment | [3447]
- □ 1st reason | [3448]
- □ Specify other | [3449]
- □ Grade | [3450]
- □ 2nd reason | [3451]
- □ Grade | [3452]
- □ 3rd reason | [3453]
- □ Grade | [3454]
- □ New dosage (mg) | [3455]
- □ Dose interruption | [4084]
- □ Number of administrations per cycle | [5546]

○ **Dose adjustment - siltuximab (switch) | [312]**

- □ Date of dose adjustment | [3481]
- □ 1st reason | [3482]
- □ Specify other | [3483]
- □ Grade | [3484]
- □ 2nd reason | [3485]
- □ Grade | [3486]
- □ 3rd reason | [3487]
- □ Grade | [3488]
- □ New dosage (mg/kg) | [3489]
- □ Dose interruption | [4085]
- □ Number of administrations per cycle | [5548]

○ **Dose adjustment - vorinostat (switch) | [313]**

- □ Date of dose adjustment | [3515]
- □ 1st reason | [3516]

- □ Specify other | [3517]
- □ Grade | [3518]
- □ 2nd reason | [3519]
- □ Grade | [3520]
- □ 3rd reason | [3521]
- □ Grade | [3522]
- □ New dosage (mg) | [3523]
- □ Dose interruption | [4086]
- □ Number of administrations per cycle | [5550]

○ **Dose adjustment - cytosin-arabinosid (switch) | [314]**

- □ Date of dose adjustment | [3549]
- □ 1st reason | [3550]
- □ Specify other | [3551]
- □ Grade | [3552]
- □ 2nd reason | [3553]
- □ Grade | [3554]
- □ 3rd reason | [3555]
- □ Grade | [3556]
- □ New dosage (mg) | [3557]
- □ Dose interruption | [4087]
- □ Number of administrations per cycle | [5552]

○ **Dose adjustment - doxorubicin-liposomal (switch) | [315]**

- □ Date of dose adjustment | [3583]
- □ 1st reason | [3584]
- □ Specify other | [3585]
- □ Grade | [3586]
- □ 2nd reason | [3587]
- □ Grade | [3588]
- □ 3rd reason | [3589]
- □ Grade | [3590]
- □ New dosage (mg/m2) | [3591]
- □ Dose interruption | [4088]
- □ Number of administrations per cycle | [5554]

○ **Dose adjustment - cemiplimab (switch) | [330]**

- □ Date of dose adjustment | [4172]
- □ 1st reason | [4173]
- □ Specify other | [4174]
- □ Grade | [4175]
- □ 2nd reason | [4176]
- □ Grade | [4177]
- □ 3rd reason | [4178]
- □ Grade | [4179]
- □ New dosage (mg) | [4180]
- □ Dose interruption | [4181]
- □ Number of administrations per cycle | [5556]

○ **Dose adjustment - belantamab mafodotin (switch) | [359]**

- ☐ Date of dose adjustment | [4485]
- ☐ 1st reason | [4486]
- ☐ Specify other | [4487]
- ☐ Grade | [4488]
- ☐ 2nd reason | [4489]
- ☐ Grade | [4490]
- ☐ 3rd reason | [4491]
- ☐ Grade | [4492]
- ☐ New dosage (mg/kg) | [4493]
- ☐ Dose interruption | [4494]
- ☐ Number of administrations per cycle | [5558]

○ **Dose adjustment - SAR442085 (switch) | [374]**

- ☐ Date of dose adjustment | [4647]
- ☐ 1st reason | [4648]
- ☐ Specify other | [4649]
- ☐ Grade | [4650]
- ☐ 2nd reason | [4651]
- ☐ Grade | [4652]
- ☐ 3rd reason | [4653]
- ☐ Grade | [4654]
- ☐ New dosage (mg) | [4655]
- ☐ Dose interruption | [4656]
- ☐ Number of administrations per cycle | [5560]

○ **Dose adjustment - iberdomide (switch) | [391]**

- ☐ Date of dose adjustment | [4976]
- ☐ 1st reason | [4977]
- ☐ Specify other | [4978]
- ☐ Grade | [4979]
- ☐ 2nd reason | [4980]
- ☐ Grade | [4981]
- ☐ 3rd reason | [4982]
- ☐ Grade | [4983]
- ☐ New dosage (mg) | [4984]
- ☐ Dose interruption | [4985]
- ☐ Number of administrations per cycle | [5562]

○ **Dose adjustment - cevostamab (switch) | [393]**

- ☐ Date of dose adjustment | [5121]
- ☐ 1st reason | [5122]
- ☐ Specify other | [5123]
- ☐ Grade | [5124]
- ☐ 2nd reason | [5125]
- ☐ Grade | [5126]
- ☐ 3rd reason | [5127]
- ☐ Grade | [5128]
- ☐ New dosage (mg) | [5129]
- ☐ Dose interruption | [5130]

- □ Number of administrations per cycle | [5564]

- **Dose adjustment - talquetamab (switch) | [406]**
  - □ Date of dose adjustment | [5651]
  - □ 1st reason | [5652]
  - □ Specify other | [5653]
  - □ Grade | [5654]
  - □ 2nd reason | [5655]
  - □ Grade | [5656]
  - □ 3rd reason | [5657]
  - □ Grade | [5658]
  - □ New dosage (mg/kg) | [5659]
  - □ Dose interruption | [5660]
  - □ Number of administrations per cycle | [5661]
- **Dose adjustment - teclistamab (switch) | [408]**
  - □ Date of dose adjustment | [5765]
  - □ 1st reason | [5766]
  - □ Specify other | [5767]
  - □ Grade | [5768]
  - □ 2nd reason | [5769]
  - □ Grade | [5770]
  - □ 3rd reason | [5771]
  - □ Grade | [5772]
  - □ New dosage (mg/kg) | [5773]
  - □ Dose interruption | [5774]
  - □ Number of administrations per cycle | [5775]
- **Drugs - overview of total cumulative doses (switch) | [172]**
  - □ dexamethason | [2496]
  - □ Total number of administrations | [1860]
  - □ Total cumulative dosage (mg) | [1861]
  - □ rituximab | [2508]
  - □ Total number of administrations | [1874]
  - □ Total cumulative dosage (mg) | [1875]
  - □ carfilzomib | [2492]
  - □ Total number of administrations | [1878]
  - □ Total cumulative dosage (mg) | [1879]
  - □ daratumumab | [2495]
  - □ Total number of administrations | [1882]
  - □ Total cumulative dosage (mg) | [1883]
  - □ Total number of intravenous administrations | [4671]
  - □ Total number of subcutaneous administrations | [4672]
  - □ Total cumulative intravenous dosage (mg) | [4673]
  - □ Total cumulative subcutaneous dosage (mg) | [4674]
  - □ In case of route of administration intravenous and change to subcutaneous or subcutaneous and change to intravenous please fill in the total number of administration and total cumulative dosage for every route of administration separately. These values will be automatically added up and filled in the questions Total number of administrations and Total comulative dosage (mg). | [4675]

□ elotuzumab | [2498]
□ Total number of administrations | [1884]
□ Total cumulative dosage (mg) | [1885]
□ ixazomib | [2501]
□ Total number of administrations | [1888]
□ Total cumulative dosage (mg) | [1889]
□ lenalidomid | [2502]
□ Total number of administrations | [1890]
□ Total cumulative dosage (mg) | [1891]
□ panobinostat | [2505]
□ Total number of administrations | [1892]
□ Total cumulative dosage (mg) | [1893]
□ pomalidomid | [2506]
□ Total number of administrations | [1894]
□ Total cumulative dosage (mg) | [1895]
□ ibrutinib | [3160]
□ Total number of administrations | [3159]
□ Total cumulative dosage (mg) | [3161]
□ isatuximab | [3171]
□ Total number of administrations | [3172]
□ Total cumulative dosage (mg) | [3173]
□ Total number of intravenous administrations | [5807]
□ Total number of subcutaneous administrations | [5808]
□ Total cumulative intravenous dosage (mg) | [5809]
□ Total cumulative subcutaneous dosage (mg) | [5810]
□ In case of route of administration intravenous and change to subcutaneous or subcutaneous and change to intravenous please fill in the total number of administration and total cumulative dosage for every route of administration separately. These values will be automatically added up and filled in the questions Total number of administrations and Total comulative dosage (mg). | [5811]
□ selinexor | [3174]
□ Total number of administrations | [3175]
□ Total cumulative dosage (mg) | [3176]
□ cobimetinib | [3218]
□ Total number of administrations | [3219]
□ Total cumulative dosage (mg) | [3220]
□ masitinib | [3252]
□ Total number of administrations | [3253]
□ Total cumulative dosage (mg) | [3254]
□ denosumab | [3320]
□ Total number of administrations | [3321]
□ Total cumulative dosage (mg) | [3322]
□ plitidepsin | [3354]
□ Total number of administrations | [3355]
□ Total cumulative dosage (mg) | [3356]
□ melflufen | [3388]
□ Total number of administrations | [3389]

- □ Total cumulative dosage (mg) | [3390]
- □ nivolumab | [3422]
- □ Total number of administrations | [3423]
- □ Total cumulative dosage (mg) | [3424]
- □ perifosine | [3456]
- □ Total number of administrations | [3457]
- □ Total cumulative dosage (mg) | [3458]
- □ siltuximab | [3490]
- □ Total number of administrations | [3491]
- □ Total cumulative dosage (mg) | [3492]
- □ vorinostat | [3524]
- □ Total number of administrations | [3525]
- □ Total cumulative dosage (mg) | [3526]
- □ venetoclax | [3984]
- □ Total number of administrations | [3985]
- □ Total cumulative dosage (mg) | [3986]
- □ cemiplimab | [4182]
- □ Total number of administrations | [4183]
- □ Total cumulative dosage (mg) | [4184]
- □ belantamab mafodotin | [4495]
- □ Total number of administrations | [4496]
- □ Total cumulative dosage (mg) | [4497]
- □ SAR442085 | [4657]
- □ Total number of administrations | [4658]
- □ Total cumulative dosage (mg) | [4659]
- □ atezolizumab | [5624]
- □ Total cumulative dosage (mg) | [5625]
- □ | [5626]
- □ talquetamab | [5662]
- □ Total number of administrations | [5663]
- □ Total cumulative dosage (mg) | [5664]
- □ elranatamab | [5700]
- □ Total number of administrations | [5701]
- □ Total cumulative dosage (mg) | [5702]
- □ teclistamab | [5776]
- □ Total number of administrations | [5777]
- □ Total cumulative dosage (mg) | [5778]
- □ cevostamab | [6824]
- □ Total number of administrations | [6825]
- □ Total cumulative dosage (mg) | [6826]

- ○ **Bispecific, Trispecific and Multispecific Antibodies (switch) | [414]**
  - □ Extended questionnaire | [6173]
  - □ Specific treatment | [6143]
  - □ Tocilizumab | [6144]
  - □ Number of applications/day | [6150]
  - □ Number of days | [6151]

□ Anakinra | [6145]
□ Number of applications/day | [6152]
□ Number of days | [6153]
□ Corticosteroids | [6146]
□ Number of applications/day | [6154]
□ Number of days | [6155]
□ Anti-Seizures therapy: levetiracetam (Keppra) (or other) | [6147]
□ Number of applications/day | [6156]
□ Number of days | [6157]
□ Other | [6148]
□ Specify other | [6149]
□ Number of applications/day | [6158]
□ Number of days | [6159]
□ IgG value before treatment by bi- and trispecific antibodies (g/l) | [6160]

○ **Toxicity during treatment (switch) | [174]**

□ Neuropathy - grade | [1902]
□ Related | [1903]
□ Nausea, vomiting - grade | [1904]
□ Related | [1905]
□ Anorexia - grade | [1906]
□ Related | [1907]
□ Diarrhoea - grade | [1908]
□ Related | [1909]
□ Constipation - grade | [1910]
□ Related | [1911]
□ Fatigue - grade | [1912]
□ Related | [1913]
□ Thrombosis/Thrombus/Embolism - grade | [1914]
□ Related | [1915]
□ Infection - grade | [1916]
□ Related | [1917]
□ Thrombocytopenia - grade | [1918]
□ Related | [1919]
□ Neutropenia - grade | [1920]
□ Related | [1921]
□ Anemia - grade | [1922]
□ Related | [1923]
□ Rash (exanthema) - grade | [4026]
□ Related | [4027]
□ IRR (infusion related reaction) - grade | [4209]
□ Dyspnoe - grade | [4373]
□ Related | [4374]
□ Related | [4210]
□ Decompensated diabetes mellitus - grade | [4375]
□ Related | [4376]
□ Hepatotoxicity - grade | [4377]

- □ Related | [4378]
- □ Cytokine release syndrom (CRS) - grade | [5490]
- □ Related | [5489]
- □ ICANS - grade | [5491]
- □ Related | [5492]
- □ Hemophagocytic lymphohistiocytosis - grade | [5493]
- □ Related | [5494]
- □ Pneumotoxicity - grade | [5495]
- □ Related | [5496]
- □ Keratopathy - grade | [5497]
- □ Related | [5498]
- □ Nail changes - grade | [5499]
- □ Related | [5500]
- □ Palmar/plantar desquamations - grade | [5501]
- □ Related | [5502]
- □ Headache – grade | [5503]
- □ Related | [5504]
- □ Hypogammaglobulinemia - grade | [6133]
- □ Related | [6246]
- □ Leukopenia - grade | [6139]
- □ Related | [6247]
- □ Lymfopenia - grade | [6140]
- □ Related | [6248]
- □ Hyponatremia - grade | [6141]
- □ Related | [6249]
- □ Hypofibrinogenemia - Grade | [6142]
- □ Related | [6250]
- □ Other neurotoxicity - grade | [6162]
- □ Related | [6251]
- □ Renal toxicity - grade | [6167]
- □ Related | [6252]
- □ Cardiotoxicity - grade | [6169]
- □ Related | [6253]
- □ CMV reactivation - grade | [6170]
- □ Related | [6254]
- □ Other unexpected toxicity | [4383]

- ○ **Other toxicity (switch) | [342]**
  - □ Specify toxicity | [4384]
  - □ Specify other toxicity | [4388]
  - □ Grade | [4385]
  - □ Related | [4386]
- ○ **Venous thromboembolism prevention (VTE prevetion) (switch) | [175]**
  - □ VTE prevention | [1930]
  - □ Type of VTE prevetion | [4507]
  - □ Acetylsalicylic acid | [4343]
  - □ Warfarin | [4344]

- □ LMWH | [4345]
- □ NOAC | [4346]
- □ Other | [4347]
- □ Specify anticoagulant treatment | [1932]

○ **Comments (switch) | [177]**

- □ Comments | [1936]

○ **Laboratory examination after treatment | [130]**

- □ Serum M-protein level after treatment (g/l) | [1425]
- □ Cannot be measured | [4095]
- □ Urine M-protein level after treatment (mg/24h) | [1426]
- □ Urine M-protein level after treatment (mg/l per 24h) | [1427]
- □ Serum M-protein - ratio after treatment/entry (%) | [1428]
- □ Urine M-protein (mg/24h) - ratio after treatment/entry (%) | [1429]
- □ Urine M-protein (mg/l per 24h) - ratio after treatment/entry (%) | [1430]
- □ Immunofixation after treatment - serum | [1431]
- □ Immunofixation after treatment - urine | [1432]
- □ Plasmocyte count (%) in bone marrow aspiration after treatment | [4235]
- □ Plasmocyte count (%) in bone marrow aspiration after treatment - exact number | [1433]
- □ Serum kappa FLC quantity after treatment (mg/l) | [4232]
- □ Serum lambda FLC quantity after treatment (mg/l) | [4233]
- □ Kappa/lambda ratio after treatment | [4234]
- □ Kappa/lambda ratio after treatment | [1436]

○ **Radiotherapy | [128]**

- □ Radiotherapy | [1414]
- □ Type of radiotherapy | [1415]
- □ Total dose [Gy] | [1416]

○ **Transplantation | [129]**

- □ Transplantation | [1417]
- □ Response before transplant | [1423]
- □ Date of transplantation | [1418]
- □ Transplantation technique | [1419]
- □ Type of conditioning regimen | [1420]
- □ Tandem autotransplantation - identical dosage? | [1421]
- □ Second conditioning regimen type | [1422]
- □ Date of subsequent transplant | [1424]

○ **Treatment withdrawal | [178]**

- □ Date of treatment withdrawal | [1937]
- □ Reason for treatment withdrawal | [1938]
- □ Specify other reason | [1939]
- □ Interruption of treatment | [1959]

○ **Interruption of treatment | [179]**

- □ Date of interruption | [1960]
- □ 1st reason | [1963]
- □ Specify other | [1964]
- □ Grade | [1965]

- □ 2nd reason | [1966]
- □ Grade | [1967]
- □ 3rd reason | [1968]
- □ Grade | [1969]

- **Response to induction treatment | [266]**
  - □ PR after cycle | [1942]
  - □ Date of partial response (for DOR calculation) | [1948]
  - □ Maximal response after cycle | [2830]
  - □ Date of maximal response | [1949]
  - □ Maximal response to treatment | [2827]
  - □ Final response after induction therapy | [3178]
- **MRD evaluation | [332]**
  - □ MRD evaluation | [3987]
- **MRD evaluation - specification | [318]**
  - □ Response in time of MRD | [4213]
  - □ Method | [3988]
  - □ Date of MRD | [3989]
  - □ Result of MRD | [3990]
  - □ PET/CT, PET/MRI evaluation | [5365]
  - □ Total number of FDG+ focuses | [5324]
  - □ Deauville score | [5326]
  - □ FDG+ focuses - skeleton | [5349]
  - □ Skull | [5325]
  - □ Axial skeleton | [5327]
  - □ Appendicular skeleton | [5344]
  - □ Fractures | [5345]
  - □ New focuses | [5328]
  - □ Number of PM lesions | [5330]
  - □ Deauville score | [5339]
  - □ Localization of PM lesions | [5338]
  - □ Skull | [5350]
  - □ Axial skeleton | [5351]
  - □ Appendicular skeleton | [5352]
  - □ New focuses | [5342]
  - □ Number of EM lesions | [5334]
  - □ Deauville score | [5329]
  - □ Localization of EM lesions | [5347]
  - □ Skin | [5353]
  - □ Muscles | [5354]
  - □ Connective tissue | [5355]
  - □ Parenchymatous organs | [5356]
  - □ CNS | [5363]
  - □ Other | [5357]
  - □ New focuses | [5343]
  - □ FDG+ lymph nodes | [5336]
  - □ Deauville score | [5341]

- □ New focuses | [5331]
- □ Bone marrow | [5348]
- □ Deauville score | [5340]
- □ CT: lytic focuses - skeleton | [5337]
- □ Localization of lytic focuses | [5364]
- □ Skull | [5358]
- □ Axial skeleton | [5359]
- □ Appendicular skeleton | [5360]
- □ New focuses | [5332]
- □ Other lesions - skeleton (FDG-) | [5346]
- □ Lesions <5 mm | [5361]
- □ Fractures | [5362]
- □ New focuses | [5333]
- □ | [5335]
- □ Sensitivity | [3991]
- □ Grade | [3992]
- □ Limit of detection (LOD) (%) | [4365]
- □ Level (%) | [4366]

○ **Consolidation treatment | [180]**
- □ Consolidation treatment (! except for PBSCT) | [1970]
- □ Specify consolidation treatment | [1971]
- □ Specify other treatment | [1972]
- □ Date of treatment initiation | [1973]
- □ Date of treatment withdrawal | [1974]
- □ Reason for treatment withdrawal | [1975]
- □ Number of cycles | [1976]
- □ Maximal response | [1977]
- □ Date of maximal response | [3689]

○ **Consolidation treatment - adverse events | [181]**
- □ Toxicity | [1978]
- □ Specify other | [1979]
- □ Grade | [1980]

○ **Maintenance therapy | [182]**
- □ Maintenance therapy | [1981]
- □ Specify maintenance therapy | [1982]
- □ Specify other treatment | [1983]
- □ Clinical study | [6758]
- □ Name of clinical study | [6759]
- □ Treatment beginning date | [1984]
- □ Date of treatment withdrawal | [1985]
- □ Reason for treatment withdrawal | [1986]
- □ Specify other reason | [4319]
- □ Maximal response | [1987]
- □ Date of maximal response | [3688]

○ **Maintenance therapy - adverse events | [183]**
- □ Toxicity | [1988]

□ Specify other | [1989]
□ Grade | [1990]

- **Maintenance therapy - Bispecific, Trispecific and Multispecific Antibodies | [423]**
  - □ Extended questionnaire | [6762]
  - □ Specific treatment | [6763]
  - □ Tocilizumab | [6764]
  - □ Number of applications/day | [6765]
  - □ Number of days | [6766]
  - □ Anakinra | [6767]
  - □ Number of applications/day | [6768]
  - □ Number of days | [6769]
  - □ Corticosteroids | [6770]
  - □ Number of applications/day | [6771]
  - □ Number of days | [6772]
  - □ Anti-Seizures therapy: levetiracetam (Keppra) (or other) | [6773]
  - □ Number of applications/day | [6774]
  - □ Number of days | [6775]
  - □ Other | [6776]
  - □ Specify other | [6777]
  - □ Number of applications/day | [6778]
  - □ Number of days | [6779]
  - □ IgG value before treatment by bi- and trispecific antibodies (g/l) | [6780]
- **Response after treatment line | [285]**
  - □ Fill in final response after . | [3179]
  - □ Final response after treatment line | [3180]
- **| [389]**
  - □ Form is fully filled | [4876]

▪ **Watch and wait | [26]**

- **After line of treatment | [288]**
  - □ After line | [3183]
- **Progression | [289]**
  - □ Date of progression | [3184]

▪ **Current status | [17]**

- **ALA associated with MM | [240]**
  - □ MM associated amyloidosis | [872]
- **Secondary malignancy | [409]**
  - □ Occurence of secondary malignancy | [5813]
  - □ Date of occurence | [5814]
  - □ Specify | [5815]
- **Current status | [87]**
  - □ EN: Do not fill in the date of form update! Fill in the date of last examination, to which „patient status“ below is related. In case of the answer „Unknown“ fill in the date of the last contact with the patient, do not fill in the date of loss of follow-up, because in this case data cannot be used for calculation of patient´s survival. CZ: Do otázky nezapisujte datum vyplnění formuláře! Zapište datum poslední kontroly pacienta, ke které se vztahuje stav pacienta v otázce níže. I v případě „Unknown“ nechávejte v otázce datum posledního kontaktu s pacientem a nepřepisujte jej na

datum, ke kterému je pacient ztracen se sledování. Data pak nelze použít k výpočtu přežití pacienta. | [4300]

- ☐ Date of the last update | [952]
- ☐ Patient status | [953]
- ☐ Patient status - alive | [954]
- ☐ Date of death | [955]
- ☐ Date of diagnosis | [959]
- ☐ Get data! | [2383]
- ☐ Date of diagnosis for transfer from Diagnostics forms is empty. | [2820]
- ☐ OS (days) | [958]
- ☐ Cause of death | [956]
- ☐ Note | [957]

- **VILP Kyprolis - mandatory questions for VILP | [24]**
  - **Characteristics at the beginning of Kyprolis treatment | [272]**
    - ☐ Height (cm) | [2905]
    - ☐ Weight (kg) | [2908]
    - ☐ Important comorbidities | [2910]
    - ☐ WHO ECOG | [2911]
    - ☐ Associated with relapse of MM? | [2912]
  - **Dose adjustment of Kyprolis | [274]**
    - ☐ Dose adjustment | [2914]
  - **Dose adjustment of Kyprolis - specification | [275]**
    - ☐ Reduction number | [2915]
    - ☐ Date of dose adjustment | [2916]
    - ☐ New dosage (mg/m2) | [2917]
    - ☐ Type of dose adjustment | [2918]
    - ☐ Reason for dose reduction: | [2919]
    - ☐ Hematological adverse events | [2928]
    - ☐ Pre-fill Hematological adverse events with GRADE 0 | [4218]
    - ☐ Anemia - grade | [2929]
    - ☐ Neutropenia - grade | [2931]
    - ☐ Febrile neutropenia - grade | [2932]
    - ☐ Thrombocytopenia - grade | [2933]
    - ☐ Other AE | [2934]
    - ☐ Specify other - text | [2935]
    - ☐ Specify other - grade | [2936]
    - ☐ Non-hematological adverse events | [2937]
    - ☐ Pre-fill Non-hematological adverse events with GRADE 0 | [4219]
    - ☐ GI events | [2938]
    - ☐ Nausea - grade | [2939]
    - ☐ Vomiting - grade | [2940]
    - ☐ Diarrhoea - grade | [2941]
    - ☐ Other AE | [2942]
    - ☐ Specify other - text | [2943]
    - ☐ Specify other - grade | [2944]
    - ☐ Cardiac events | [2945]

□ Cardiac failure - grade | [2946]
□ Acute coronary syndrome - grade | [2947]
□ Arrhythmia - grade | [2948]
□ Other AE | [2949]
□ Specify other - text | [2950]
□ Specify other - grade | [2951]
□ Vascular events | [2952]
□ Hypertension - grade | [2953]
□ Venous thromboembolism - grade | [2954]
□ Other AE | [2955]
□ Specify other - text | [2956]
□ Specify other - grade | [2957]
□ Pulmonary events | [2987]
□ Dyspnoe - grade | [2988]
□ Pulmonary hypertension - grade | [2989]
□ Pulmonary embolism - grade | [2990]
□ Other AE | [2991]
□ Specify other - text | [2992]
□ Specify other - grade | [2993]
□ Infections - grade | [2958]
□ Upper respiratory infection - grade | [2959]
□ Pneumonia - grade | [2960]
□ Sepsis - grade | [2961]
□ Other AE | [2962]
□ Specify other - text | [2963]
□ Specify other - grade | [2964]
□ Renal impairment | [2965]
□ Acute renal failure - grade | [2966]
□ Other AE | [2967]
□ Specify other - text | [2968]
□ Specify other - grade | [2969]
□ Infusion reactions | [2970]
□ Pyrexia - grade | [2971]
□ Other AE | [2972]
□ Specify other - text | [2973]
□ Specify other - grade | [2974]
□ Peripheral neuropathy | [3059]
□ Peripheral neuropathy - grade | [2975]
□ Fatigue | [3060]
□ Fatigue - grade | [2976]
□ Other AE | [3061]
□ Other AE | [2977]
□ Specify other - text | [2978]
□ Specify other - grade | [2979]
□ Other non-AE related reasons | [2924]
□ Disease progression | [2925]

- ☐ Specify other - text | [2926]

- **Treatment withdrawal - Kyprolis | [276]**
  - ☐ Date of Kyprolis treatment withdrawal | [2930]
  - ☐ Reason for Kyprolis treatment withdrawal | [2994]
  - ☐ Specify other reason | [2995]
  - ☐ Date of lenalidomide treatment withdrawal | [2996]
  - ☐ Date of dexamethasone treatment withdrawal | [2997]
- **AE as reason for permanent discontinuation of Kyprolis | [277]**
  - ☐ Hematological adverse events | [2998]
  - ☐ Pre-fill Hematological adverse events with GRADE 0 | [4216]
  - ☐ Anemia - grade | [2999]
  - ☐ Neutropenia - grade | [3000]
  - ☐ Febrile neutropenia - grade | [3001]
  - ☐ Thrombocytopenia - grade | [3002]
  - ☐ Other AE | [3003]
  - ☐ Specify other - text | [3004]
  - ☐ Specify other - grade | [3005]
  - ☐ Non-hematological adverse events | [3006]
  - ☐ Pre-fill Non-hematological adverse events with GRADE 0 | [4217]
  - ☐ GI events | [3007]
  - ☐ Nausea - grade | [3008]
  - ☐ Vomiting - grade | [3009]
  - ☐ Diarrhoea - grade | [3010]
  - ☐ Other AE | [3011]
  - ☐ Specify other - text | [3012]
  - ☐ Specify other - grade | [3013]
  - ☐ Cardiac events | [3014]
  - ☐ Cardiac failure - grade | [3015]
  - ☐ Acute coronary syndrome - grade | [3016]
  - ☐ Arrhythmia - grade | [3017]
  - ☐ Other AE | [3018]
  - ☐ Specify other - text | [3019]
  - ☐ Specify other - grade | [3020]
  - ☐ Vascular events | [3021]
  - ☐ Hypertension - grade | [3022]
  - ☐ Venous thromboembolism - grade | [3023]
  - ☐ Other AE | [3024]
  - ☐ Specify other - text | [3025]
  - ☐ Specify other - grade | [3026]
  - ☐ Pulmonary events | [3027]
  - ☐ Dyspnoe - grade | [3028]
  - ☐ Pulmonary hypertension - grade | [3029]
  - ☐ Pulmonary embolism - grade | [3030]
  - ☐ Other AE | [3031]
  - ☐ Specify other - text | [3032]
  - ☐ Specify other - grade | [3033]

□ Infections | [3034]
□ Upper respiratory infection - grade | [3035]
□ Pneumonia - grade | [3036]
□ Sepsis - grade | [3037]
□ Other AE | [3038]
□ Specify other - text | [3039]
□ Specify other - grade | [3040]
□ Renal impairment | [3041]
□ Acute renal failure - grade | [3042]
□ Other AE | [3043]
□ Specify other - text | [3044]
□ Specify other - grade | [3045]
□ Infusion reactions | [3046]
□ Pyrexia - grade | [3047]
□ Other AE | [3048]
□ Specify other - text | [3049]
□ Specify other - grade | [3050]
□ Peripheral neuropathy | [3062]
□ Peripheral neuropathy - grade | [3051]
□ Fatigue | [3063]
□ Fatigue - grade | [3052]
□ Other AE | [3064]
□ Other AE | [3053]
□ Specify other - text | [3054]
□ Specify other - grade | [3055]

- **VILP Kyprolis - Adverse event | [23]**
  - **AE during treatment with Kyprolis | [268]**

□ Adverse event reporting as part of data collection within the registry is not a substitute for the legal obligation to report any adverse effects to the State Institute for Drug Control (SUKL). Hlášení NP v rámci sběru dat v registru nenahrazuje z legislativy plynoucí povinnosti hlásit nežádoucí účinek na SÚKL. | [2913]

□ Date of onset of adverse event | [2841]
□ End date of adverse event duration | [2842]
□ Is it serious adverse event | [2843]
□ * Choose any one or more of the following checkbox: | [2927]
□ Patient died | [2844]
□ Event endangered the patient's life | [2845]
□ Permanent disability | [2846]
□ Teratogenic effects | [2847]
□ Medically significant event | [2848]
□ Supposed relationship with Kyprolis | [2849]
□ Hospitalization connected to adverse event | [2850]
□ Treatment due to AE | [2856]

  - **Hospitalization | [269]**

□ Date of hospitalization | [2852]
□ Length of hospitalization (days) | [2853]

  - **Treatment due to adverse event | [270]**

- ☐ Specification of treatment | [2854]
- ☐ Length of treatment (days) | [2855]

- **Type of adverse event | [271]**
  - ☐ Hematological adverse events | [2857]
  - ☐ Pre-fill Hematological adverse events with GRADE 0 | [4214]
  - ☐ Anemia - grade | [2858]
  - ☐ Neutropenia - grade | [2859]
  - ☐ Febrile neutropenia - grade | [2860]
  - ☐ Thrombocytopenia - grade | [2861]
  - ☐ Other AE | [2862]
  - ☐ Specify other - text | [2863]
  - ☐ Specify other - grade | [2871]
  - ☐ Non-hematological adverse events | [2864]
  - ☐ Pre-fill Non-hematological adverse events with GRADE 0 | [4215]
  - ☐ GI events | [2865]
  - ☐ Nausea - grade | [2866]
  - ☐ Vomiting - grade | [2867]
  - ☐ Diarrhoea - grade | [2868]
  - ☐ Other AE | [2869]
  - ☐ Specify other - text | [2870]
  - ☐ Specify other - grade | [2872]
  - ☐ Cardiac events | [2873]
  - ☐ Cardiac failure - grade | [2874]
  - ☐ Acute coronary syndrome - grade | [2875]
  - ☐ Arrhythmia - grade | [2876]
  - ☐ Other AE | [2877]
  - ☐ Specify other - text | [2878]
  - ☐ Specify other - grade | [2879]
  - ☐ Vascular events | [2880]
  - ☐ Hypertension - grade | [2881]
  - ☐ Venous thromboembolism - grade | [2882]
  - ☐ Other AE | [2883]
  - ☐ Specify other - text | [2884]
  - ☐ Specify other - grade | [2885]
  - ☐ Pulmonary events | [2980]
  - ☐ Dyspnoe - grade | [2981]
  - ☐ Pulmonary hypertension - grade | [2982]
  - ☐ Pulmonary embolism - grade | [2983]
  - ☐ Other AE | [2984]
  - ☐ Specify other - text | [2985]
  - ☐ Specify other - grade | [2986]
  - ☐ Infections | [2886]
  - ☐ Upper respiratory infection - grade | [2887]
  - ☐ Pneumonia - grade | [2888]
  - ☐ Sepsis - grade | [2889]
  - ☐ Other AE | [2890]

□ Specify other - text | [2891]
□ Specify other - grade | [2892]
□ Renal impairment | [2893]
□ Acute renal failure - grade | [2894]
□ Other AE | [2895]
□ Specify other - text | [2896]
□ Specify other - grade | [2897]
□ Infusion reactions | [2898]
□ Pyrexia - grade | [2899]
□ Other AE | [2900]
□ Specify other - text | [2901]
□ Specify other - grade | [2902]
□ Peripheral neuropathy | [3056]
□ Peripheral neuropathy - grade | [2903]
□ Fatigue | [3057]
□ Fatigue - grade | [2904]
□ Other AE | [3058]
□ Other AE | [2906]
□ Specify other - text | [2907]
□ Specify other - grade | [2909]

- **VILP Revlimid - mandatory questions for VILP | [29]**
  - **Characteristics at the beginning of Revlimid treatment | [319]**
    □ Second primary cancer | [3994]
    □ Invasive | [3995]
    □ Non-invasive (non-melanoma skin cancer) | [3996]
    □ Type of invasive cancer | [3997]
    □ * Choose any one or more of the following checkbox: | [4089]
    □ Hematologic | [3998]
    □ Solid tumor | [3999]
    □ WHO ECOG | [4000]
    □ Specify the reason of ECOG 3 or 4 | [4001]
  - **Basic characteristics of therapy | [333]**
    □ Switch from dexamethasone to prednisone | [4224]
    □ Date of switch from dexamethasone to prednisone | [4225]
  - **Dosage of prednisone | [334]**
    □ Dosage (mg) | [4226]
    □ Number of administrations per cycle | [4227]
    □ Number of cycles | [4228]
    □ Total number of administrations | [4229]
    □ Total cumulative dosage (mg) | [4230]
- **VILP Revlimid - Adverse events | [28]**
  - **AE during treatment with Revlimid | [320]**
    □ Adverse event reporting as part of data collection within the registry is not a substitute for the legal obligation to report any adverse effects to the State Institute for Drug Control (SUKL). Hlášení NP v rámci sběru dat v registru nenahrazuje z legislativy plynoucí povinnosti hlásit nežádoucí účinek na SÚKL. | [4002]
    □ Date of onset of adverse event | [4003]

□ End date of adverse event duration | [4004]
□ Is it serious adverse event | [4005]
□ * Choose any one or more of the following checkbox: | [4006]
□ Patient died | [4007]
□ Event endangered the patient's life | [4008]
□ Permanent disability | [4009]
□ Teratogenic effects | [4010]
□ Medically significant event | [4011]
□ Supposed relationship with Revlimid | [4012]
□ Hospitalization connected to adverse event | [4013]
□ Treatment due to AE | [4014]

- **Hospitalization | [321]**
  - □ Date of hospitalization | [4015]
  - □ Length of hospitalization (days) | [4016]
- **Treatment due to adverse event | [322]**
  - □ Specification of treatment | [4017]
  - □ Length of treatment (days) | [4018]
- **Type of adverse event | [323]**
  - □ Type of adverse event | [4019]
  - □ Specify other | [4020]
  - □ Grade of the adverse event | [4021]

- **VILP Empliciti - mandatory questions for VILP | [30]**
  - **Treatment in previous lines | [326]**
    - □ Line of therapy with Empliciti | [4106]
    - □ Previous transplantation | [4107]
    - □ Previous therapy with bortezomib | [4108]
    - □ Previous therapy with thalidomide | [4109]
    - □ Previous therapy with lenalidomide | [4110]
    - □ Reaction to last previous therapy with lenalidomide | [4111]
    - □ Time to relapse/progression after last dose of lenalidomide | [4112]
    - □ Number of cycles in last previous therapy with lenalidomide | [4113]
    - □ Reason for treatment withdrawal in last previous therapy with lenalidomide | [4114]
    - □ Response to most recent line of therapy | [4115]
  - **Characteristics at the beginning of Empliciti treatment | [325]**
    - □ WHO ECOG | [4102]
    - □ Associated with relapse of MM? | [4103]
    - □ If therapy carried out in 2nd line one of following has to be positive: | [4116]
    - □ del(17)(p13) | [4104]
    - □ t(4;14) | [4105]
- **VILP Ninlaro - mandatory questions for VILP | [31]**
  - **Treatment in previous lines | [327]**
    - □ Line of therapy with Ninlaro | [4124]
    - □ Previous transplantation | [4125]
    - □ Previous therapy with bortezomib | [4126]
    - □ Reaction to last previous therapy with bortezomib | [4127]

□ Previous therapy with thalidomide | [4128]
□ Reaction to last previous therapy with thalidomide | [4129]
□ Previous therapy with lenalidomide | [4130]
□ Reaction to last previous therapy with lenalidomide | [4131]

- **Characteristics at the beginning of Ninlaro treatment | [328]**
  - □ Disease category | [4132]
  - □ WHO ECOG | [4133]
  - □ Associated with relapse of MM? | [4134]
  - □ Cytogenetic risk | [4135]
  - □ Treatment does not meet inclusion criteria If therapy carried out in 2nd or 5th or higher line and standard risk selected. | [4139]
  - □ del(17)(p13) | [4136]
  - □ t(4;14) | [4137]
  - □ t(14;16) | [4138]

- **VILP Revlimid maintenance - mandatory questions for VILP | [34]**
  - **Patient's characteristics | [339]**
    - □ Second primary cancer | [4317]
    - □ Specify second primary cancer | [4318]
  - **Baseline characteristics at initiation of induction regimen | [337]**
    - □ WHO ECOG | [4308]
  - **Dosage of Revlimid | [338]**
    - □ Date of treatment episode initiation | [4309]
    - □ Dose (mg) | [4310]
    - □ Number of doses in 28-days cycle | [4311]
    - □ Change in treatment protocol | [4312]
    - □ Specify change | [4313]
    - □ Date of treatment episode withdrawal | [4314]
    - □ Reason for treatment episode withdrawal | [4315]
    - □ Specify other | [4316]
- **VILP Darzalex - mandatory questions for VILP | [32]**
  - **Refractory disease | [324]**
    - □ Refractory to last line of therapy | [4188]
    - □ Refractory to lenalidomide | [4189]
    - □ Refractory to proteasome inhibitor only | [4190]
    - □ Refractory to immunomodulatory drug only | [4191]
    - □ Refractory to proteasome inhibitor and immunomodulatory drug | [4192]
  - **Characteristics at the beginning of Darzalex treatment | [331]**
    - □ Height (cm) | [4193]
    - □ Weight (kg) | [4194]
    - □ Important comorbidities | [4195]
    - □ Specify important comorbidities | [4196]
    - □ WHO ECOG | [4198]
    - □ Associated with relapse of MM? | [4197]
    - □ Cytogenetic risk | [4199]
    - □ del(17)(p13) | [4200]
    - □ t(4;14) | [4201]

□ t(14;16) | [4202]

- **VILP VRd - mandatory questions for VILP | [40]**
  - **Characteristics at the beginning of treatment | [360]**
    - □ Height (cm) | [4193]
    - □ Weight (kg) | [4194]
    - □ Important comorbidities | [4195]
    - □ Specify important comorbidities | [4196]
    - □ WHO ECOG | [4509]
    - □ Associated with MM? | [4501]
  - **Bortezomib | [361]**
    - □ Change from VRd (21-days cycle) to VRd regimen (28-days cycle) | [4504]
    - □ Date of change from VRd to VRd regimen | [4505]
  - **Next treatment | [362]**
    - □ Intent to transplant in next treatment (any following treatment line) | [4508]
- **Covid-19 | [33]**
  - **Record of COVID-19 infection for RMG | [335]**
    - □ Date of COVID-19 diagnosis | [4236]
    - □ Test used | [4237]
    - □ PCR | [4238]
    - □ Antigen test | [4348]
    - □ Tested material | [4240]
    - □ Bronchoalveolar lavage (fluid) | [4280]
    - □ Nasopharyngeal swab | [4281]
    - □ Throat swab | [4282]
    - □ Other material | [4283]
    - □ Specify other tested material | [4241]
    - □ Course of infection | [4242]
    - □ Symptoms * Choose any one or more of the following checkboxes: | [4243]
    - □ Fever > 37 °C | [4244]
    - □ Cough | [4245]
    - □ Shortness of breath or difficulty breathing | [4246]
    - □ Chills | [4247]
    - □ Muscle or joint pains | [4248]
    - □ Headache | [4249]
    - □ Sore throat | [4250]
    - □ New loss of taste or smell | [4251]
    - □ „Covid toe“ (itchy rash on toes) | [4252]
    - □ Nausea/vomiting | [4349]
    - □ Diarrhoea | [4350]
    - □ Neuropathy | [4351]
    - □ Neurologic symptoms | [4352]
    - □ Other | [4353]
    - □ Specify other | [4354]
    - □ Severity | [4253]

- ☐ Hospitalization | [4254]
- ☐ Type of hospitalization | [4255]
- ☐ Standard department | [4284]
- ☐ Intensive care unit | [4285]
- ☐ Length of hospitalization (days) | [4256]
- ☐ Breath support | [4257]
- ☐ Without support | [4286]
- ☐ AIRVO or non-invasive LV | [4287]
- ☐ ALV | [4288]
- ☐ ECMO | [4289]
- ☐ Oxygen | [4290]
- ☐ Treatment used | [4258]
- ☐ Without treatment | [4291]
- ☐ Convalescent plasma | [4292]
- ☐ Lopinavir + ritonavir | [4293]
- ☐ Favipiravir | [4294]
- ☐ Hydroxychloroquine + clarithromycin | [4295]
- ☐ Remdesivir | [4296]
- ☐ Other treatment | [4297]
- ☐ Specify other treatment | [4298]
- ☐ Date of negative test | [4259]
- ☐ Length of positivity (days) | [4260]
- ☐ Antibody test performed | [4261]
- ☐ Comorbidities | [4278]
- ☐ * Choose any one or more of the following checkboxes: | [4264]
- ☐ Diabetes mellitus | [4265]
- ☐ Heart disease | [4266]
- ☐ Hypertension | [4267]
- ☐ Lung disease | [4268]
- ☐ Obesity (BMI > 30) | [4269]
- ☐ Other comorbidity | [4270]
- ☐ Specify other comorbidity | [4271]
- ☐ Bacterial superinfection | [4272]
- ☐ Specify type of bacterial superinfection | [4273]
- ☐ Relation to neutropenia < 0.5 | [4274]
- ☐ Thrombotic complications during COVID-19 infection | [4275]
- ☐ Specify complications | [4276]
- ☐ Final state | [4277]

- **Antibody detection | [336]**
  - ☐ Date of test | [4262]
  - ☐ Antibody detected? | [4263]
  - ☐ Time from diagnosis | [4299]
- **| [389]**
  - ☐ Form is fully filled | [4876]

- **Covid-19 vaccination | [35]**
  - **Covid-19 vaccination | [340]**

- ☐ Vaccination date (1st dose) | [4355]
- ☐ Received as scheduled (all doses) | [4356]
- ☐ Vaccine type | [4357]
- ☐ Specify other vaccine | [4358]
- ☐ Antibody test performed | [4359]
- ☐ Date of antibody test | [4360]
- ☐ Result (IgG) | [4361]
- ☐ Serum virus neutralization test performed | [4362]
- ☐ Date of test | [4363]
- ☐ Result | [4364]

| [389]

- ☐ Form is fully filled | [4876]

AMYL | [5]

Diagnostics | [19]

Characteristic of amyloidosis | [185]

- ☐ Date of AMYL diagnosis | [1995]
- ☐ Type of amyloidosis | [1996]
- ☐ Diffused | [1997]
- ☐ Localization | [2398]
- ☐ Node | [1999]
- ☐ GIT | [2000]
- ☐ Tracheobronchial | [2001]
- ☐ Pulmonary | [2002]
- ☐ Kidney | [2003]
- ☐ Heart | [2004]
- ☐ Skin | [2005]
- ☐ Other | [2006]
- ☐ Specify other | [2007]

Laboratory - serum (protein analysis) | [186]

- ☐ M-protein type | [2008]
- ☐ Light chain type | [2009]
- ☐ Serum M-protein quantity (g/l) | [2010]
- ☐ Cannot be measured | [2786]
- ☐ Total M-protein quantity (g/l) | [2011]
- ☐ Albumin level (g/l) | [2012]
- ☐ Serum kappa FLC quantity (mg/l) | [2013]
- ☐ Serum lambda FLC quantity (mg/l) | [2014]
- ☐ Kappa/lambda ratio | [2015]
- ☐ IgG quantity (g/l) | [2016]
- ☐ IgA quantity (g/l) | [2017]
- ☐ IgM quantity (g/l) | [2018]
- ☐ IgG HLC ratio | [2021]
- ☐ IgA HLC ratio | [2024]
- ☐ IgM HLC ratio | [2027]

Analysis of a heart indicators | [187]

- ☐ Troponin T (ng/l) | [2028]

- □ NT-proBNP (ng/l) | [2029]
- □ Mayo stage | [2030]
- □ Revised Mayo stage | [2031]

○ **Other parameters | [188]**

- □ Leukocyte count (10E9/l) | [2033]
- □ Hemoglobin level (g/l) | [2034]
- □ Thrombocyte count (10E9/l) | [2035]
- □ Factor X deficit | [2036]
- □ Creatinine level (µmol/l) | [2037]
- □ Uric acid level (µmol/l) | [2038]
- □ Glom. filtration according to MDRD (ml/s/1,73m2) | [2039]
- □ Beta2 microglobulin (mg/l) | [2040]
- □ LDH (µkat/l) | [2041]
- □ ALP (µkat/l) | [2042]
- □ Calcium (mmol/l) | [2043]

○ **Analysis of urine | [189]**

- □ Total protein in the urine (g/day) | [2044]
- □ Urine M-protein type | [2045]
- □ Free light chain urine type | [2046]
- □ Urine M-protein quantity (mg/24h) | [2047]
- □ Urine M-protein quantity (mg/l per 24h) | [2048]
- □ Urine albumin level (mg/24 h) | [2049]

○ **Bone marrow analysis | [190]**

- □ Bone marrow aspiration cytology performed | [2050]
- □ Monoclonal plasmocyte count (%) in aspiration | [2051]
- □ Bone marrow histology performed | [2052]
- □ Monoclonal plasmocyte count (%) by histology | [2053]
- □ Clonal plasma cells count (%) in histology | [2054]

○ **Flow cytometry | [191]**

- □ Flow cytometry – plasma cells (bone marrow) | [2055]
- □ Plasmocyte count FC (%) | [2056]
- □ Clonal PC (%) | [2060]
- □ Polyclonal PC (%) | [2061]
- □ Flow cytometry – circulating plasma cells (peripheral blood) | [4868]
- □ cPCs (%) - peripheral blood | [4869]
- □ cPCs (absolute value/uL) - peripheral blood | [4870]
- □ Detection limit (LOD) | [4871]

○ **Cytogenetic | [192]**

- □ Cytogenetics | [4562]
- □ Date of sample collection | [2063]
- □ Conventional | [4563]
- □ Result | [4564]
- □ FISH | [2062]
- □ Method used | [4565]
- □ Purity (%) | [4566]
- □ FISH Result | [4567]

- □ At least one result of cytogenetic must be performed: | [2823]
- □ IGH disruption | [2064]
- □ t(11,14) | [2065]
- □ t(11;14) (%) | [2066]
- □ t(4,14) | [2067]
- □ t(4;14) (%) | [2068]
- □ t(6,14) | [2069]
- □ t(6;14) (%) | [2070]
- □ t(14,16) | [2071]
- □ t(14;16) (%) | [2072]
- □ del(13)(q14)/monosomy 13 | [2073]
- □ del(13)(q14)/monosomy 13 (%) | [2074]
- □ gain 1q21 | [2075]
- □ gain 1q21 (%) | [2076]
- □ del(17)(p13) | [2077]
- □ del(17)(p13) (%) | [2078]
- □ Hyperdiploidy | [2079]

○ **Echocardiography | [193]**

- □ Echocardiography | [2080]
- □ Left ventricular ejection fraction (%) | [2081]
- □ Interventricular septum diastolic diameter (mm) | [2082]
- □ Left atrium diameter (mm) | [2083]
- □ Mitral regurgitation | [2084]

○ **MR of myocardium | [194]**

- □ MR of myocardium | [2085]
- □ Left ventricular ejection fraction (%) | [2086]
- □ Interventricular septum diastolic diameter (mm) | [2087]
- □ Delayed enhancement | [2088]
- □ Type of involvement | [2089]

○ **ECG | [195]**

- □ ECG | [2090]
- □ Basic rhythm | [2091]
- □ Ventricular rate | [2092]
- □ Low voltage of limb leads under 5 mm | [2094]
- □ QS - "pseudoinfarct pattern" of anterior wall | [2095]

○ **Characteristic of patient | [196]**

- □ WHO status performance | [2096]
- □ Other serious diseases (not related with AL and damages of organs) | [2097]
- □ Specify other | [2098]
- □ Height (cm) | [2099]
- □ Weight (kg) | [2100]
- □ BMI | [2101]
- □ Blood pressure - systolic (mmHg) | [2102]
- □ Blood pressure - diastolic (mmHg) | [2103]

○ **Characteristic of disease | [197]**

- □ Liver width (cm) | [2104]

        - ☐ Nefrotic syndrome | [2105]
        - ☐ Heart failure | [2106]
        - ☐ NYHA | [2107]
        - ☐ Orthostatic hypotension | [2108]
        - ☐ Peripheral neuropathy | [2109]
        - ☐ Hepatopathy | [2110]
        - ☐ GIT | [2111]
        - ☐ Skin | [2112]
        - ☐ Other signs | [2399]
        - ☐ Macroglossia | [2113]
        - ☐ Periorbital purpura | [2114]
        - ☐ Carpal Tunnel Syndrome | [2115]
        - ☐ Shoulder pad sign | [2116]
    - **Amyloid positive biopsy | [199]**
        - ☐ Detection method used | [2119]
        - ☐ Specify other | [2120]
        - ☐ Subcutaneous fat | [2121]
        - ☐ Tongue, buccal mucosa | [2122]
        - ☐ Rectum | [2123]
        - ☐ Bone marrow | [2124]
        - ☐ Kidney | [2125]
        - ☐ Endomyocardial biopsy | [2126]
        - ☐ Other | [2127]
        - ☐ Specify other | [2128]
    - **| [389]**
        - ☐ Form is fully filled | [4876]
- **Treatment | [21]**
    - **Line of treatment | [201]**
        - ☐ Line of treatment | [2137]
    - **Relapse/progression | [254]**
        - ☐ Reason for treatment | [2741]
        - ☐ Date of relapse/progression | [2742]
    - **Treatment | [202]**
        - ☐ Treatment regimen | [2138]
        - ☐ Specify combination of 6 or more drugs | [2140]
        - ☐ Uncategorizable treatment specification | [2141]
        - ☐ Rewritten | [2799]
        - ☐ Length of cycle (days) | [2145]
        - ☐ Date of treatment initiation | [2146]
    - **Drugs - overview | [203]**
        - ☐ bortezomib | [2631]
        - ☐ Dosage (mg/m2) | [2152]
        - ☐ Route of administration | [2153]
        - ☐ Number of administrations per cycle | [2154]
        - ☐ Number of cycles | [2155]
        - ☐ Dose adjustment | [2156]

□ carfilzomib | [2632]
□ Dosage (mg/m2) | [2157]
□ Route of administration | [2158]
□ Number of administrations per cycle | [2159]
□ Number of cycles | [2160]
□ Dose adjustment | [2161]
□ daratumumab | [4544]
□ Dosage | [4545]
□ Units | [4661]
□ Do you really want to enter value different from 16 mg/kg? | [4878]
□ Route of administration | [4546]
□ Number of administrations per cycle | [4547]
□ Number of cycles | [4548]
□ Dose adjustment | [4549]
□ cyklofosfamid | [2633]
□ Dosage (mg) | [2162]
□ Number of administrations per cycle | [2164]
□ Number of cycles | [2165]
□ dexamethason | [2634]
□ Dosage (mg) | [2167]
□ Number of administrations per cycle | [2169]
□ Number of cycles | [2170]
□ ixazomib | [2635]
□ Dosage (mg) | [2172]
□ Number of administrations per cycle | [2174]
□ Number of cycles | [2175]
□ Dose adjustment | [2176]
□ lenalidomid | [2636]
□ Dosage (mg) | [2177]
□ Number of administrations per cycle | [2179]
□ Number of cycles | [2180]
□ Dose adjustment | [2181]
□ melphalan | [2637]
□ Dosage (mg/m2) | [2187]
□ Number of administrations per cycle | [2189]
□ Number of cycles | [2190]
□ methylprednisolon | [2638]
□ Dosage (mg) | [2192]
□ Number of administrations per cycle | [2194]
□ Number of cycles | [2195]
□ prednison | [2640]
□ Dosage (mg) | [2197]
□ Number of administrations per cycle | [2199]
□ Number of cycles | [2200]
□ pomalidomid | [2639]
□ Dosage (mg) | [2202]

- □ Number of administrations per cycle | [2204]
- □ Number of cycles | [2205]
- □ Dose adjustment | [2206]
- □ thalidomid | [2641]
- □ Dosage (mg) | [2207]
- □ Number of administrations per cycle | [2209]
- □ Number of cycles | [2210]
- □ Dose adjustment | [2642]
- □ birtamimab | [5134]
- □ Dosage (mg/kg) | [5135]
- □ Route of administration | [5173]
- □ Number of administrations per cycle | [5136]
- □ Number of cycles | [5137]
- □ Dose adjustment | [5138]

○ **Dose adjustment - bortezomib | [204]**

- □ Date of dose adjustment | [2643]
- □ 1st reason | [2644]
- □ Specify other | [2645]
- □ Grade | [2646]
- □ 2nd reason | [2647]
- □ Grade | [2648]
- □ 3rd reason | [2649]
- □ Grade | [2650]
- □ New dosage (mg/m2) | [2651]
- □ Dose interruption | [4033]
- □ Number of administrations per cycle | [5573]

○ **Dose adjustment - thalidomid | [214]**

- □ Date of dose adjustment | [2732]
- □ 1st reason | [2733]
- □ Specify other | [2734]
- □ Grade | [2735]
- □ 2nd reason | [2736]
- □ Grade | [2737]
- □ 3rd reason | [2738]
- □ Grade | [2739]
- □ New dosage (mg) | [2740]
- □ Dose interruption | [4034]
- □ Number of administrations per cycle | [5575]

○ **Dose adjustment - lenalidomid | [209]**

- □ Date of dose adjustment | [2688]
- □ 1st reason | [2774]
- □ Specify other | [2689]
- □ Grade | [2690]
- □ 2nd reason | [2691]
- □ Grade | [2692]
- □ 3rd reason | [2693]

- □ Grade | [2694]
- □ New dosage (mg) | [2695]
- □ Dose interruption | [4035]
- □ Number of administrations per cycle | [5577]

○ **Dose adjustment - pomalidomid | [212]**

- □ Date of dose adjustment | [2714]
- □ 1st reason | [2715]
- □ Specify other | [2716]
- □ Grade | [2717]
- □ 2nd reason | [2718]
- □ Grade | [2719]
- □ 3rd reason | [2720]
- □ Grade | [2721]
- □ New dosage (mg) | [2722]
- □ Dose interruption | [4036]
- □ Number of administrations per cycle | [5579]

○ **Dose adjustment - carfilzomib | [205]**

- □ Date of dose adjustment | [2652]
- □ 1st reason | [2653]
- □ Specify other | [2654]
- □ Grade | [2655]
- □ 2nd reason | [2656]
- □ Grade | [2657]
- □ 3rd reason | [2658]
- □ Grade | [2659]
- □ New dosage (mg/m2) | [2660]
- □ Dose interruption | [4037]
- □ Number of administrations per cycle | [5581]

○ **Dose adjustment - ixazomib | [208]**

- □ Date of dose adjustment | [2679]
- □ 1st reason | [2680]
- □ Specify other | [2681]
- □ Grade | [2682]
- □ 2nd reason | [2683]
- □ Grade | [2684]
- □ 3rd reason | [2685]
- □ Grade | [2686]
- □ New dosage (mg) | [2687]
- □ Dose interruption | [4038]
- □ Number of administrations per cycle | [5583]

○ **Dose adjustment - daratumumab | [369]**

- □ Date of dose adjustment | [4550]
- □ 1st reason | [4551]
- □ Specify other | [4552]
- □ Grade | [4553]
- □ 2nd reason | [4554]

- □ Grade | [4555]
- □ 3rd reason | [4556]
- □ Grade | [4557]
- □ New dosage | [4558]
- □ Do you really want to enter value different from 16 mg/kg? | [4877]
- □ Units | [4662]
- □ Dose interruption | [4559]
- □ Number of administrations per cycle | [5585]

○ **Dose adjustment - birtamimab | [394]**

- □ Date of dose adjustment | [5139]
- □ 1st reason | [5140]
- □ Specify other | [5141]
- □ Grade | [5142]
- □ 2nd reason | [5143]
- □ Grade | [5144]
- □ 3rd reason | [5145]
- □ Grade | [5146]
- □ New dosage (mg/kg) | [5147]
- □ Dose interruption | [5148]
- □ Number of administrations per cycle | [5587]

○ **Drugs - overview of total cumulative doses | [215]**

- □ bortezomib | [2761]
- □ Total number of administrations | [2213]
- □ Total cumulative dosage (mg) | [2214]
- □ thalidomid | [2768]
- □ Total number of administrations | [2235]
- □ Total cumulative dosage (mg) | [2236]
- □ carfilzomib | [2769]
- □ Total number of administrations | [2237]
- □ Total cumulative dosage (mg) | [2238]
- □ daratumumab | [4537]
- □ Total number of administrations | [4538]
- □ Total cumulative dosage (mg) | [4539]
- □ Total number of intravenous administrations | [4676]
- □ Total number of subcutaneous administrations | [4677]
- □ Total cumulative intravenous dosage (mg) | [4678]
- □ Total cumulative subcutaneous dosage (mg) | [4679]
- □ In case of route of administration intravenous and change to subcutaneous or subcutaneous and change to intravenous please fill in the total number of administration and total cumulative dosage for every route of administration separately. These values will be automatically added up and filled in the questions Total number of administrations and Total comulative dosage (mg). | [4680]
- □ ixazomib | [2771]
- □ Total number of administrations | [2247]
- □ Total cumulative dosage (mg) | [2248]
- □ lenalidomid | [2772]
- □ Total number of administrations | [2249]

- □ Total cumulative dosage (mg) | [2250]
- □ pomalidomid | [2773]
- □ Total number of administrations | [2253]
- □ Total cumulative dosage (mg) | [2254]

○ **Toxicity before treatment | [316]**

- □ Grade of thrombocytopenia before treatment | [3658]
- □ Grade of neuropathy before treatment | [3659]

○ **Toxicity during treatment | [317]**

- □ Neuropathy - grade | [3660]
- □ Related | [3661]
- □ Nausea, vomiting - grade | [3662]
- □ Related | [3663]
- □ Anorexia - grade | [3664]
- □ Related | [3665]
- □ Diarrhoea - grade | [3666]
- □ Related | [3667]
- □ Constipation - grade | [3668]
- □ Related | [3669]
- □ Fatigue - grade | [3670]
- □ Related | [3671]
- □ Thrombosis/Thrombus/Embolism - grade | [3672]
- □ Related | [3673]
- □ Infection - grade | [3674]
- □ Related | [3675]
- □ Thrombocytopenia - grade | [3676]
- □ Related | [3677]
- □ Neutropenia - grade | [3678]
- □ Related | [3679]
- □ Anemia - grade | [3680]
- □ Related | [3681]
- □ Rash (exanthema) - grade | [4028]
- □ Related | [4029]
- □ IRR (infusion related reaction) - grade | [4211]
- □ Related | [4212]
- □ Dyspnoe - grade | [4415]
- □ Related | [4416]
- □ Decompensated diabetes mellitus - grade | [4418]
- □ Related | [4419]
- □ Hepatotoxicity - grade | [4420]
- □ Related | [4421]
- □ Cytokine release syndrom (CRS) - grade | [5474]
- □ Related | [5473]
- □ ICANS - grade | [5475]
- □ Related | [5476]
- □ Hemophagocytic lymphohistiocytosis - grade | [5477]
- □ Related | [5478]

- ☐ Pneumotoxicity - grade | [5479]
- ☐ Related | [5480]
- ☐ Keratopathy - grade | [5481]
- ☐ Related | [5482]
- ☐ Nail changes - grade | [5483]
- ☐ Related | [5484]
- ☐ Palmar/plantar desquamations - grade | [5485]
- ☐ Related | [5486]
- ☐ Headache – grade | [5487]
- ☐ Related | [5488]
- ☐ Other unexpected toxicity | [4535]

○ **Other toxicity | [341]**
- ☐ Specify toxicity | [4380]
- ☐ Specify other toxicity | [4387]
- ☐ Grade of toxicity | [4381]
- ☐ Related | [4382]

○ **Switch of therapy | [136]**
- ☐ Switch of therapy regimen | [1475]
- ☐ Reason for switch | [1476]

○ **Treatment (switch) | [375]**
- ☐ Treatment regimen | [4683]
- ☐ Specify combination of 6 or more drugs | [4684]
- ☐ Length of cycle (days) | [4687]
- ☐ Date of treatment initiation | [4688]

○ **Drugs - overview (switch) | [376]**
- ☐ bortezomib | [4689]
- ☐ Dosage (mg/m2) | [4690]
- ☐ Route of administration | [4691]
- ☐ Number of administrations per cycle | [4692]
- ☐ Number of cycles | [4693]
- ☐ Dose adjustment | [4694]
- ☐ carfilzomib | [4695]
- ☐ Dosage (mg/m2) | [4696]
- ☐ Route of administration | [4697]
- ☐ Number of administrations per cycle | [4698]
- ☐ Number of cycles | [4699]
- ☐ Dose adjustment | [4700]
- ☐ daratumumab | [4701]
- ☐ Dosage | [4702]
- ☐ Units | [4703]
- ☐ Do you really want to enter value different from 16 mg/kg? | [4879]
- ☐ Route of administration | [4704]
- ☐ Number of administrations per cycle | [4705]
- ☐ Number of cycles | [4706]
- ☐ Dose adjustment | [4707]
- ☐ cyklofosfamid | [4708]

- □ Dosage (mg) | [4709]
- □ Number of administrations per cycle | [4710]
- □ Number of cycles | [4711]
- □ dexamethason | [4712]
- □ Dosage (mg) | [4713]
- □ Number of administrations per cycle | [4714]
- □ Number of cycles | [4715]
- □ ixazomib | [4716]
- □ Dosage (mg) | [4717]
- □ Number of administrations per cycle | [4718]
- □ Number of cycles | [4719]
- □ Dose adjustment | [4720]
- □ lenalidomid | [4721]
- □ Dosage (mg) | [4722]
- □ Number of administrations per cycle | [4723]
- □ Number of cycles | [4724]
- □ Dose adjustment | [4725]
- □ melphalan | [4726]
- □ Dosage (mg/m2) | [4727]
- □ Number of administrations per cycle | [4728]
- □ Number of cycles | [4729]
- □ methylprednisolon | [4730]
- □ Dosage (mg) | [4731]
- □ Number of administrations per cycle | [4732]
- □ Number of cycles | [4733]
- □ prednison | [4734]
- □ Dosage (mg) | [4735]
- □ Number of administrations per cycle | [4736]
- □ Number of cycles | [4737]
- □ pomalidomid | [4738]
- □ Dosage (mg) | [4739]
- □ Number of administrations per cycle | [4740]
- □ Number of cycles | [4741]
- □ Dose adjustment | [4742]
- □ thalidomid | [4743]
- □ Dosage (mg) | [4744]
- □ Number of administrations per cycle | [4745]
- □ Number of cycles | [4746]
- □ Dose adjustment | [4747]
- □ birtamimab | [5152]
- □ Dosage (mg/kg) | [5153]
- □ Route of administration | [5174]
- □ Number of administrations per cycle | [5154]
- □ Number of cycles | [5155]
- □ Dose adjustment | [5156]

- **Dose adjustment - bortezomib (switch) | [377]**

- ☐ Date of dose adjustment | [4749]
- ☐ 1st reason | [4750]
- ☐ Specify other | [4751]
- ☐ Grade | [4752]
- ☐ 2nd reason | [4753]
- ☐ Grade | [4754]
- ☐ 3rd reason | [4755]
- ☐ Grade | [4756]
- ☐ New dosage (mg/m2) | [4757]
- ☐ Dose interruption | [4758]
- ☐ Number of administrations per cycle | [5574]

○ **Dose adjustment - thalidomid (switch) | [378]**

- ☐ Date of dose adjustment | [4765]
- ☐ 1st reason | [4759]
- ☐ Specify other | [4760]
- ☐ Grade | [4761]
- ☐ 2nd reason | [4762]
- ☐ Grade | [4763]
- ☐ 3rd reason | [4764]
- ☐ Grade | [4766]
- ☐ New dosage (mg) | [4767]
- ☐ Dose interruption | [4768]
- ☐ Number of administrations per cycle | [5576]

○ **Dose adjustment - lenalidomid (switch) | [379]**

- ☐ Date of dose adjustment | [4769]
- ☐ 1st reason | [4770]
- ☐ Specify other | [4771]
- ☐ Grade | [4772]
- ☐ 2nd reason | [4773]
- ☐ Grade | [4774]
- ☐ 3rd reason | [4775]
- ☐ Grade | [4776]
- ☐ New dosage (mg) | [4777]
- ☐ Dose interruption | [4778]
- ☐ Number of administrations per cycle | [5578]

○ **Dose adjustment - pomalidomid (switch) | [380]**

- ☐ Date of dose adjustment | [4779]
- ☐ 1st reason | [4780]
- ☐ Specify other | [4781]
- ☐ Grade | [4782]
- ☐ 2nd reason | [4783]
- ☐ Grade | [4784]
- ☐ 3rd reason | [4785]
- ☐ Grade | [4786]
- ☐ New dosage (mg) | [4787]
- ☐ Dose interruption | [4788]

- □ Number of administrations per cycle | [5580]

- **Dose adjustment - carfilzomib (switch) | [381]**
  - □ Date of dose adjustment | [4795]
  - □ 1st reason | [4789]
  - □ Specify other | [4790]
  - □ Grade | [4791]
  - □ 2nd reason | [4792]
  - □ Grade | [4793]
  - □ 3rd reason | [4794]
  - □ Grade | [4796]
  - □ New dosage (mg/m2) | [4797]
  - □ Dose interruption | [4798]
  - □ Number of administrations per cycle | [5582]
- **Dose adjustment - ixazomib (switch) | [382]**
  - □ Date of dose adjustment | [4799]
  - □ 1st reason | [4800]
  - □ Specify other | [4801]
  - □ Grade | [4802]
  - □ 2nd reason | [4803]
  - □ Grade | [4804]
  - □ 3rd reason | [4805]
  - □ Grade | [4806]
  - □ New dosage (mg) | [4807]
  - □ Dose interruption | [4808]
  - □ Number of administrations per cycle | [5584]
- **Dose adjustment - daratumumab (switch) | [383]**
  - □ Date of dose adjustment | [4809]
  - □ 1st reason | [4810]
  - □ Specify other | [4811]
  - □ Grade | [4812]
  - □ 2nd reason | [4813]
  - □ Grade | [4814]
  - □ 3rd reason | [4815]
  - □ Grade | [4819]
  - □ New dosage | [4816]
  - □ Units | [4817]
  - □ Do you really want to enter value different from 16 mg/kg? | [4880]
  - □ Dose interruption | [4818]
  - □ Number of administrations per cycle | [5586]
- **Dose adjustment - birtamimab (switch) | [395]**
  - □ Date of dose adjustment | [5157]
  - □ 1st reason | [5158]
  - □ Specify other | [5159]
  - □ Grade | [5160]
  - □ 2nd reason | [5161]
  - □ Grade | [5162]

- □ 3rd reason | [5163]
- □ Grade | [5164]
- □ New dosage (mg/kg) | [5165]
- □ Dose interruption | [5166]
- □ Number of administrations per cycle | [5588]

○ **Drugs - overview of total cumulative doses (switch) | [384]**

- □ bortezomib | [4820]
- □ Total number of administrations | [4821]
- □ Total cumulative dosage (mg) | [4822]
- □ thalidomid | [4823]
- □ Total number of administrations | [4824]
- □ Total cumulative dosage (mg) | [4825]
- □ carfilzomib | [4826]
- □ Total number of administrations | [4827]
- □ Total cumulative dosage (mg) | [4828]
- □ daratumumab | [4829]
- □ Total number of administrations | [4830]
- □ Total cumulative dosage (mg) | [4831]
- □ Total number of intravenous administrations | [4832]
- □ Total number of subcutaneous administrations | [4833]
- □ Total cumulative intravenous dosage (mg) | [4834]
- □ Total cumulative subcutaneous dosage (mg) | [4835]
- □ In case of route of administration intravenous and change to subcutaneous or subcutaneous and change to inctravenous please fill in the total number of administration and total cumulative dosage for every route of administration separately. These values will be automatically added up and filled in the questions Total number of administrations and Total comulative dosage (mg). | [4836]
- □ ixazomib | [4839]
- □ Total number of administrations | [4837]
- □ Total cumulative dosage (mg) | [4838]
- □ lenalidomid | [4840]
- □ Total number of administrations | [4841]
- □ Total cumulative dosage (mg) | [4842]
- □ pomalidomid | [4843]
- □ Total number of administrations | [4844]
- □ Total cumulative dosage (mg) | [4845]

○ **Toxicity before treatment (switch) | [173]**

- □ Grade of thrombocytopenia before treatment | [1900]
- □ Grade of neuropathy before treatment | [1901]

○ **Toxicity during treatment (switch) | [174]**

- □ Neuropathy - grade | [1902]
- □ Related | [1903]
- □ Nausea, vomiting - grade | [1904]
- □ Related | [1905]
- □ Anorexia - grade | [1906]
- □ Related | [1907]
- □ Diarrhoea - grade | [1908]

□ Related | [1909]
□ Constipation - grade | [1910]
□ Related | [1911]
□ Fatigue - grade | [1912]
□ Related | [1913]
□ Thrombosis/Thrombus/Embolism - grade | [1914]
□ Related | [1915]
□ Infection - grade | [1916]
□ Related | [1917]
□ Thrombocytopenia - grade | [1918]
□ Related | [1919]
□ Neutropenia - grade | [1920]
□ Related | [1921]
□ Anemia - grade | [1922]
□ Related | [1923]
□ Rash (exanthema) - grade | [4026]
□ Related | [4027]
□ IRR (infusion related reaction) - grade | [4209]
□ Dyspnoe - grade | [4373]
□ Related | [4374]
□ Related | [4210]
□ Decompensated diabetes mellitus - grade | [4375]
□ Related | [4376]
□ Hepatotoxicity - grade | [4377]
□ Related | [4378]
□ Cytokine release syndrom (CRS) - grade | [5490]
□ Related | [5489]
□ ICANS - grade | [5491]
□ Related | [5492]
□ Hemophagocytic lymphohistiocytosis - grade | [5493]
□ Related | [5494]
□ Pneumotoxicity - grade | [5495]
□ Related | [5496]
□ Keratopathy - grade | [5497]
□ Related | [5498]
□ Nail changes - grade | [5499]
□ Related | [5500]
□ Palmar/plantar desquamations - grade | [5501]
□ Related | [5502]
□ Headache – grade | [5503]
□ Related | [5504]
□ Hypogammaglobulinemia - grade | [6133]
□ Related | [6246]
□ Leukopenia - grade | [6139]
□ Related | [6247]
□ Lymfopenia - grade | [6140]

- □ Related | [6248]
- □ Hyponatremia - grade | [6141]
- □ Related | [6249]
- □ Hypofibrinogenemia - Grade | [6142]
- □ Related | [6250]
- □ Other neurotoxicity - grade | [6162]
- □ Related | [6251]
- □ Renal toxicity - grade | [6167]
- □ Related | [6252]
- □ Cardiotoxicity - grade | [6169]
- □ Related | [6253]
- □ CMV reactivation - grade | [6170]
- □ Related | [6254]
- □ Other unexpected toxicity | [4383]

○ **Other toxicity (switch) | [342]**

- □ Specify toxicity | [4384]
- □ Specify other toxicity | [4388]
- □ Grade | [4385]
- □ Related | [4386]

○ **Transplantation | [216]**

- □ Transplantation | [2259]
- □ Response before transplant | [2266]
- □ Date of transplantation | [2260]
- □ Special transplantation technique | [2262]
- □ Type of conditioning regimen | [2263]
- □ Tandem autotransplantation - identical dosage? | [2264]
- □ Second conditioning regimen type | [2265]
- □ Date of subsequent transplant | [2267]

○ **Treatment withdrawal | [217]**

- □ Date of treatment withdrawal | [2268]

○ **Response to treatment | [218]**

- □ Time since diagnosis to treatment initiation (days) | [2270]
- □ Date of first treatment response | [2272]
- □ Date of maximal response | [2273]
- □ Maximal response to treatment | [2828]
- □ Final response | [2271]
- □ NT-proBNP (ng/l) in time of maximal response | [2274]
- □ TnT in time of maximal response | [2275]
- □ Level of proteinuria in time of maximal response (g/l/24 hod) | [2276]

○ **Laboratory - serum (protein analysis) in time of maximal response | [219]**

- □ M-protein type | [2277]
- □ Light chain type | [2278]
- □ Serum M-protein quantity (g/l) | [2279]
- □ Cannot be measured | [2787]
- □ Total M-protein quantity (g/l) | [2280]
- □ Albumin level (g/l) | [2281]

□ Serum kappa FLC quantity (mg/l) | [2282]
□ Serum lambda FLC quantity (mg/l) | [2283]
□ Kappa/lambda ratio | [2284]

- **Analysis of urine in time of maximal response | [220]**
  - □ Total protein in the urine (g/day) | [2285]
  - □ Urine M-protein type | [2286]
  - □ Free light chain urine type | [2287]
  - □ Urine M-protein quantity (mg/24h) | [2288]
  - □ Urine M-protein quantity (mg/l per 24h) | [2289]
  - □ Urine albumin level (mg/24 h) | [2290]
- **Characteristic of disease in time of maximal response | [221]**
  - □ Liver width (cm) | [2291]
- **Echocardiography in time of maximal response | [222]**
  - □ Echocardiography | [2292]
  - □ Left ventricular ejection fraction (%) | [2293]
  - □ Interventricular septum diastolic diameter (mm) | [2294]
  - □ Left atrium diameter (mm) | [2295]
  - □ Mitral regurgitation | [2296]
- **| [389]**
  - □ Form is fully filled | [4876]

- **Watch and wait | [27]**
  - **After line of treatment | [290]**
    - □ After line | [3185]
  - **Progression | [291]**
    - □ Date of progression | [3186]
- **Current status | [20]**
  - **Current status | [200]**
    - □ Date of the last update | [2129]
    - □ Patient status | [2130]
    - □ Patient status - alive | [2131]
    - □ Date of death | [2132]
    - □ Date of diagnosis | [2136]
    - □ Get data! | [2400]
    - □ Date of diagnosis for transfer from Diagnostics forms is empty. | [2821]
    - □ OS (days) | [2135]
    - □ Cause of death | [2133]
    - □ Note | [2134]
- **ALA associated with MM | [22]**
  - **Characteristic of amyloidosis | [224]**
    - □ Date of diagnosis | [2298]
    - □ Type of amyloidosis | [2299]
    - □ Diffused | [2300]
    - □ Localization | [2396]
    - □ Node | [2302]
    - □ GIT | [2303]
    - □ Tracheobronchial | [2304]

- ☐ Pulmonary | [2305]
- ☐ Kidney | [2306]
- ☐ Heart | [2307]
- ☐ Skin | [2308]
- ☐ Other | [2309]
- ☐ Specify other | [2310]

○ **Laboratory - serum (protein analysis) | [225]**
- ☐ Light chain type | [2311]
- ☐ Serum kappa FLC quantity (mg/l) | [2312]
- ☐ Serum lambda FLC quantity (mg/l) | [2313]

○ **Analysis of a heart indicators | [226]**
- ☐ Troponin T (ng/l) | [2314]
- ☐ NT-proBNP (ng/l) | [2315]
- ☐ Mayo stage | [2316]
- ☐ Revised Mayo stage | [2317]

○ **Other parameters | [227]**
- ☐ Factor X deficit | [2318]
- ☐ Uric acid level (µmol/l) | [2319]
- ☐ Glom. filtration according to MDRD (ml/s/1,73m2) | [2320]
- ☐ ALP (µkat/l) | [2321]
- ☐ Calcium (mmol/l) | [2322]

○ **Analysis of urine | [228]**
- ☐ Total protein in the urine (g/day) | [2323]
- ☐ Urine M-protein type | [2324]
- ☐ Free light chain urine type | [2325]
- ☐ Urine M-protein quantity (mg/24h) | [2326]
- ☐ Urine M-protein quantity (mg/l per 24h) | [2327]
- ☐ Urine albumin level (mg/24 h) | [2328]

○ **Echocardiography | [229]**
- ☐ Echocardiography | [2329]
- ☐ Left ventricular ejection fraction (%) | [2330]
- ☐ Interventricular septum diastolic diameter (mm) | [2331]
- ☐ Left atrium diameter (mm) | [2332]
- ☐ Mitral regurgitation | [2333]

○ **MR of myocardium | [230]**
- ☐ MR of myocardium | [2334]
- ☐ Left ventricular ejection fraction (%) | [2335]
- ☐ Interventricular septum diastolic diameter (mm) | [2336]
- ☐ Delayed enhancement | [2337]
- ☐ Type of involvement | [2338]

○ **ECG | [231]**
- ☐ ECG | [2339]
- ☐ Basic rhythm | [2340]
- ☐ Ventricular rate | [2341]
- ☐ Low voltage of limb leads under 5 mm | [2343]
- ☐ QS - "pseudoinfarct pattern" of anterior wall | [2344]

- **Characteristic of patient | [232]**
  - ☐ Other serious diseases (not related with AL and damages of organs) | [2345]
  - ☐ Specify other | [2346]
  - ☐ Height (cm) | [2347]
  - ☐ Weight (kg) | [2348]
  - ☐ BMI | [2349]
  - ☐ Blood pressure - systolic (mmHg) | [2350]
  - ☐ Blood pressure - diastolic (mmHg) | [2351]
- **Characteristic of disease | [233]**
  - ☐ Liver width (cm) | [2352]
  - ☐ Nefrotic syndrome | [2353]
  - ☐ Heart failure | [2354]
  - ☐ NYHA | [2355]
  - ☐ Orthostatic hypotension | [2356]
  - ☐ Peripheral neuropathy | [2357]
  - ☐ Hepatopathy | [2358]
  - ☐ GIT | [2359]
  - ☐ Skin | [2360]
  - ☐ Other signs | [2397]
  - ☐ Macroglossia | [2361]
  - ☐ Periorbital purpura | [2362]
  - ☐ Carpal Tunnel Syndrome | [2363]
  - ☐ Shoulder pad sign | [2364]
- **Amyloid positive biopsy | [235]**
  - ☐ Detection method used | [2367]
  - ☐ Specify other | [2368]
  - ☐ Subcutaneous fat | [2369]
  - ☐ Tongue, buccal mucosa | [2370]
  - ☐ Rectum | [2371]
  - ☐ Bone marrow | [2372]
  - ☐ Kidney | [2373]
  - ☐ Endomyocardial biopsy | [2374]
  - ☐ Other | [2375]
  - ☐ Specify other | [2376]
- **| [389]**
  - ☐ Form is fully filled | [4876]

Data import from NIS | [7]

- **Laboratory values | [41]**
  - **Laboratory values | [385]**
    - ☐ Date of examination | [4863]
    - ☐ M-protein type | [4846]
    - ☐ Serum M-protein quantity (g/l) | [4847]
    - ☐ Serum kappa FLC quantity (mg/l) | [4848]
    - ☐ Serum lambda FLC quantity (mg/l) | [4849]
    - ☐ IgG quantity (g/l) | [4850]
    - ☐ IgA quantity (g/l) | [4851]

□ IgM quantity (g/l) | [4852]
□ Beta2 microglobulin (mg/l) | [4853]
□ Albumin level (g/l) | [4854]
□ LDH (µkat/l) | [4855]
□ CRP (mg/l) | [4856]
□ Creatinine level (µmol/l) | [4857]
□ Calcium total level (mmol/l) | [4858]
□ Urine M-protein quantity (g/l per 24h) | [4859]
□ Urine M-protein quantity (mg/24h) | [6370]
□ Hemoglobin level (g/l) | [4860]
□ Thrombocyte count (10E9/l) | [4861]
□ Bone marrow aspiration cytogology - Plasmocyte count (%) | [4862]